WO2018031979A1 - Antifolates alpha et gamma-d de polyglutamates et leurs utilisations. - Google Patents

Antifolates alpha et gamma-d de polyglutamates et leurs utilisations. Download PDF

Info

Publication number
WO2018031979A1
WO2018031979A1 PCT/US2017/046666 US2017046666W WO2018031979A1 WO 2018031979 A1 WO2018031979 A1 WO 2018031979A1 US 2017046666 W US2017046666 W US 2017046666W WO 2018031979 A1 WO2018031979 A1 WO 2018031979A1
Authority
WO
WIPO (PCT)
Prior art keywords
alpha
polyglutamated
gamma
antifolate
cancer
Prior art date
Application number
PCT/US2017/046666
Other languages
English (en)
Inventor
Clet Niyikiza
Victor Mandla MOYO
Original Assignee
L.E.A.F. Holdings Group Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US15/675,701 external-priority patent/US20180236098A1/en
Priority to EP17840396.0A priority Critical patent/EP3496756A4/fr
Priority to US16/324,823 priority patent/US11344628B2/en
Priority to MX2019001756A priority patent/MX2019001756A/es
Priority to KR1020237032981A priority patent/KR102708209B1/ko
Priority to BR112019002497-2A priority patent/BR112019002497A2/pt
Priority to CN201780052159.XA priority patent/CN109689104A/zh
Priority to JP2019507107A priority patent/JP7227123B2/ja
Priority to EA201990324A priority patent/EA201990324A1/ru
Priority to KR1020247030844A priority patent/KR20240141854A/ko
Application filed by L.E.A.F. Holdings Group Llc filed Critical L.E.A.F. Holdings Group Llc
Priority to CA3033077A priority patent/CA3033077C/fr
Priority to EP22167260.3A priority patent/EP4052729A1/fr
Priority to AU2017308158A priority patent/AU2017308158B2/en
Priority to KR1020197005253A priority patent/KR102584446B1/ko
Publication of WO2018031979A1 publication Critical patent/WO2018031979A1/fr
Priority to US17/544,196 priority patent/US20220088220A1/en
Priority to US17/544,182 priority patent/US20220088218A1/en
Priority to US17/544,191 priority patent/US20220088219A1/en
Priority to US17/745,138 priority patent/US20230115624A1/en
Priority to JP2023018363A priority patent/JP7538268B2/ja
Priority to AU2023263441A priority patent/AU2023263441A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/645—Polycationic or polyanionic oligopeptides, polypeptides or polyamino acids, e.g. polylysine, polyarginine, polyglutamic acid or peptide TAT
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers

Definitions

  • This disclosure generally relates to alpha and D-gamma polyglutamated antifolate compositions, including delivery vehicles such as liposomes filled with the alpha (L-alpha or D-alpha) or D-gamma polyglutamated antifolates, and methods of making and using the compositions to treat diseases including hyperproliferative diseases such as cancer, disorders of the immune system such as rheumatoid arthritis and infectious diseases such as HIV.
  • delivery vehicles such as liposomes filled with the alpha (L-alpha or D-alpha) or D-gamma polyglutamated antifolates
  • diseases including hyperproliferative diseases such as cancer, disorders of the immune system such as rheumatoid arthritis and infectious diseases such as HIV.
  • Folates are indispensable for cell growth and tissue regeneration. Mammalian cells do not synthesize folates de novo and rely on extracellular folates taken up by three major folate uptake systems: a reduced folate carrier (RFC) system; a system of folate receptors (FRs) a and ⁇ ; and a folate symporter (PCFT) system.
  • ROC reduced folate carrier
  • FRs folate receptors
  • PCFT folate symporter
  • Antifolates that target folate-dependent biosynthetic pathways function as anti-proliferative agents.
  • Naturally occurring folates exist within cells as polyglutamates through the action of the enzyme folylpolyglutamyl synthetase (FPGS), which may add up to 6 glutamyl groups in a L-gamma peptide linkage to the folate substrate.
  • L gamma polyglutamation serves at least 3 main purposes: (1) it facilitates the accumulation of intracellular folates in vast excess of the monoglutamate pool, which is freely transportable into and out of cells; (2) it allows selective intracellular retention of these relatively large anionic molecules; and (3) it greatly enhances folate cofactor affinity for several folate-dependent enzymes, including thymidylate synthase and AICAR transformylase (see, e.g., FIG. 2).
  • Antifolates are a class of antiproliferatives that were first developed more than 70 years ago as "folic acid mimic molecule" cytotoxic agents. The rationale was to design a class of molecules that would counter the action of folic acid in fast replicating cells such as cancer cells, taking advantage of physiological folate transport mechanism and their facilitative intracellular mode of action for DNA replication during the cell division.
  • antifolates were designed to mimic folic acid in its systemic transport, physiologic cell uptake (e.g., via reduced folate carriers (RFCs) and proton- coupled folate transporters (PCFTs)) and intracellular processing. Antifolates act specifically during DNA and RNA synthesis, exerting a cytotoxic effect during the S- phase of the cell cycle. As a result, they have a greater toxic effect on rapidly dividing cells such as malignant and myeloid cells.
  • ROCs reduced folate carriers
  • PCFTs proton- coupled folate transporters
  • Antifolates are widely recognized for their inhibition of folate metabolism.
  • Major antifolate enzyme targets and exemplary antifolates that target these enzymes include: (a) dihydrofolate reductase (DHFR) [e.g., methotrexate (MTX) and pralatrexate], (b) thymidylate synthase (TS) [e.g., raltitrexed (RTX), GW1843U, and pemetrexed (PMX)], (c) ⁇ -glycinamide ribonucleotide formyl transferase (GARFTase) [e.g., lometrexol (LMX), PMX] and (d) 5-aminoimidazole-4-carboxamide ribonucleotide formyl transferase (AICARFTase) [e.g., PMX].
  • DHFR dihydrofolate reductase
  • MTX methotrexate
  • hyperproliferative diseases including hematologic malignancies and solid tumors, as well as disorders of the immune system such as rheumatoid arthritis.
  • RFC reduced folate carrier
  • Pemetrexed is a antifolate containing a 6-5 fused pyrrolo[2,3,-d]pyrimidine nucleus that inhibits thymidylate synthase (TS), glycinamide ribonucleotide formyltransferase (GARFT), and dihydrofolate reductase (DHFR), folate-dependent enzymes involved in the synthesis of thymidine and purine nucleotides.
  • TS thymidylate synthase
  • GARFT glycinamide ribonucleotide formyltransferase
  • DHFR dihydrofolate reductase
  • pemetrexed is transported into cells by the RFC and membrane folate-binding proteins, where it is L gamma polyglutamated by folylpoly-gamma-glutamate synthetase.
  • pemetrexed have greater intracellular retention and have greater affinity for TS and GARFT compared to pemetrexed monoglutamate.
  • Pemetrexed is approved for the treatment of mesothelioma and non-small lung carcinoma (NSCLC).
  • NSCLC non-small lung carcinoma
  • Myelosuppression is typically the dose-limiting toxicity with pemetrexed therapy and has limited the clinical applications of this drug.
  • Pretreatment with folic acid and vitamin B is now used to ameliorate the most frequent side effects that include bone marrow suppression, fatigue, and skin rash.
  • WO 2016/25882 describes liposomal formulations of antifolates that are targeted to cancer cells using, for example, antibodies having a specific affinity for folate receptors expressed by many cancer cells. This formulation can reduce and/or minimize the effects of the antifolates on healthy cells, meaning that patients can experience fewer side effects.
  • compositions and methods that address these needs.
  • This disclosure generally relates novel alpha and D-gamma polyglutamated antifolate compositions, including delivery vehicles such as liposomes filled with the alpha and D-gamma polyglutamated antifolates, and methods of making and using the compositions to treat diseases including hyperproliferative diseases such as cancer, disorders of the immune system such as rheumatoid arthritis and infectious diseases such as HIV.
  • delivery vehicles such as liposomes filled with the alpha and D-gamma polyglutamated antifolates
  • diseases including hyperproliferative diseases such as cancer, disorders of the immune system such as rheumatoid arthritis and infectious diseases such as HIV.
  • the disclosure further relates to alpha and D-gamma pentaglutamated and hexaglutamated antifolate compositions, including delivery vehicles such as liposomes filled with the alpha and/or D-gamma pentaglutamated and hexaglutamated antifolates, and methods of making and using the compositions to treat diseases including hyperproliferative diseases, disorders of the immune system and infectious disease.
  • delivery vehicles such as liposomes filled with the alpha and/or D-gamma pentaglutamated and hexaglutamated antifolates
  • liposome compositions that contain alpha (e.g., L-alpha and D-alpha) and D-gamma
  • polyglutamated e.g., pentaglutamated and hexaglutamated
  • these compositions provide improvements to the efficacy and safety of delivering antifolates to cancer cells by providing the preferential delivery of a more cytotoxic payload (e.g., polyglutamated antifolates) compared to the cytotoxicity of the corresponding antifolate in its administered monoglutamated state. Therefore, in one aspect the disclosure provided liposomal antifolate composition that is untargeted. That is the liposomal antifolate composition does not have specific affinity towards a specific epitope.
  • the disclosure also provides targeted liposome compositions (targeted composition comprising liposomal antifolate composition) that contain a targeting moiety having a specific affinity for an epitope (antigen) expressed on the surface of a target cell of interest.
  • targeted liposomes provide further improvements to the efficacy and safety of delivering antifolates to cancer cells by specifically delivering polyglutamated (e.g., pentaglutamated and hexaglutamated) antifolates to the target cell.
  • the disclosure provides a composition comprising an alpha (e.g., L-alpha and D-alpha) or D-gamma polyglutamated antifolate (e.g., pentaglutamated and hexaglutamated).
  • the composition comprises an alpha (e.g., L-alpha and D-alpha) or D-gamma pentaglutamated or hexaglutamated antifolate.
  • the alpha (e.g., L-alpha and D-alpha) or D-gamma polyglutamated antifolate is a member selected from the group consisting of: polyglutamated methotrexate (MTX), polyglutamated pemetrexed (PMX), polyglutamated lometrexol (LTX), polyglutamated AG2034, polyglutamated raltitrexed (RTX), polyglutamated piritrexim, polyglutamated pralatrexate, polyglutamated AG2034, polyglutamated GW1843, polyglutamated aminopterin, and polyglutamated LY309887.
  • MTX polyglutamated methotrexate
  • PMX polyglutamated pemetrexed
  • LTX polyglutamated lometrexol
  • RTX polyglutamated raltitrexed
  • piritrexim polyglutamated piritrexim
  • polyglutamated pralatrexate polyglutamated
  • the alpha (L-alpha or D-alpha) or D-gamma polyglutamated member is pentaglutamated. In further embodiments, the alpha (L-alpha or D-alpha) or D-gamma polyglutamated member is hexaglutamated.
  • the composition comprises an alpha polyglutamated PMX, MTX, RTX, or LTX. In a further embodiment the composition comprises an alpha pentaglutamated PMX, MTX, RTX, or LTX. In a further embodiment the composition comprises an alpha hexaglutamated PMX, MTX, RTX, or LTX.
  • the composition comprises an alpha polyglutamated PMX. In a further embodiment the composition comprises an alpha pentaglutamated PMX. In a further embodiment the composition comprises an alpha hexaglutamated PMX.
  • the composition comprises an alpha polyglutamated MTX. In a further embodiment the composition comprises pentaglutamated MTX. In a further embodiment the composition comprises hexaglutamated MTX.
  • the composition comprises an alpha polyglutamated RTX.
  • the composition comprises pentaglutamated RTX.
  • the composition comprises hexaglutamated RTX.
  • composition comprises an alpha
  • composition comprises
  • composition comprises
  • the composition comprises an alpha polyglutamated PMX, MTX, RTX, or LTX. In a further embodiment the composition comprises pentaglutamated PMX, MTX, RTX, or LTX. In a further embodiment the composition comprises hexaglutamated PMX, MTX, RTX, or LTX.
  • the composition comprises an L-alpha polyglutamated PMX. In a further embodiment the composition comprises an L-alpha pentaglutamated PMX. In a further embodiment the composition comprises an L-alpha hexaglutamated PMX. [0021] In another embodiment, the composition comprises polyglutamated MTX. In a further embodiment the composition comprises an L-alpha pentaglutamated MTX. In a further embodiment the composition comprises an L-alpha hexaglutamated MTX.
  • composition comprises an L-alpha
  • composition comprises an L-alpha pentaglutamated RTX. In a further embodiment the composition comprises an L-alpha hexaglutamated RTX.
  • the composition comprises an L-alpha polyglutamated LTX. In a further embodiment the composition comprises an L-alpha pentaglutamated LTX. In a further embodiment the composition comprises an L-alpha hexaglutamated LTX.
  • the composition comprises a D-alpha polyglutamated PMX, MTX, RTX, or LTX. In a further embodiment the composition comprises a D- alpha pentaglutamated PMX, MTX, RTX, or LTX. In a further embodiment the composition comprises a D-alpha hexaglutamated PMX, MTX, RTX, or LTX
  • the composition comprises a D-alpha polyglutamated PMX. In a further embodiment the composition comprises a D-alpha pentaglutamated PMX. In a further embodiment the composition comprises a D-alpha hexaglutamated PMX.
  • the composition comprises a D-alpha polyglutamated MTX. In a further embodiment the composition comprises a D-alpha pentaglutamated MTX. In a further embodiment the composition comprises a D-alpha hexaglutamated MTX.
  • the composition comprises a D-alpha polyglutamated RTX.
  • the composition comprises a D-alpha pentaglutamated RTX.
  • the composition comprises a D-alpha hexaglutamated RTX.
  • the composition comprises a D-alpha polyglutamated LTX. In a further embodiment the composition comprises a D-alpha pentaglutamated LTX. In a further embodiment the composition comprises a D-alpha hexaglutamated LTX. [0029] In one embodiment, the composition comprises a D-gamma polyglutamated PMX, MTX, RTX, or LTX. In a further embodiment the composition comprises a D- gamma pentaglutamated PMX, MTX, RTX, or LTX. In a further embodiment the composition comprises a D-gamma hexaglutamated PMX, MTX, RTX, or LTX.
  • the composition comprises a D-gamma polyglutamated PMX. In a further embodiment the composition comprises a D-gamma pentaglutamated PMX. In a further embodiment the composition comprises a D-gamma hexaglutamated PMX.
  • composition comprises a D-gamma
  • composition comprises a D-gamma pentaglutamated MTX. In a further embodiment the composition comprises a D-gamma hexaglutamated MTX.
  • composition comprises a D-gamma
  • composition comprises a D-gamma pentaglutamated RTX. In a further embodiment the composition comprises a D-gamma hexaglutamated RTX.
  • the composition comprises a D-gamma polyglutamated LTX. In a further embodiment the composition comprises a D-gamma pentaglutamated LTX. In a further embodiment the composition comprises a D-gamma hexaglutamated LTX.
  • the disclosure provides a liposomal alpha (L-alpha or D-alpha) or D-gamma polyglutamated antifolate (LP A) composition that comprises an alpha or D-gamma polyglutamated (e.g., pentaglutamated or hexaglutamated) antifolate.
  • LP A D-gamma polyglutamated antifolate
  • the alpha (L-alpha or D-alpha) or D-gamma polyglutamed antifolate may be in a HEPES buffered solution within a liposome.
  • the LPA composition is pegylated (PLPA).
  • the PLPA composition comprises an alpha (L-alpha or D-alpha) or D-gamma pentaglutamated antifolate. In some embodiments, the PLPA composition comprises an alpha (L-alpha or D-alpha) or D-gamma hexaglutamated antifolate. In some embodiments, the PLPA liposome is anionic or neutral. In other embodiments, the PLPA liposome is cationic. In some embodiments, the PLPA composition comprises at least 10% liposome, at least 20%, or at least 30% liposome entrapped alpha (L-alpha or D-alpha) or D-gamma polyglutamated antifolate.
  • the PLPA liposomes have a diameter in the range of 20 nm to 200 nm, 30nm to 175 nm, or 50 nm to 150 nm. In some embodiments, the PLPA liposomes have a diameter in the range of 30nm to 175 nm or 50 nm to 150 nm. In further embodiments, the PLPA liposomes have a diameter in the range of 80 nm to 120 nm.
  • the PLPA composition comprises an alpha (L-alpha or D-alpha) or D-gamma polyglutamated antifolate selected from the group consisting of: polyglutamated MTX, polyglutamated PMX, polyglutamated LTX, polyglutamated AG2034, polyglutamated RTX, polyglutamated piritrexim, polyglutamated pralatrexate, polyglutamated AG2034, polyglutamated GW1843, polyglutamated aminopterin, and polyglutamated LY309887.
  • the alpha (L-alpha or D-alpha) or D- gamma polyglutamated antifolate is pentaglutamated.
  • the PLPA composition comprises alpha (L-alpha or D-alpha) or D-gamma polyglutamated PMX, MTX, RTX, or LTX.
  • the alpha (L-alpha or D-alpha) or D- gamma polyglutamated antifolate is hexaglutamated.
  • the PLPA composition comprises alpha (L-alpha or D-alpha) or D-gamma polyglutamated PMX, MTX, RTX, or LTX.
  • the PLPA composition comprises an alpha (L-alpha or D-alpha) or D-gamma pentaglutamated PMX, MTX, RTX, or LTX. In a further embodiment the PLPA composition comprises an alpha (L-alpha or D-alpha) or D-gamma hexaglutamated PMX, MTX, RTX, or LTX.
  • the PLPA composition comprises an alpha
  • the PLPA composition comprises an alpha pentaglutamated PMX. In a further embodiment the PLPA composition comprises an alpha hexaglutamated PMX.
  • the PLPA composition comprises an alpha polyglutamated MTX.
  • the PLPA comprises pentaglutamated MTX.
  • the PLPA comprises hexaglutamated MTX.
  • the PLPA composition comprises an alpha polyglutamated RTX. In a further embodiment the PLPA composition comprises an alpha pentaglutamated RTX. In a further embodiment the PLPA composition comprises an alpha hexaglutamated RTX. [0039] In an additional embodiment, the PLPA composition comprises an alpha polyglutamated LTX. In a further embodiment the PLPA composition comprises an alpha pentaglutamated LTX. In a further embodiment the PLPA composition comprises an alpha hexaglutamated LTX.
  • the PLPA composition comprises an L-alpha
  • the PLPA composition comprises an L- alpha pentaglutamated PMX. In a further embodiment the PLPA composition comprises an L-alpha hexaglutamated PMX.
  • the PLPA composition comprises an L-alpha polyglutamated MTX.
  • the PLPA comprises an L-alpha pentaglutamated MTX.
  • the PLPA comprises an L-alpha hexaglutamated MTX.
  • the PLPA composition comprises an L-alpha polyglutamated RTX. In a further embodiment the PLPA composition comprises an L- alpha pentaglutamated RTX. In a further embodiment the PLPA composition comprises an L-alpha hexaglutamated RTX
  • the PLPA composition comprises an L-alpha polyglutamated LTX. In a further embodiment the PLPA composition comprises an L- alpha pentaglutamated LTX. In a further embodiment the PLPA composition comprises an L-alpha hexaglutamated LTX.
  • the PLPA composition comprises a D-alpha
  • the PLPA composition comprises a D- alpha pentaglutamated PMX. In a further embodiment the PLPA composition comprises a D-alpha hexaglutamated PMX.
  • the PLPA composition comprises a D-alpha polyglutamated MTX.
  • the PLPA comprises a D-alpha pentaglutamated MTX.
  • the PLPA comprises a D-alpha hexaglutamated MTX.
  • the PLPA composition comprises a D-alpha polyglutamated RTX.
  • the PLPA composition comprise a D- alpha pentaglutamated RTX.
  • the PLPA composition comprise a D-alpha hexaglutamated RTX.
  • the PLPA composition comprises a D-alpha polyglutamated LTX. In a further embodiment the PLPA composition comprises a D- alpha pentaglutamated LTX. In a further embodiment the PLPA composition comprises a D-alpha hexaglutamated LTX
  • the PLPA composition comprises a D-gamma
  • the PLPA composition comprises a D- gamma pentaglutamated PMX. In a further embodiment the PLPA composition comprises a D-gamma hexaglutamated PMX.
  • the PLPA composition comprises a D-gamma polyglutamated MTX.
  • the PLPA comprises a D-gamma pentaglutamated MTX.
  • the PLPA comprises a D-gamma hextaglutamated MTX.
  • the PLPA composition comprises a D-gamma polyglutamated RTX. In a further embodiment the PLPA composition comprises a D- gamma pentaglutamated RTX. In a further embodiment the PLPA composition comprises a D-gamma hexaglutamated RTX.
  • the PLPA composition comprises a D-gamma polyglutamated LTX. In a further embodiment the PLPA composition comprises a D- gamma pentaglutamated LTX. In a further embodiment the PLPA composition comprises a D-gamma hexaglutamated LTX.
  • the disclosure provides a liposomal alpha (L-alpha or D-alpha) or D-gamma polyglutamated antifolate composition wherein the liposome is pegylated and comprises a alpha (L-alpha or D-alpha) or D-gamma polyglutamated antifolate and targeting moiety attached to one or both of a PEG and the exterior of the liposome, and wherein the targeting moiety has a specific affinity for a surface antigen on a target cell of interest.
  • the targeting moiety is a polypeptide.
  • the targeting moiety is an antibody or a fragment of an antibody.
  • the targeting moiety comprises one or more of an antibody, a humanized antibody, an antigen binding fragment of an antibody, a single chain antibody, a single-domain antibody, a bi-specific antibody, a synthetic antibody, a pegylated antibody, and a multimeric antibody.
  • the targeting moiety has the specific affinity for an epitope on a tumor cell surface antigen that is present on a tumor cell but absent or inaccessible on a non-tumor cell.
  • the targeting moiety-PLPA further comprises one or more of an immunostimulatory agent, a detectable marker and a maleimide disposed on at least one of the PEG and the exterior of the liposome.
  • the targeting moiety-PLPA liposome is anionic or neutral. In other embodiments, the targeting moiety-PLPA liposome is cationic. In some embodiments, the targeting moiety-PLPA composition comprises at least 10% liposome entrapped alpha (L-alpha or D-alpha) or D-gamma polyglutamated antifolate. In additional embodiments, the targeting moiety-PLPA liposomes have a diameter in the range of 20 nm to 200 nm. In further embodiments, the liposomes have a diameter in the range of 80 nm to 120 nm.
  • the targeting moiety-PLPA comprises a polypeptide targeting moiety such as an antibody or an antibody fragment and the targeting moiety binds a target antigen with an equilibrium dissociation constant (Kd) in a range of 0.5x10 " 10 to lOxlO "6 as determined using BIACORE analysis.
  • the targeting moiety comprises a polypeptide that specifically binds a folate receptor.
  • the folate receptor bound by the targeting moiety is one or more folate receptors selected from the group consisting of: folate receptor alpha (FR-a), folate receptor beta (FR- ⁇ ), and folate receptor delta (FR- ⁇ ).
  • the disclosure also provides a method of killing a hyperproliferative cell that comprises contacting the hyperproliferative cell with a PLPA and/or LPA composition.
  • the hyperproliferative cell is a cancer cell.
  • the method is performed in vivo.
  • the method is performed in vitro.
  • the cancer cell is a primary cell or a cell from a cell line
  • a cancer selected from the group consisting of: lung cancer, pancreatic, breast cancer, ovarian cancer, lung cancer, prostate cancer, head and neck cancer, gastric cancer, gastrointestinal cancer, colon cancer, esophageal cancer, cervical cancer, kidney cancer, biliary duct cancer, gallbladder cancer, and a hematologic malignancy.
  • the disclosure provides a method for treating cancer that comprises administering an effective amount of a liposomal alpha (L-alpha or D-alpha) or D-gamma polyglutamated (e.g., pentaglutamated and hexaglutamated) antifolate (LP A) composition and/or a pegylated-LPA (PLPA) composition, to a subject having or at risk of having cancer.
  • a liposomal alpha L-alpha or D-alpha
  • D-gamma polyglutamated e.g., pentaglutamated and hexaglutamated
  • PLPA pegylated-LPA
  • the method is administered to treat a cancer selected from the group consisting of: lung cancer, pancreatic, breast cancer, ovarian cancer, lung cancer, prostate cancer, head and neck cancer, gastric cancer, gastrointestinal cancer, colon cancer, esophageal cancer, cervical cancer, kidney cancer, biliary duct cancer, gallbladder cancer, and a hematologic malignancy.
  • a cancer selected from the group consisting of: lung cancer, pancreatic, breast cancer, ovarian cancer, lung cancer, prostate cancer, head and neck cancer, gastric cancer, gastrointestinal cancer, colon cancer, esophageal cancer, cervical cancer, kidney cancer, biliary duct cancer, gallbladder cancer, and a hematologic malignancy.
  • the administered alpha (L-alpha or D-alpha) or D-gamma polyglutamated antifolate is a member selected from the group consisting of: polyglutamated
  • the administered composition comprises alpha (L-alpha or D-alpha) or D- gamma pentaglutamated antifolates.
  • the administered composition comprises alpha (L-alpha or D-alpha) or D- gamma pentaglutamated antifolates.
  • composition comprises alpha (L-alpha or D-alpha) or D-gamma hexaglutamated antifolates.
  • the administered composition comprises the alpha (L- alpha or D-alpha) or D-gamma polyglutamated form of PMX, MTX, RTX, or LTX.
  • the administered composition comprises the pentaglutamated form of PMX, MTX, RTX, or LTX.
  • the administered composition comprises the hexaglutamated form of PMX, MTX, RTX, or LTX.
  • the administered composition comprises the pentaglutamated form of PMX.
  • the administered composition comprises the pentaglutamated form of MTX.
  • the administered composition comprises the pentaglutamated form of RTX. In an additional embodiment, the administered composition comprises the pentaglutamated form of LTX. In one embodiment, the administered composition comprises the hexaglutamated form of PMX. In another embodiment, the administered composition comprises the hexaglutamated form of MTX. In another embodiment, the administered composition comprises the hexaglutamated form of RTX. In an additional embodiment, the administered composition comprises the hexaglutamated form of LTX.
  • the disclosure provides a method for treating cancer that comprises administering an effective amount and wherein the liposome is optionally pegylated), to a subject having or at risk of having cancer.
  • the method is administered to treat a cancer selected from the group consisting of: lung cancer, pancreatic, breast cancer, ovarian cancer, lung cancer, prostate cancer, head and neck cancer, gastric cancer, gastrointestinal cancer, colon cancer, esophageal cancer, cervical cancer, kidney cancer, biliary duct cancer, gallbladder cancer, and a hematologic malignancy.
  • a cancer selected from the group consisting of: lung cancer, pancreatic, breast cancer, ovarian cancer, lung cancer, prostate cancer, head and neck cancer, gastric cancer, gastrointestinal cancer, colon cancer, esophageal cancer, cervical cancer, kidney cancer, biliary duct cancer, gallbladder cancer, and a hematologic malignancy.
  • the administered alpha (L-alpha or D-alpha) or D-gamma polyglutamated antifolate is a member selected from the group consisting of: polyglutamated methotrexate (MTX), polyglutamated pemetrexed (PMX), polyglutamated lometrexol (LTX), polyglutamated AG2034, polyglutamated raltitrexed (RTX), polyglutamated piritrexim, polyglutamated pralatrexate, polyglutamated AG2034, polyglutamated GW1843, polyglutamated aminopterin, and polyglutamated LY309887.
  • the administered composition comprises alpha (L-alpha or D- alpha) or D-gamma pentaglutamated antifolates.
  • the administered composition comprises alpha (L-alpha or D- alpha) or D-gamma pentaglutamated antifolates.
  • the administered composition comprises alpha (L-alpha or D- alpha) or D-gam
  • administered composition comprises alpha (L-alpha or D-alpha) or D-gamma
  • the administered composition comprises the alpha (L-alpha or D-alpha) or D-gamma polyglutamated form of PMX, MTX, RTX, or LTX. In some embodiments, the administered composition comprises the pentaglutamated form of PMX, MTX, RTX, or LTX. In some embodiments, the administered composition comprises the hexaglutamated form of PMX, MTX, RTX, or LTX. In a further embodiment, the administered composition comprises the alpha (L- alpha or D-alpha) or D-gamma pentaglutamated form of PMX.
  • the administered composition comprises the alpha (L-alpha or D-alpha) or D-gamma hexaglutamated form of PMX. In another further embodiment, the administered composition comprises the alpha (L-alpha or D-alpha) or D-gamma pentaglutamated form of MTX. In another further embodiment, the administered composition comprises the alpha (L-alpha or D-alpha) or D-gamma hexaglutamated form of MTX. In another further embodiment, the administered composition comprises the pentaglutamated form of RTX. In another further embodiment, the administered composition comprises the hexaglutamated form of RTX. In an additional further embodiment, the administered composition comprises the pentaglutamated form of LTX. In an additional further embodiment, the administered composition comprises the hexaglutamated form of LTX.
  • the disclosure provides a method of treating cancer that comprises administering an effective amount of a LPA composition and/or a pegylated- LPA (PLPA) composition to a subject having or at risk of having cancer, wherein the PLPA and/or LPA composition further contains a targeting moiety having a specific affinity for a surface antigen (epitope) on the cancer.
  • PLPA pegylated- LPA
  • the disclosure provides a method for treating cancer that comprises administering a liposomal alpha (L-alpha or D-alpha) or D-gamma polyglutamated antifolate composition that comprises a polyglutamated antifolate and a targeting moiety that has a specific binding affinity for a folate receptor to a subject having or at risk of having cancer expresses on its surface the folate receptor bound by the targeting moiety.
  • the targeting moiety has a specific binding affinity for folate receptor alpha (FR-a), folate receptor beta (FR- ⁇ ), and/or folate receptor delta (FR- ⁇ ).
  • the method is administered to treat a cancer selected from the group consisting of: lung cancer, pancreatic, breast cancer, ovarian cancer, lung cancer, prostate cancer, head and neck cancer, gastric cancer, gastrointestinal cancer, colon cancer, esophageal cancer, cervical cancer, kidney cancer, biliary duct cancer, gallbladder cancer, and a hematologic malignancy.
  • a cancer selected from the group consisting of: lung cancer, pancreatic, breast cancer, ovarian cancer, lung cancer, prostate cancer, head and neck cancer, gastric cancer, gastrointestinal cancer, colon cancer, esophageal cancer, cervical cancer, kidney cancer, biliary duct cancer, gallbladder cancer, and a hematologic malignancy.
  • a cancer selected from the group consisting of: lung cancer, pancreatic, breast cancer, ovarian cancer, lung cancer, prostate cancer, head and neck cancer, gastric cancer, gastrointestinal cancer, colon cancer, esophageal cancer, cervical cancer, kidney cancer, biliary duct cancer,
  • administered alpha (L-alpha or D-alpha) or D-gamma polyglutamated antifolate is a member selected from the group consisting of: polyglutamated methotrexate (MTX), polyglutamated pemetrexed (PMX), polyglutamated lometrexol (LTX), polyglutamated AG2034, polyglutamated raltitrexed (RTX), polyglutamated piritrexim, polyglutamated pralatrexate, polyglutamated AG2034, polyglutamated GW1843, polyglutamated aminopterin, and polyglutamated LY309887.
  • the administered composition comprises pentaglutamated antifolates.
  • the administered composition comprises hexaglutamated antifolates.
  • the administered composition comprises the alpha (L-alpha or D-alpha) or D-gamma polyglutamated form of PMX, MTX, RTX, or LTX.
  • the administered composition comprises the pentaglutamated form of PMX, MTX, RTX, or LTX.
  • the administered composition comprises the hexaglutamated form of PMX, MTX, RTX, or LTX.
  • the administered composition comprises the pentaglutamated form of PMX.
  • the administered composition comprises the hexaglutamated form of PMX.
  • the administered composition comprises the pentaglutamated form of MTX.
  • the administered composition comprises the administered composition comprises the administered composition comprises the administered composition to the pentaglutamated form of MTX.
  • the administered composition comprises the pentaglutamated form of RTX.
  • the administered composition comprises the hexaglutamated form of RTX In an additional further embodiment, the administered composition comprises the pentaglutamated form of LTX. In an additional further embodiment, the administered composition comprises the hexaglutamated form of LTX
  • the disclosure provides a method for cancer maintenance therapy that comprises administering an effective amount of a LPA composition and/or a PLPA composition to a subject that is undergoing or has undergone cancer therapy.
  • the disclosure provides a method for treating a disorder of the immune system that comprises administering an effective amount a liposomal alpha (L-alpha or D-alpha) or D-gamma polyglutamated (e.g., pentaglutamated and hexaglutamated) antifolate composition that comprises a liposomal alpha (L-alpha or D-alpha) or D-gamma polyglutamated (e.g., pentaglutamated and hexaglutamated) antifolate containing a targeting moiety that has a specific affinity for a surface antigen on the immune cell of interest (and wherein the liposome is optionally pegylated), to a subject having or at risk of having an immune system disorder.
  • a liposomal alpha (L-alpha or D-alpha) or D-gamma polyglutamated (e.g., pentaglutamated and hexaglutamated) antifolate composition that comprises a liposomal alpha
  • the method is administered to treat an autoimmune disease. In a further embodiment the method is administered to treat rheumatoid arthritis.
  • the administered polyglutamated antifolate is a member selected from the group consisting of: polyglutamated methotrexate (MTX), polyglutamated pemetrexed (PMX),
  • the administered composition comprises pentaglutamated antifolates. In further embodiments, the administered composition comprises
  • the administered composition comprises the alpha (L-alpha or D-alpha) or D-gamma polyglutamated form of PMX, MTX, RTX, or LTX. In some embodiments, the administered composition comprises the pentaglutamated form of PMX, MTX, RTX, or LTX. In some embodiments, the administered composition comprises the hexaglutamated form of PMX, MTX, RTX, or LTX. In another further embodiment, the administered composition comprises the pentaglutamated form of MTX. In another further embodiment, the administered composition comprises the hexaglutamated form of MTX. In a further embodiment, the administered composition comprises the pentaglutamated form of PMX. In a further embodiment, the administered composition comprises the hexaglutamated form of PMX. In another further embodiment, the administered composition comprises the administered composition comprises the administered composition comprises the administered composition comprises the hexaglutamated form of PMX. In another further embodiment, the administered composition comprises the administered composition comprises the administered composition comprises the
  • the administered composition comprises the hexaglutamated form of RTX. In another further embodiment, the administered composition comprises the pentaglutamated form of LTX. In an additional further embodiment, the administered composition comprises the hexaglutamated form of LTX.
  • the disclosure also provides a method of delivering alpha (L-alpha or D- alpha) or D-gamma polyglutamated antifolate to a tumor that comprises: administering tumor to a subject having the tumor, a liposomal alpha (L-alpha or D-alpha) or D-gamma polyglutamated (e.g., pentaglutamated and hexaglutamated) antifolate (LP A) composition and/or a pegylated-LPA (PLPA) comprising a targeting moiety that has a specific binding affinity for a surface antigen on the tumor, and wherein the targeted-PLPA and/or targeted-LPA composition is delivered to the tumor in a therapeutically effective dose.
  • the disclosure provides a method of preparing a composition that comprises a liposomal alpha (L-alpha or D-alpha) or D-gamma polyglutamated antifolate composition, the method comprising: forming a mixture comprising: liposomal components; polyglutamated antifolate in solution; homogenizing the mixture to form liposomes in the solution; and processing the mixture to form liposomes containing polyglutamated antifolate.
  • compositions comprising a liposomal alpha (L-alpha or D- alpha) or D-gamma polyglutamated (e.g., pentaglutamated and hexaglutamated) antifolate (LP A) composition and/or a pegylated-LPA (PLPA) composition and optionally further comprising a targeting moiety that has a specific affinity for a surface antigen on the surface of a target cell of interest are also provided.
  • LP A liposomal alpha
  • PLPA pegylated-LPA
  • FIG. 1 depicts homeostasis of folates and cellular accumulation of antifolates. Influx and efflux (anti)folates transporters. Once inside the cell, (anti)folates undergo polyglutamation in the cytosol and mitochondria, whereas the counteracting process of hydrolysis occurs in the lysosome.
  • FIG. 1 is adapted from Gonen et al., Drug Resistance Updates 15: 183-210 (2012).
  • FIG. 2 depicts cellular folate metabolism and its compartmentalization in the cytosol and mitochondria.
  • FIG. 2 is adapted from Gonen et al., Drug Resistance Updates 15: 183-210 (2012).
  • FIGS. 3A and 3B depict the disruption of cell polarity and tissue
  • normal simple epithelium comprises a monolayer of individual cells that display a distinct apical-basal polarity. Cells are tightly packed and connected to each other by the apical junctional complexes, which separate apical and basolateral membrane domains.
  • FR-a is attached at the apical surface of cells situated away from, and out of direct contact with folates in the blood circulation.
  • cells in high-grade epithelial tumors display loss of apical-basal polarity and overall tissue disorganization, putting FR-a in direct contact with folates in blood circulation.
  • This feature of tumor tissue cells has significance for antimetabolites based therapies while minimizing associated severe and sometime life-threatening toxicities.
  • an alpha (L-alpha or D-alpha) or D-gamma polyglutamate form of antifolates in a manner that selectively targets specifically folate receptor alpha while avoiding RFCs, one could possibly increase exposure of polyglutamated forms of antifolates to tumor tissue cells only, because these tumor tissue cells overexpress folate receptor alpha while this receptor is concurrently in direct contact with blood circulation, which is not the case for normal tissues in which folate receptor alpha is expressed in a restricted manner and away from contact with circulating blood (FIG 3A and 3B).
  • FIG. 4 shows molecular mechanisms underlying antifolate resistance in cancer.
  • FIG. 4 is adapted from Gonen et al., Drug Resistance Updates 15: 183-210 (2012).
  • FIG. 5 shows chemical formula of alpha pentaglutamate and hexaglutamate pemetrexed.
  • FIG. 6 shows chemical formulae of exemplary L-gamma pentaglutamate and hexaglutamate antifolate compositions encompassed by the disclosure.
  • FIG. 7 presents the relative potency of liposomal pemetrexed L-Gamma hexaglutamate (liposomal gG6) and its mirror image (enantiomer) liposomal pemetrexed gamma-D hexaglutamate (liposomal gDG6), and liposomal pemetrexed alpha-L hexaglutamate (liposomal aG6) and its mirror image, liposomal alpha-D hexaglutamate (liposomal aDG6) relative to pemetrexed following exposure of the cancer cell lines SW620 (CRC), HT-29 (colon cancer), HI 806 (triple negative breast cancer), OAW28 (ovarian cancer), H292 (NSCLC, adenocarcinoma subtype), and H2342 (NSCLC, adenocarcinoma subtype), over 48 hours.
  • CRC cancer cell lines
  • HT-29 colon cancer
  • HI 806 trip
  • FIG. 8 presents the treatment effect on HCC1806 triple negative breast cancer cells following exposure of liposomal pemetrexed L-Gamma hexaglutamate (Lps Hexa gG6), liposomal pemetrexed alpha-L hexaglutamate (Lps Hexa aG6), liposomal pemetrexed gamma-D hexaglutamate (Lps Hexa gDG6), liposomal pemetrexed alpha-D hexaglutamate (Lps Hexa aDG6), and to pemetrexed over 48 hours.
  • Lps Hexa gG6 liposomal pemetrexed L-Gamma hexaglutamate
  • Lps Hexa aG6 liposomal pemetrexed alpha-L hexaglutamate
  • Lps Hexa aG6 liposomal pemetrexed gamma
  • FIG. 9 presents the treatment effect on H292 non-small cell lung cancer cells following exposure of liposomal pemetrexed L-Gamma hexaglutamate (Lps Hexa gG6), pemetrexed L-Gamma hexaglutamate (Lps Hexa gG6), liposomal pemetrexed alpha-L hexaglutamate (Lps Hexa aG6), liposomal pemetrexed gamma-D hexaglutamate (Lps Hexa gDG6), liposomal pemetrexed alpha-D hexaglutamate (Lps Hexa aDG6), and to pemetrexed over 48 hours.
  • Lps Hexa gG6 liposomal pemetrexed L-Gamma hexaglutamate
  • Lps Hexa gG6 pemetrexed L-Gamma hex
  • FIG. 10 presents the treatment effect on OAW28 ovarian cancer cells following exposure of liposomal pemetrexed L-Gamma hexaglutamate (Lps Hexa gG6) hexaglutamated pemetrexed isomer liposomes liposomal pemetrexed L-Gamma hexaglutamate (Lps Hexa gG6), liposomal pemetrexed alpha-L hexaglutamate (Lps Hexa aG6), liposomal pemetrexed gamma-D hexaglutamate (Lps Hexa gDG6), liposomal pemetrexed alpha-D hexaglutamate (Lps Hexa aDG6), as compared to pemetrexed over 48 hours.
  • Lps Hexa gG6 hexaglutamated pemetrexed isomer liposomes liposomal pemetrex
  • FIG. 11 presents the treatment effect on H292 non-small cell lung cancer cells following exposure of various dose levels ranging from 16 to 128 nM of liposomal pemetrexed L-Gamma hexaglutamate (Liposomal gG6), liposomal pemetrexed alpha-L hexaglutamate (Liposomal aG6), liposomal pemetrexed gamma-D hexaglutamate (Liposomal gDG6), liposomal pemetrexed alpha-D hexaglutamate (Liposomal aDG6), and pemetrexed over 48 hours.
  • the liposomal pemetrexed gG6 formulation is superior to inhibiting H292 non-small cell lung cancer cells compared to pemetrexed.
  • FIG. 12 presents the treatment effect on HCC1806 triple negative breast cancer cells following exposure of 16 nM, 32 nM, 64 nM, and 128 nM of liposomal pemetrexed L-Gamma hexaglutamate (Liposomal gG6), liposomal pemetrexed alpha-L hexaglutamate (Liposomal aG6), liposomal pemetrexed gamma-D hexaglutamate (Liposomal gDG6), liposomal pemetrexed alpha-D hexaglutamate (Liposomal aDG6), and pemetrexed over 48 hours.
  • the liposomal pemetrexed gG6 formulation is superior to pemetrexed in inhibiting HCC1806 triple negative breast cancer cells.
  • FIG. 13 presents the treatment effect on OAW28 ovarian cancer cells of liposomal pemetrexed L-Gamma hexaglutamate (Liposomal gG6), liposomal alpha-L hexaglutamate (Liposomal aG6), liposomal gamma-D hexaglutamate (Liposomal gDG6), liposomal alpha-D hexaglutamate (Liposomal aDG6), and pemetrexed following exposure over 48 hours following exposure over a range of concentrations.
  • Liposomal gG6 liposomal pemetrexed L-Gamma hexaglutamate
  • Liposomal aG6 liposomal alpha-L hexaglutamate
  • Liposomal gDG6 liposomal gamma-D hexaglutamate
  • Liposomal aDG6 liposomal alpha-D
  • pemetrexed appears to more effective than the Liposomal pemetrexed gG6 liposomal formulation, whereas the liposomal formulation at the dose of 32 nM and 64 nM has a better treatment effect than pemetrexed; at 16 nM the Liposomal pemetrexed gG6 treatment effect is similar in to pemetrexed.
  • FIG. 14 shows the toxicity of liposomal pemetrexed L-Gamma hexaglutamate (Liposomal gG6), liposomal pemetrexed alpha-L hexaglutamate (Liposomal aG6), liposomal pemetrexed gamma-D hexaglutamate (Liposomal gG6), liposomal pemetrexed alpha-D hexaglutamate (Liposomal aDG6),and pemetrexed on differentiating human neutrophils at 16 nM, 32 nM, 64 nM, 128 nM, and 264 nM.
  • the figure demonstrates that liposomal pemetrexed gG6 is significantly less toxic to differentiating human neutrophils then pemetrexed.
  • FIG. 15 shows the effect of liposomal pemetrexed L-Gamma hexaglutamate (liposomal gG6), liposomal pemetrexed alpha-L hexaglutamate (liposomal aG6), liposomal gamma-D hexaglutamate (liposomal gDG6), liposomal alpha-D hexaglutamate (liposomal aDG6), and pemetrexed on pentagulutmated and pemetrexed on neutrophils (differentiated from CD34+ cells) following exposure of various dose levels ranging from 16 to 128 nM of the corresponding agent over 48 hours.
  • FIG. 16 shows the effect of liposomal pemetrexed L-Gamma hexaglutamate (liposomal gG6), liposomal pemetrexed alpha-L hexaglutamate (liposomal aG6), liposomal pemetrexed gamma-D hexaglutamate (liposomal gDG6), liposomal
  • pemetrexed alpha-D hexaglutamate liposomal aDG6
  • pemetrexed on AML12 liver cells following exposure over 48 hours at 16 nM, 32 nM, and 64 nM, and 128 nM of the corresponding agent. Strikingly, there does not appear to be any toxicity to the AML12 liver cells following treatment with a liposomal pemetrexed gG6 at any of the liposomal agents at the dose levels tested. In contrast, pemetrexed treatment results in a reduction in the AML12 liver cell counts of approximately 40% at all doses studied.
  • FIG. 17 shows the effect of liposomal pemetrexed L-Gamma hexaglutamate (liposomal gG6), liposomal pemetrexed alpha-L hexaglutamate (liposomal aG6), liposomal pemetrexed gamma-D hexaglutamate (liposomal gDG6), liposomal
  • pemetrexed alpha-D hexaglutamate liposomal aDG6
  • pemetrexed on CCD841 colon epithelium cells following exposure over 48 hours at 16 nM, 32 nM, and 64 nM, and 128 nM, of the corresponding agent.
  • pemetrexed leads to approximately a >50% decrease in the number of CCD841 colon epithelium cells compared to approximately a 20% or less decrease in cell number after treatment with each of the liposomal agents tested.
  • the present application describes advances over prior cancer treatments and methods of delivering antifolates to cancer cells.
  • the disclosure relates to a class of antifolates that were previously unable to be exploited due to issues relating to cellular uptake and unknown toxicity.
  • polyglutamated antifolates such as, but not limited to, pemetrexed polyglutamate and Lometrexol polyglutamate.
  • the encapsulated pemetrexed polyglutamate is targeted using a targeting moiety with a specific affinity for one or more folate receptors alpha, beta and delta.
  • the encapsulated pemetrexed polyglutamate may also be untargeted.
  • Folate is a water-soluble B vitamin.
  • the primary role of folate in the body/cell is as a cofactor to various methyltransferases involved in serine, methionine, thymidine and purine biosynthesis that are critical processes involved in cell division.
  • the major function of folate is to mediate the transfer of one-carbon unit involved in nucleotide biosynthesis, the remethylation of homocysteine (Hey), and biological methylation reactions.
  • Hey homocysteine
  • folate plays an important role in DNA synthesis, stability and integrity, and repair.
  • Folate also provides the primary methyl group donor for the methylation of DNA (regulates gene expression), proteins (important post-translational modifications), and lipids (important in their synthesis, for example phosphatidylcholine).
  • antifolates were developed as a treatment for cancer with intent to block the actions of folate, thereby inhibiting cell division, DNA/RNA synthesis and repair as well as protein synthesis.
  • folate occurs in animal products and in leafy vegetables in polyglutamated forms.
  • Polyglutamates are not amenable to physiological transport. Natural polyglutamates are broken down in the jejunum primarily into monoglutamates before they are physiologically transported and taken up by the cell. Dietary folate in the form of the polyglutamates is then cleaved to the monoglutamate in the jejunum where it is absorbed. Once absorbed by enterocytes, folate is either polyglutamated and retained within the cells or released into portal circulation for various compartments for metabolism, storage, or enterohepatic recirculation. Folates enter plasma and are rapidly cleared by entering hepatocytes and other cells.
  • the liver takes up the majority of folate that enters portal circulation, while the remaining folate passes through the liver, enters the general circulation and is taken up by other tissues where it is converted into its polyglutamate form for intracellular storage.
  • the liver is the primary reservoir of folates. Surgical biliary drainage can result in a reduction in serum folate within six hours, whereas dietary restriction does not produce a comparable fall for three weeks, presumably because total body stores of folate are estimated to be between 500 to 20,000 meg. This observation indicates that there is a large enterohepatic circulation of folate.
  • Monoglutamates are the only circulating forms of folates in the blood and the only form of folate that is transported across the cell membrane. Once absorbed by enterocytes, folate is either polyglutamated and retained within the cells or released into portal circulation for various compartments for metabolism, storage, or enterohepatic recirculation. Once monoglutamates are taken up into cells, intracellular folates exist primarily as polyglutamates, a form that is biologically active as a cofactor to various methyltransferases involved in serine, methionine, thymidine and purine biosynthesis that are critical processes involved in cell division.
  • Polyglutamation involves the addition of glutamate group(s) in gamma linkage to the end carboxyl group of the neighboring folyl glutamate by the enzyme folylpolyglutamate synthetase (FPGS) using ATP as its energy source.
  • FPGS folylpolyglutamate synthetase
  • the alpha and gamma forms of a polyglutamated drug, such as pemetrexed pentaglutamate have the same elemental composition and molecular mass but different structures.
  • the glutamic acid residues are linked via amide bonds, but the spacing between these amide bonds differs.
  • Polyglutamation refers to the addition of glutamic acid residue(s) to a molecule (such as an antifolate) so that the resultant molecule after the polyglutamation has more than one glutamic acid residue.
  • the literature has used multiple names to refer to the glutamic acid residue such as glutamate, glutamyl group, glutamyl radical, and the like.
  • Each of the glutamic acid residues (glutamyl groups) may independently be in the L-form or the D-form.
  • pemetrexed whose chemical name is "N-[4-2-(2-Amino-4,7- dihydro-4-oxo-lH-pyrrolo[2,3-d]pyrimidin-5-yl)ethyl]benzoyl]-l-glutamic acid" already has one glutamyl group (monoglutamated).
  • glutamic acid residue(s) to pemetrexed as described herein results in polyglutamated pemetrexed.
  • pemetrexed For example, the addition of 5 more glutamic acid residue to pemetrexed would lead to a total of 6 glutamyl groups (one from pemetrexed and 5 additional glutamyl groups added) and is referred to in this document as hexaglutamated pemetrexed or pemetrexed
  • hexaglutamate In the literature this may also be referred to as pentaglutamated pemetrexed or pemetrexed pentaglutamate.
  • Gamma polyglutamation refers to the addition of glutamic acid residue(s) to a molecule as described above, where the peptide bonds are between the amino group of glutamic acid and the carboxyl group at gamma carbon of the glutamic acid side chain.
  • Alpha polyglutamation refers to the addition of glutamic acid residue(s) to a molecule, as described above, where the peptide bonds are between the amino group of glutamic acid and the carboxyl group at alpha carbon of the glutamic acid side chain.
  • a single molecule may be formed by gamma polyglutamation only, alpha polyglutamation only, or a combination of gamma polyglutamation and alpha polyglutamation.
  • Antifolates were developed more than 70 years ago as "folic acid mimic molecule" cytotoxic agents. The rationale was to design a class of molecules that would counter the action of folic acid in fast replicating cells such as cancer cells, taking advantage of physiological folate transport mechanism and their facilitative intracellular mode of action for DNA replication during the cell division. Specifically, antifolates were designed to mimic folic acid in its systemic transport, physiologic cell uptake (e.g., via reduced folate carriers (RFCs) and proton-coupled folate transporters (PCFTs)) and intracellular processing. Antifolates act specifically during DNA and RNA synthesis, exerting a cytotoxic effect during the S-phase of the cell cycle. As a result, they have a greater toxic effect on rapidly dividing cells such as malignant and myeloid cells.
  • ROCs reduced folate carriers
  • PCFTs proton-coupled folate transporters
  • RFCs are saturable anion dependent cell membrane carriers with a greater affinity for reduced folates and hydrophilic antifolates such as MTX or PMX and affinity for PMX that is 2-fold higher than that for MTX. They are members of the superfamily of solute carriers, and utilize the high transmembrane anion gradient, particularly the organic phosphate gradient which is modulated by energy status of the cell in order to achieve uphill folate transport into the cell.
  • Folate receptors alpha, beta and delta are high-affinity folate-binding proteins that are anchored in the cell membrane by the
  • FRs glycosylphosphatidylinositol (GPI) anchor domain.
  • FRs have an especially high affinity for FA. They transport folates into cells via an endocytosis mechanism. Once in the cytoplasm, when the vesicle acidifies to a pH of 6.0-6.5, folate is released from the receptor and is exported from the endosome by a mechanism that has been proposed to be mediated in part by PCFT.
  • FR-a has a higher affinity for its preferred substrates than RFC
  • its folate transport into the cell requires a series of steps such as binding, invagination, vesicle formation and translocation, acidification, and export of substrate from the vesicle into cytoplasm. Because of these multiple steps required for transport into the cell, the rate of FR-mediated folate transport is 1% of the rate mediated by RFC.
  • the proton-coupled folate transporter is a folate-H+symporter that functions most efficiently in an acidic extracellular environment that is, among others, characteristic of hypoxic environment.
  • the important difference between RFC and PCFT is the optimum pH that impacts their affinities for transport substrates.
  • the transport of antifolates is mediated predominantly by RFC as RFC activity is optimal and the activity of PCFT is minimized.
  • PCFT activity is more prominent as pH is decreased.
  • PCFT may play a role, in folate receptor-mediated endocytosis.
  • ATP -Binding-Cassette Transporters are low-affinity, high capacity ATP-dependent efflux pumps of folates and antifolates. These include the multi drug-resistance-associated proteins, MRP1-MRP5 and the breast-cancer resistance protein, BCRP. All of these drug resistance efflux pumps are not just involved in pumping antifolates out of the cells, but have also been shown to pump out of cells other classes of drugs.
  • Intracellular folate is converted to polyglutamates by FPGS, whereas GGH removes the terminal glutamates, thereby facilitating the export of folate out of the cell back to extra-cellular circulation by the ATP -Binding-Cassette Transporters, sometime also referred to as folate efflux pumps.
  • ATP -Binding-Cassette Transporters sometime also referred to as folate efflux pumps.
  • polyglutamated folates are thought to be better retained in cells because they are poor substrates of the ATP -binding cassette transporters.
  • polyglutamated folates are believed to be better substrates for intracellular folate dependent enzymes compared to monoglutamates.
  • antifolates such as MTX, PMX are RTX are believed to be retained in the tumor and normal cells by FPGS-induced polyglutamation and are exported from cells, after hydrolysis to monoglutamates, by GGH.
  • polyglutamated antifolates are retained in cells longer, thereby increasing their cytotoxicity by extending the length of exposure.
  • Polyglutamated antifolates generally have a higher affinity for and as a result inhibit their target folate- dependent enzymes in thymidylate and purine biosynthesis to a greater extent than monoglutamate forms.
  • FPGS and GGH are considered to be important enzymes for the maintenance of intracellular homeostasis of folates and antifolates for optimal folate-dependent one-carbon transfer reactions and antifolate- induced cytotoxic effects.
  • folates and antifolates are polyglutamated by FPGS into
  • polyglutamates This process is required for biological activity. For example, polyglutamation facilitates retention (increases intracellular concentrations) and increases affinity for folate-dependent enzymes (including thymidylate synthase).
  • the ability of cells to form polyglutamates also enhances the cytotoxic action of an antifolate, thereby making antifolates very effective cytotoxic agents.
  • polyglutamated forms of antifolates to assess their effectiveness in treating cancerous cells. Because polyglutamated forms of antifolates are not taken up by either normal or cancer cells (as discussed in greater detail below), the applicant postulated that if such polyglutamated forms could be directly delivered to cancer cells, the toxicity of the antifolates could be improved, with reduced undesirable toxicities to normal cells that may occur as a result of efflux of excess antifolate in the cancer cells.
  • excess amounts of antifolate present in the cancer cells may be returned to the circulatory system via high capacity ATP-dependent efflux pumps of folates and antifolates.
  • the efflux of excess of the delivered antifolate can be returned to the circulatory system and be taken up by normal cells, resulting in undesirable toxicities.
  • polyglutamates especially polyglutamates
  • pentaglutamates and higher order glutamates can permit a cell to more efficiently retain its folate pools.
  • polyglutamates such as pentaglutamates and hexaglutamated have no known cross cell membrane transport substrates.
  • the present disclosure describes advanced and improved techniques to deliver to cancer cells a different class of antifolates (e.g., polyglutamates) which were previously not able to be taken up by cancer cells. Because of the lack of cross cell membrane transport, the polyglutamates delivered to the cancer cells are effectively retained within the cancer cells. This reduces and/or eliminates toxicities associated with, for example, non-polyglutamated antifolates, such as monoglutamated antifolates because the polyglutamates are not returned to the circulatory system. Indeed, even if they were, they would not be picked up by healthy cells.
  • non-polyglutamated antifolates such as monoglutamated antifolates because the polyglutamates are not returned to the circulatory system. Indeed, even if they were, they would not be picked up by healthy cells.
  • the active form of many cytotoxic agents, and antifolates in particular is in the alpha (L-alpha or D-alpha) or D-gamma polyglutamated form and therefore, the delivery of the previously undeliverable polyglutamated form of the antifolate means that the drug is immediately active.
  • some solid tumors are low or deficient in FPGS activity and polyglutamation level. This means that tumors that are low in FPGS activity are more resistant to chemotherapy via non-polyglutamated drugs because the drugs, after entry into the cells, are still dependent on the low endogenous FPGS activity for activation.
  • non-polyglutamated drugs such as, non-polyglutamated pemetrexed
  • have limited retention in cells because they can be actively transported out of the cell.
  • the transport of non-polyglutamated drugs is in itself a two-fold problem.
  • non-polyglutamated drug if it is transported out of the cell, it can no longer act within the cancer cell for treatment.
  • cytotoxic agents such as antifolates that are located outside of the cell can reenter other cells, including normal cells, and cause undesirable toxicity to normal cells. It is possible that upon entry into the cell, certain cellular processes might function to reduce the alpha (L-alpha or D-alpha) or D- gamma polyglutamated antifolates provided herein to monoglutamates.
  • alpha L-alpha or D-alpha
  • D-gamma polyglutamated antifolates provided herein to monoglutamates.
  • current testing suggests that the toxicity and activity of the provided polyglutamated antifolates kill the cells before such reduction occurs.
  • the administration of the alpha (L-alpha or D-alpha) or D- gamma polyglutamated antifolate drug may be performed only for a limited time, therefore further reducing potential undesirable toxicity to normal tissue.
  • a reduced administration time also improves patient comfort and reduces cost since the length of administration in a clinical setting can be
  • the retention of the alpha (L-alpha or D-alpha) or D-gamma polyglutamated antifolate within for example, tumor cells means that the tumor cells would be less likely to recover from the treatement, even after the drug is removed from the extracellular milieu (e.g., intravenous administration is stopped).
  • the activity of the disclosed liposomal alpha (L-alpha or D-alpha) or D-gamma polyglutamated antifolates is undiminished in tumors even if the tumor is FPGS deficient. That is because there is no reliance of FPGS to activate the drug.
  • the untargeted and targeted pegylated liposomal alpha (L-alpha or D-alpha) or D-gamma polyglutamated antifolate has a higher therapeutic index than a non polyglutamated antifolate that is delivered in the same method. That is, the inventors expect the drug to have minimal/reduced toxicity and for patients to tolerate higher dosages of the drug with lower side effects.
  • the benefits described above are absent in an administered drug that is not polyglutamated.
  • polyglutamated antifolates that are encompassed by the compositions and methods of the disclosure include polyglutamated methotrexate (MTX), polyglutamated pemetrexed (PMX), polyglutamated lometrexol (LTX), polyglutamated AG2034, polyglutamated raltitrexed (RTX), polyglutamated piritrexim, polyglutamated pralatrexate,
  • the alpha (L-alpha or D-alpha) or D-gamma pentaglutamated antifolate is a member selected from the group consisting of:
  • MTX methotrexate
  • PMX pentaglutamated pemetrexed
  • LTX lometrexol
  • RTX pentaglutamated raltitrexed
  • piritrexim pentaglutamated pralatrexate
  • the alpha (L-alpha or D-alpha) or D-gamma hexaglutamated antifolate is a member selected from the group consisting of:
  • MTX methotrexate
  • PMX hexaglutamated pemetrexed
  • LTX hexaglutamated lometrexol
  • AG203 hexaglutamated AG2034
  • RTX hexaglutamated raltitrexed
  • hexaglutamated piritrexim hexaglutamated piritrexim
  • hexaglutamated pralatrexate hexaglutamated AG2034, hexaglutamated GW1843, hexaglutamated aminopterin, and hexaglutamated LY309887.
  • the polyglutamated antifolate compositions e.g., polyglutamates and delivery vehicles such as liposomes containing the polyglutamates
  • the term isolated refers to a composition which is in a form not found in nature. Isolated polyglutamated antifolate compositions include those which have been purified to a degree that they are no longer in a form in which they are found in nature. In some embodiments, a polyglutamated antifolate compositions composition which is isolated is substantially pure.
  • Isolated compositions will be free or substantially free of material with which they are naturally associated such as other cellular components such as proteins and nucleic acids with which they may potentially be found in nature, or the environment in which they are prepared (e.g., cell culture).
  • the polyglutamated antifolate compositions may be formulated with diluents or adjuvants and still for practical purposes be isolated - for example, the polyglutamated antifolate compositions will normally be mixed with pharmaceutically acceptable carriers or diluents when used in diagnosis or therapy.
  • the isolated polyglutamated antifolate compositions e.g., polyglutamates and delivery vehicles such as liposomes containing the polyglutamates contain at less than 1% or less than 0.1% DNA or proteins.
  • greater than 70%, 80% or 90% of the polyglutamated antifolate in a provided liposomal composition is pentaglutamated.
  • greater than 70%, 80% or 90% of the polyglutamated antifolate in a provided composition is pentaglutamated. In some embodiments, greater than 70%, 80% or 90% of the polyglutamated antifolate in a liposomal composition is pentaglutamated. In some embodiments, greater than 70%, 80% or 90% of the polyglutamated antifolate in a provided composition is hexaglutamated. In some embodiments, greater than 70%, 80% or 90%) of the polyglutamated antifolate in a liposomal composition is hexaglutamated. In some embodiments, greater than 70%, 80% or 90% of the polyglutamated antifolate in the composition has 5-10 or > 4 glutamyl groups. In some embodiments, greater than 70%), 80%) or 90%) of the polyglutamated antifolate in a liposomal composition has 5-10 or > 4 glutamyl groups.
  • the alpha (L-alpha or D-alpha) or D-gamma polyglutamated antifolate compositions are in an aqueous solution.
  • the polyglutamated antifolate is at a concentration of lOOng/ml to 700 mg/ml.
  • the polyglutamated antifolate is at a concentration of greater than lOOng/ml, 250 ng/ml, 500 ng/ml, 750 ng/ml, 1 ug/ml, 100 ug/ml, 250 ug/ml, 500 ug/ml, 750 ug/ml, 1 mg/ml, 100 mg/ml, 250 mg/ml, or 500 mg/ml.
  • the concentration of the liposomes containing the polyglutamated antifolates is at a concentration of lOOng/ml to 1 mg/ml.
  • Pemetrexed for example, is a multitargeted antifolate that inhibits at least three enzymes involved in folate metabolism and purine and pyrimidine synthesis. These enzymes are thymidylate synthase (TS), dihydrofolate reductase (DHFR), and glycinamide ribonucleotide formyltransferase (GARFT) (see, FIG. 2). Pemetrexed is approved and remains an important treatment for mesothelioma and non-small-cell lung cancers.
  • TS thymidylate synthase
  • DHFR dihydrofolate reductase
  • GARFT glycinamide ribonucleotide formyltransferase
  • pemetrexed is approved in combination with cisplatin for the therapy of malignant mesothelioma, and for the initial as well as maintenance treatment of patients with non-small-cell lung cancers.
  • Pemetrexed has demonstrated equivalent efficacy to docetaxel, but with significantly less toxicity, in second-line treatment of non-small-cell lung cancer.
  • the most common and serious toxicities of pemetrexed— myelosuppresion and mucositis— have been significantly ameliorated by folic acid and vitamin B 12 supplementation, but undesirable toxicities remain.
  • the alpha (L-alpha or D- alpha) or D-gamma polyglutamated antifolate is polyglutamated pemetrexed (PMX). In further embodiments, the alpha or D-gamma polyglutamated antifolate is
  • the alpha or D-gamma polyglutamated antifolate is hexaglutamated PMX.
  • the alpha (L-alpha or D-alpha) or D-gamma polyglutamated antifolate is polyglutamated pemetrexed (PMX).
  • the alpha or D-gamma polyglutamated antifolate is pentaglutamated PMX.
  • the alpha or D-gamma polyglutamated antifolate is hexaglutamated PMX.
  • the alpha or D-gamma polyglutamated antifolate is polyglutamated raltitrexed (RTX). In further embodiments, the alpha or D- gamma polyglutamated antifolate is pentaglutamated RTX. In further embodiments, the alpha or D-gamma polyglutamated antifolate is hexaglutamated RTX.
  • Lometrexol was the first potent antifolate inhibitory to purine synthesis due to its direct suppression of glycinamide ribonucleotide transferase (GARFT) activity.
  • GARFT glycinamide ribonucleotide transferase
  • the alpha (L-alpha or D-alpha) or D-gamma polyglutamated antifolate is polyglutamated lometrexol (LTX).
  • the alpha or D- gamma polyglutamated antifolate is pentaglutamated LTX).
  • the alpha or D-gamma polyglutamated antifolate is hexaglutamated LTX.
  • the factors described herein are also at the core of the mechanisms of resistance to antifolates in general and those whose antitumor activity is potentiated by polyglutamation such as methotrexate, pemetrexed, lometrexol, and raltitrexed.
  • the disclosed polyglutamated antifolates provide a strategy for overcoming the pharmacological challenges associated with the dose limiting toxicities, associated with antifolate drugs.
  • the provided methods deliver to tumor cells a previously undeliverable (due to lack of transport mechanisms) polyglutamate form of the antifolate payload while (1) minimizing/reducing exposure to normal tissue cells, (2)
  • the alpha (L-alpha or D-alpha) or D-gamma polyglutamated chemical entities provided herein achieve many advantages over counterpart antifolates that are not delivered to cells in a polyglutamated form.
  • the alpha or D-gamma polyglutamated antifolates are administered as a bolus that bypass the FPGS-induced polyglutamation activity required for antifolates such as PMX, MTX, RTX, and LTX to have increased activity (via increased binding affinity for folate-dependent enzymes) and cellular retention.
  • retention of higher polyglutamates e.g., drugs containing 4, 5, or more than 5 glutamate groups
  • retention of higher polyglutamates is the direct function of their chain length.
  • significant fractions of unbound MTX-Glu4 and most of MTX-Glu5 remain in the cells for at least 24 hours after removal of extracellular drug and continue to exert an inhibitory effect on DHFR, DNA synthesis, and cell viability.
  • the new chemical entities are designed not only to increase and/or maximize tumor intracellular concentration of polyglutamated form of antifolates by carefully leveraging cell and molecular biology of the folate pathways, but also by exploiting the differential cell polarity between tumor and normal tissue, where a cancer specific morphology has been unappreciated as useful to the goal to mitigating the clinical and pharmacological challenges associated with the use of antifolates for cancer treatment. Furthermore, the new chemical entities will minimize tumor cell resistance treatment that is mediated by cell efflux pumps.
  • polyglutamated antifolate composition may include a pegylated liposome including an entrapped and/or encapsulated alpha (L-alpha or D-alpha) or D-gamma polyglutamated antifolate; and a targeting moiety comprising an amino acid chain (e.g., an antibody or antibody fragment), the amino acid chain comprising a plurality of amino acids, the targeting moiety having a specific affinity for at least one type of folate receptor, the targeting moiety attached to one or both of a PEG and an exterior of the liposome.
  • a targeting moiety comprising an amino acid chain (e.g., an antibody or antibody fragment), the amino acid chain comprising a plurality of amino acids, the targeting moiety having a specific affinity for at least one type of folate receptor, the targeting moiety attached to one or both of a PEG and an exterior of the liposome.
  • the liposome-encapsulated alpha or D-gamma polyglutamated antifolate may be a pentaglutamate or hexaglutamate form of pemetrexed or pentaglutamate or hexaglutamate form of any suitable antifolate.
  • the targeted, optionally pegylated, liposomal polyglutamated antifolate composition includes a pegylated liposome including an entrapped and/or encapsulated alpha (L-alpha or D-alpha) or D-gamma polyglutamated antifolate; and a targeting moiety comprising an amino acid chain (e.g., an antibody or antibody fragment), the amino acid chain comprising a plurality of amino acids, the targeting moiety having a specific affinity for at least one type of folate receptor.
  • a targeting moiety comprising an amino acid chain (e.g., an antibody or antibody fragment), the amino acid chain comprising a plurality of amino acids, the targeting moiety having a specific affinity for at least one type of folate receptor.
  • the specific affinity may be defined, for example, and without limitation, to include an equilibrium dissociation constant (Kd) in a range of 0.5xl0 "10 to lOxlO "6 moles [0.05 nanoMole to 10 ⁇ ] for at least one type of folate receptor, the targeting moiety attached to one or both of a PEG and an exterior of the liposome.
  • Kd equilibrium dissociation constant
  • the targeted, optionally pegylated, liposomal composition comprisses a pegylated liposome including an entrapped (e.g.,
  • a targeting moiety comprising an amino acid chain (e.g., an antibody or antibody fragment), the amino acid chain comprising a plurality of amino acids, the targeting moiety having a specific affinity for at least one type of folate receptor.
  • the specific affinity of the targeting moiety is an equilibrium dissociation constant (Kd) in a range of 0.5xl0 "10 to lOxlO "6 moles for at least one type of folate receptor.
  • the targeting moiety is attached to one or both of a PEG and an exterior of the liposome.
  • the new chemical entities contemplated and disclosed herein are designed to address these fundamental limitations. These limitations include the following.
  • the first limitation is toxicity to normal tissue cells; this toxicity is due to cell uptake of the monoglutamate form, via RFCs or PCFTs for example, and its subsequent intracellular conversion by FPGS into the alpha (L-alpha or D-alpha) or D-gamma polyglutamated forms with enhanced cellular cytotoxicity coupled with prolonged cell retention in normal tissue cells.
  • the second limitation is delivering adequate amount of the most active
  • polyglutamate form of the drug because such compound cannot cross the cell membrane. Instead, its intracellular availability depends on the ability of the cell to polyglutamate the monoglutamate form of the drug transported from extracellular environment.
  • the third limitation is retaining within the tumor cells adequate levels of the most cytotoxic forms such as the pentaglutamate or hexaglutamate forms of the antifolate.
  • the polyglumated antifolate new chemical entities contemplated and disclosed herein do not suffer from the above drawbacks and limitations, and are designed to address the three limitations described herein. Indeed, the new chemical entities will minimize the pharmacological challenges associated with systemic transport, cell uptake and intra tumor cell accumulation of the active form of the drug.
  • the new chemical entities of the present disclosure preferentially target tumor cells for exposure to polyglutamated forms (e.g., pentaglutamated and hexaglutamated) of antifolate and/or minimizes exposure of such antifolate drug cocktail to normal cells, especially the high turnover (e.g., fast replicating) normal cells in the bone marrow and in the epithelial lining of the gastrointestinal tract.
  • the disclosure provides a composition comprising an alpha (L-alpha or D-alpha) or D-gamma polyglutamated antifolate.
  • the composition comprises an alpha (L-alpha or D-alpha) or D-gamma pentaglutamated antifolate. In further embodiments, the composition comprises an alpha (L-alpha or D-alpha) or D-gamma hexaglutamated antifolate.
  • the polyglutamated antifolate contains 1, 2, 3, 4, 5, 6,
  • the polyglutamated antifolate contains 1, 2, 3, 4, 5, 6, 7, 8, 9, or 1-10 L-alpha peptide linkages. In some embodiments, the polyglutamated antifolate contains 1 1, 2, 3, 4, 5, 6, 7, 8, 9, or 1-10 D- alpha peptide linkages. In some embodiments, the polyglutamated antifolate contains 1, 2, 3, 4, 5, 6, 7, 8, 9, or 1-10, or 1-10 D-gamma peptide linkages. In some embodiments, the polyglutamated antifolate further contains 0, 1, 2, 3, 4, 5, 6, 8, 8, 9, or 1-10 L-gamma peptide linkages in addition to one or more of the above-described linkages. For example, in some embodiments, the polyglutamated antifolate contains 1, 2, 3, 4, 5, 6, 7,
  • the polyglutamated antifolate contains 1, 2, 3, 4, 5, 6, 7, 8, 9, or 1-10 L- alpha peptide linkages and 1 1, 2, 3, 4, 5, 6, 7, 8, 9, or 1-10 L-gamma peptide linkages.
  • the polyglutamated antifolate contains 1, 2, 3, 4, 5, 6, 7, 8, 9, or 1-10 D- alpha peptide linkages and 1, 2, 3, 4, 5, 6, 7, 8, 9, or 1-10 L-gamma peptide linkages.
  • the polyglutamated antifolate contains 1, 2, 3, 4, 5, 6, 7, 8, 9, or 1-10 D-gamma peptide linkages and 1, 2, 3, 4, 5, 6, or 1-10 L-gamma peptide linkages. In additional embodiments, the polyglutamated antifolate contains 1, 2, 3, 4, 5, 6, 7, 8, 9, or 1-10 L- alpha peptide linkages and 1, 2, 3, 4, 5, 6, 7, 8, 9, or 1-10 D-alpha peptide linkages. In some embodiments, the polyglutamated antifolate contains 1, 2, 3, 4, 5 or 1-10 L-alpha peptide linkages and 1, 2, 3, 4, 5, 6, 7, 8, 9, or 1-10 D-gamma peptide linkages. In some embodiments, the polyglutamated antifolate contains 1, 2, 3, 4, 5, 6, 7, 8, 9, or 1-10 D-alpha peptide linkages and 1, 2, 3, 4, 5, 6, 7, 8, 9, or 1-10 D-gamma peptide linkages.
  • the alpha (L-alpha or D-alpha) or D-gamma polyglutamated antifolate is a member selected from the group consisting of:
  • MTX methotrexate
  • PMX polyglutamated pemetrexed
  • polyglutamated lometrexol LTX
  • polyglutamated AG2034 polyglutamated raltitrexed
  • polyglutamated piritrexim polyglutamated pralatrexate
  • polyglutamated AG2034 polyglutamated GW1843, polyglutamated aminopterin, and polyglutamated LY309887.
  • the alpha or D-gamma polyglutamated member is
  • the alpha or D-gamma polyglutamated member is hexaglutamated
  • the composition comprises alpha or D-gamma
  • composition comprises alpha or D-gamma pentaglutamated PMX, MTX, RTX, or LTX.
  • the composition comprises alpha or D-gamma
  • composition comprises alpha or D-gamma hexaglutamated PMX, MTX, RTX, or LTX.
  • the composition comprises alpha or D-gamma
  • composition comprises alpha or D- gamma pentaglutamated PMX.
  • the composition comprises alpha or D-gamma
  • composition comprises alpha or D- gamma hexaglutamated PMX.
  • composition comprises alpha or D-gamma polyglutamated MTX.
  • composition comprises alpha or D- gamma pentaglutamated MTX.
  • the composition comprises alpha or D-gamma polyglutamated MTX. In a further embodiment the composition comprises alpha or D- gamma hexaglutamated MTX.
  • the composition comprises alpha or D-gamma polyglutamated RTX. In a further embodiment the composition comprises alpha or D- gamma pentaglutamated RTX.
  • the composition comprises alpha or D-gamma polyglutamated RTX. In a further embodiment the composition comprises alpha or D- gamma hexagglutamated RTX.
  • the composition comprises alpha or D-gamma polyglutamated LTX. In a further embodiment the composition comprises alpha or D- gamma pentaglutamated LTX.
  • alpha or D-gamma the alpha or D-gamma
  • polyglutamated member is pentaglutamated.
  • the alpha or D- gamma polyglutamated member is hexaglutamated
  • the composition comprises alpha or D-gamma polyglutamated PMX, MTX, RTX, or LTX. In a further embodiment the composition comprises alpha or D-gamma pentaglutamated PMX, MTX, RTX, or LTX. In a further embodiment the composition comprises alpha or D-gamma hexaglutamated PMX, MTX, RTX, or LTX.
  • the composition comprises alpha or D-gamma polyglutamated PMX. In a further embodiment the composition comprises alpha or D- gamma pentaglutamated PMX. In a further embodiment the composition comprises alpha or D-gamma hexaglutamated PMX. [0148] In another embodiment, the composition comprises alpha or D-gamma polyglutamated MTX. In a further embodiment the composition comprises alpha or D- gamma pentaglutamated MTX. In a further embodiment the composition comprises alpha or D-gamma hexaglutamated MTX.
  • the composition comprises alpha or D-gamma polyglutamated RTX. In a further embodiment the composition comprises alpha or D- gamma pentaglutamated RTX. In a further embodiment the composition comprises alpha or D-gamma hexaglutamated RTX.
  • the composition comprises alpha or D-gamma polyglutamated LTX. In a further embodiment the composition comprises alpha or D- gamma pentaglutamated LTX. In a further embodiment the composition comprises alpha or D-gamma hexaglutamated LTX.
  • the composition comprises L-alpha polyglutamated PMX, MTX, RTX, or LTX. In a further embodiment the composition comprises L-alpha pentaglutamated PMX, MTX, RTX, or LTX. In a further embodiment the composition comprises L-alpha hexaglutamated PMX, MTX, RTX, or LTX.
  • the composition comprises L-alpha polyglutamated PMX. In a further embodiment the composition comprises L-alpha pentaglutamated PMX. In a further embodiment the composition comprises L-alpha hexaglutamated PMX.
  • the composition comprises L-alpha polyglutamated MTX. In a further embodiment the composition comprises L-alpha pentaglutamated MTX. In a further embodiment the composition comprises L-alpha hexaglutamated MTX.
  • the composition comprises L-alpha polyglutamated RTX. In a further embodiment the composition comprises L-alpha pentaglutamated RTX. In a further embodiment the composition comprises L-alpha hexaglutamated RTX.
  • composition comprises L-alpha
  • composition comprises L-alpha pentaglutamated LTX. In a further embodiment the composition comprises L-alpha hexaglutamated LTX [0156] In one embodiment, the composition comprises D-alpha polyglutamated PMX, MTX, RTX, or LTX. In a further embodiment the composition comprises D-alpha pentaglutamated PMX, MTX, RTX, or LTX. In a further embodiment the composition comprises D-alpha hexaglutamated PMX, MTX, RTX, or LTX.
  • the composition comprises D-alpha polyglutamated PMX. In a further embodiment the composition comprises D-alpha pentaglutamated PMX. In a further embodiment the composition comprises D-alpha hexaglutamated PMX.
  • the composition comprises D-alpha polyglutamated MTX. In a further embodiment the composition comprises D-alpha pentaglutamated MTX. In a further embodiment the composition comprises D-alpha hexaglutamated MTX.
  • the composition comprises D-alpha polyglutamated RTX. In a further embodiment the composition comprises D-alpha pentaglutamated RTX. In a further embodiment the composition comprises D-alpha hexaglutamated RTX.
  • composition comprises D-alpha
  • composition comprises D-alpha pentaglutamated LTX. In a further embodiment the composition comprises D-alpha hexaglutamated LTX.
  • the composition comprises D-gamma polyglutamated PMX, MTX, RTX, or LTX. In a further embodiment the composition comprises D- gamma pentaglutamated PMX, MTX, RTX, or LTX. In a further embodiment the composition comprises D-gamma hexaglutamated PMX, MTX, RTX, or LTX
  • the composition comprises D-gamma polyglutamated PMX. In a further embodiment the composition comprises D-gamma pentaglutamated PMX. In a further embodiment the composition comprises D-gamma hexaglutamated PMX.
  • the composition comprises D-gamma polyglutamated MTX. In a further embodiment the composition comprises D-gamma pentaglutamated MTX. In a further embodiment the composition comprises D-gamma hexaglutamated MTX. [0164] In another embodiment, the composition comprises D-gamma polyglutamated RTX. In a further embodiment the composition comprises D-gamma pentaglutamated RTX. In a further embodiment the composition comprises D-gamma hexaglutamated RTX.
  • the composition comprises D-gamma polyglutamated LTX. In a further embodiment the composition comprises D-gamma pentaglutamated LTX. In a further embodiment the composition comprises D-gamma hexaglutamated LTX.
  • the disclosure provides a liposomal alpha (L-alpha or D-alpha) or D-gamma polyglutamated antifolate composition
  • a liposomal alpha (L-alpha or D-alpha) or D-gamma polyglutamated antifolate composition comprising a
  • the liposome is optionally pegylated (PLPA).
  • the PLPA composition comprises a pentaglutamated antifolate.
  • the PLPA composition comprises a hexaglutamated antifolate.
  • the PLPA liposome is anionic or neutral.
  • the PLPA liposome is cationic.
  • the PLPA composition comprises at least 10% liposome entrapped comprises alpha or D-gamma polyglutamated antifolate.
  • the PLPA liposomes have a diameter in the range of 20 nm to 200 nm. In further embodiments, the liposomes have a diameter in the range of 80 nm to 120 nm.
  • the PLPA comprises an alpha (L-alpha or D-alpha) or D-gamma polyglutamated antifolate selected from the group consisting of: polyglutamated MTX, polyglutamated PMX, polyglutamated LTX, polyglutamated AG2034, polyglutamated RTX, polyglutamated piritrexim, polyglutamated pralatrexate, polyglutamated AG2034, polyglutamated GW1843, polyglutamated aminopterin, and polyglutamated LY309887.
  • the alpha or D-gamma selected from the group consisting of: polyglutamated MTX, polyglutamated PMX, polyglutamated LTX, polyglutamated AG2034, polyglutamated RTX, polyglutamated piritrexim, polyglutamated pralatrexate, polyglutamated AG2034, polyglutamated GW1843, polyglutamated aminopterin, and polyglutamated LY309887.
  • polyglutamated antifolate is pentaglutamated.
  • the alpha or D- gamma polyglutamated antifolate is hexaglutamated.
  • the PLPA comprises an alpha (L-alpha or D-alpha) or D- gamma polyglutamated PMX, MTX, RTX, or LTX. In a further embodiment the PLPA comprises alpha or D-gamma pentaglutamated PMX, MTX, RTX, or LTX. In a further embodiment the PLPA comprises alpha or D-gamma hexaglutamated PMX, MTX, RTX, or LTX.
  • the PLPA comprises alpha (L-alpha or D-alpha) or D- gamma polyglutamated PMX. In a further embodiment the PLPA comprises alpha or D- gamma pentaglutamated PMX. In a further embodiment the PLPA comprises alpha or D- gamma hexaglutamated PMX.
  • the PLPA comprises alpha (L-alpha or D-alpha) or D- gamma polyglutamated MTX. In a further embodiment the PLPA comprises alpha or D- gamma pentaglutamated MTX. In a further embodiment the PLPA comprises alpha or D- gamma hexaglutamated MTX.
  • the PLPA comprises alpha (L-alpha or D-alpha) or D- gamma polyglutamated RTX. In a further embodiment the PLPA comprises alpha or D- gamma pentaglutamated RTX. In a further embodiment the PLPA comprises alpha or D- gamma hexaglutamated RTX.
  • the PLPA comprises alpha (L-alpha or D-alpha) or D-gamma polyglutamated LTX. In a further embodiment the PLPA comprises alpha or D-gamma pentaglutamated LTX. In a further embodiment the PLPA comprises alpha or D-gamma hexaglutamated LTX.
  • the PLPA comprises an alpha (L-alpha or D-alpha) polyglutamated antifolate selected from the group consisting of: polyglutamated MTX, polyglutamated PMX, polyglutamated LTX, polyglutamated AG2034,
  • polyglutamated RTX polyglutamated piritrexim, polyglutamated pralatrexate, polyglutamated AG2034, polyglutamated GW1843, polyglutamated aminopterin, and polyglutamated LY309887.
  • the alpha polyglutamated antifolate is pentaglutamated.
  • the alpha polyglutamated antifolate is hexaglutamated.
  • the PLPA comprises an alpha (L-alpha or D-alpha) polyglutamated PMX, MTX, RTX, or LTX. In a further embodiment the PLPA comprises alpha pentaglutamated PMX, MTX, RTX, or LTX. In a further embodiment the PLPA comprises alpha hexaglutamated PMX, MTX, RTX, or LTX [0175] In one embodiment, the PLPA comprises alpha (L-alpha or D-alpha) polyglutamated PMX. In a further embodiment the PLPA comprises alpha
  • the PLPA comprises alpha
  • the PLPA comprises alpha (L-alpha or D-alpha) polyglutamated MTX. In a further embodiment the PLPA comprises alpha
  • the PLPA comprises alpha
  • the PLPA comprises alpha (L-alpha or D-alpha) polyglutamated RTX. In a further embodiment the PLPA comprises alpha
  • the PLPA comprises alpha
  • the PLPA comprises alpha (L-alpha or D-alpha) polyglutamated LTX. In a further embodiment the PLPA comprises alpha
  • the PLPA comprises alpha
  • the PLPA comprises L-alpha
  • polyglutamated antifolate selected from the group consisting of: polyglutamated MTX, polyglutamated PMX, polyglutamated LTX, polyglutamated AG2034, polyglutamated RTX, polyglutamated piritrexim, polyglutamated pralatrexate, polyglutamated AG2034, polyglutamated GW1843, polyglutamated aminopterin, and polyglutamated LY309887.
  • the L-alpha polyglutamated antifolate is pentaglutamated.
  • the L-alpha polyglutamated antifolate is hexaglutamated.
  • the PLPA comprises L-alpha polyglutamated PMX, MTX, RTX, or LTX. In a further embodiment the PLPA comprises L-alpha
  • the PLPA comprises L-alpha hexaglutamated PMX, MTX, RTX, or LTX
  • the PLPA comprises L-alpha polyglutamated PMX. In a further embodiment the PLPA comprises L-alpha pentaglutamated PMX. In a further embodiment the PLPA comprises L-alpha hexaglutamated PMX. [0182] In another embodiment, the PLPA comprises L-alpha polyglutamated MTX. In a further embodiment the PLPA comprises L-alpha pentaglutamated MTX. In a further embodiment the PLPA comprises L-alpha hexaglutamated MTX.
  • the PLPA comprises L-alpha polyglutamated RTX. In a further embodiment the PLPA comprises L-alpha pentaglutamated RTX. In a further embodiment the PLPA comprises L-alpha hexaglutamated RTX.
  • the PLPA comprises L-alpha polyglutamated LTX. In a further embodiment the PLPA comprises L-alpha pentaglutamated LTX. In a further embodiment the PLPA comprises L-alpha hexaglutamated LTX.
  • the PLPA comprises D-alpha
  • polyglutamated antifolate selected from the group consisting of: polyglutamated MTX, polyglutamated PMX, polyglutamated LTX, polyglutamated AG2034, polyglutamated RTX, polyglutamated piritrexim, polyglutamated pralatrexate, polyglutamated AG2034, polyglutamated GW1843, polyglutamated aminopterin, and polyglutamated LY309887.
  • the D-alpha polyglutamated antifolate is pentaglutamated.
  • the D-alpha polyglutamated antifolate is hexaglutamated.
  • the PLPA comprises D-alpha polyglutamated PMX, MTX, RTX, or LTX. In a further embodiment the PLPA comprises D-alpha
  • the PLPA comprises D-alpha hexaglutamated PMX, MTX, RTX, or LTX.
  • the PLPA comprises alpha D-alpha polyglutamated PMX. In a further embodiment the PLPA comprises D-alpha pentaglutamated PMX. In a further embodiment the PLPA comprises D-alpha hexaglutamated PMX.
  • the PLPA comprises D-alpha polyglutamated MTX. In a further embodiment the PLPA comprises D-alpha pentaglutamated MTX. In a further embodiment the PLPA comprises D-alpha hexaglutamated MTX.
  • the PLPA comprises D-alpha polyglutamated RTX. In a further embodiment the PLPA comprises D-alpha pentaglutamated RTX. In a further embodiment the PLPA comprises D-alpha hexaglutamated RTX. [0190] In an additional embodiment, the PLPA comprises D-alpha polyglutamated
  • the PLPA comprises D-alpha pentaglutamated LTX. In a further embodiment the PLPA comprises D-alpha hexaglutamated LTX.
  • the PLPA comprises D-gamma
  • polyglutamated antifolate selected from the group consisting of: polyglutamated MTX, polyglutamated PMX, polyglutamated LTX, polyglutamated AG2034, polyglutamated
  • RTX polyglutamated piritrexim, polyglutamated pralatrexate, polyglutamated AG2034, polyglutamated GW1843, polyglutamated aminopterin, and polyglutamated LY309887.
  • the D-gamma polyglutamated antifolate is pentaglutamated. In further embodiments, the D-gamma polyglutamated antifolate is hexaglutamated.
  • the PLPA comprises D-gamma polyglutamated PMX
  • the PLPA comprises D-gamma
  • the PLPA comprises D-gamma hexaglutamated PMX, MTX, RTX, or LTX.
  • the PLPA comprises D-gamma polyglutamated PMX. In a further embodiment the PLPA comprises D-gamma pentaglutamated PMX. In a further embodiment the PLPA comprises D-gamma hexaglutamated PMX.
  • the PLPA comprises D-gamma polyglutamated MTX.
  • the PLPA comprises D-gamma pentaglutamated MTX. In a further embodiment the PLPA comprises D-gamma hexaglutamated MTX.
  • the PLPA comprises D-gamma polyglutamated RTX.
  • the PLPA comprises D-gamma pentaglutamated RTX. In a further embodiment the PLPA comprises D-gamma hexaglutamated RTX.
  • the PLPA comprises D-gamma polyglutamated
  • the PLPA comprises D-gamma pentaglutamated LTX. In a further embodiment the PLPA comprises D-gamma hexaglutamated LTX.
  • an untargeted or targeted pegylated liposomal alpha (L-alpha or D-alpha) or D-gamma polyglutamated antifolate is provided.
  • the targeted pegylated liposomal polyglutamated antifolate may comprise a liposome including an interior space; an alpha (L-alpha or D-alpha) or D-gamma polyglutamated antifolate disposed within the interior space; a PEG molecule attached to an exterior of the liposome; and a targeting moiety comprising a protein (e.g., an antibody or antibody fragment) with specific affinity for at least one antigen expressed on the surface of the cancer cell (e.gs., a folate receptor (e.g., FR-a, FR- ⁇ and/or FR- ⁇ )) the targeting moiety attached to at least one of the PEG and the exterior of the liposome.
  • a folate receptor e.g., FR-a, FR- ⁇ and/or
  • the liposomes contained in the disclosed liposome composition can be any liposome known in the art. However, it will be understood by one skilled in the art that liposomal encapsulation of any particular drug, such as, and without limitation, the alpha (L-alpha or D-alpha) or D-gamma polyglutamated antifolates discussed herein, may involve substantial routine experimentation to achieve a useful and functional liposomal formulation.
  • the provided liposomes may have any liposome structure, e.g., structures having an inner space sequestered from the outer medium by one or more lipid bilayers, or any microcapsule that has a semi-permeable membrane with a lipophilic central part where the membrane sequesters an interior.
  • the lipid bilayer can be any arrangement of amphiphilic molecules characterized by a hydrophilic part (hydrophilic moiety) and a hydrophobic part (hydrophobic moiety). Usually amphiphilic molecules in a bilayer are arranged into two dimensional sheets in which hydrophobic moieties are oriented inward the sheet while hydrophilic moieties are oriented outward.
  • Amphiphilic molecules forming the provided liposomes can be any known or later discovered amphiphilic molecules, e.g., lipids of synthetic or natural origin or biocompatible lipids.
  • the liposomes can also be formed by amphiphilic polymers and surfactants, e.g., polymerosomes and niosomes. For the purpose of this disclosure, without limitation, these liposome-forming materials also are referred to as "lipids".
  • the liposome composition formulations provided herein can be in liquid or dry form such as a dry powder or dry cake.
  • the dry powder or dry cake may have undergone primary drying under, for example, lyophilization conditions or optionally, the dry cake or dry powder may have undergone both primary drying only or both primary drying and secondary drying.
  • the powder or cake may, for example, have between 1% to 6% moisture, for example, such as between 2% to 5% moisture or between 2% to 4% moisture.
  • One example method of drying is lyophilization (also called freeze-drying, or cyrodessication).
  • compositions and methods of the disclosure may include liposomes, lyophilized liposomes or liposomes reconstituted from lyophilized liposomes.
  • the disclosed compositions and methods include one or more lyoprotectants or cryoprotectants. These protectants are typically polyhydroxy compounds such as sugars (mono-, di-, and polysaccharides), polyalcohols, and their derivatives, glycerol, or polyethyleneglycol, trehalose, maltose, sucrose, glucose, lactose, dextran, glycerol, or aminoglycosides.
  • the lyoprotectants or cryoprotectants comprise up to 10% or up to 20% of a solution outside the liposome, inside the liposome, or both outside and inside the liposome.
  • the liposomes include a steric stabilizer that increases their longevity in circulation.
  • a steric stabilizer such as a hydrophilic polymer (Polyethylene glycol (PEG)), a glycolipid (monosialoganglioside (GM1)) or others occupies the space immediately adjacent to the liposome surface and excludes other macromolecules from this space. Consequently, access and binding of blood plasma opsonins to the liposome surface are hindered, and thus interactions of macrophages with such liposomes, or any other clearing mechanism, are inhibited and longevity of the liposome in circulation is enhanced.
  • PEG Polyethylene glycol
  • GM1 glycolipid
  • the steric stabilizer or the population of steric stabilizers is a PEG or a combination comprising PEG.
  • the steric stabilizer is a PEG or a combination comprising PEG with a number average molecular weight (Mn) of 200 to 5000 daltons.
  • Mn number average molecular weight
  • These PEG(s) can be of any structure such as linear, branched, star or comb structure and are commercially available.
  • the diameter of the disclosed liposomes is not particularly limited.
  • the liposomes have a diameter in the range of for example, 30-150 nm (nanometer). In other embodiments, the liposomes have a diameter in the range of 40-70 nm.
  • the properties of liposomes are influenced by the nature of lipids used to make the liposomes.
  • lipids have been used to make liposomes. These include cationic, anionic and neutral lipids.
  • the liposomes comprising the alpha (L-alpha or D-alpha) or D-gamma polyglutamated antifolate are anionic or neutral.
  • the provided liposomes are cationic.
  • the determination of the charge e.g., anionic, neutral or cationic
  • the determination of the charge can routinely be determined by measuring the zeta potential of the liposome.
  • the zeta potential of the liposome can be positive, zero or negative.
  • the zeta potential of the liposome is less than or equal to zero. In some embodiments, the zeta potential of the liposome is in a range of 0 to -150 mV. In another embodiment, the zeta potential of the liposome is in the range of -30 to -50 mV.
  • cationic lipids are used to make cationic liposomes which are commonly used as gene transfection agents.
  • the positive charge on cationic liposomes enables interaction with the negative charge on cell surfaces. Following binding of the cationic liposomes to the cell, the liposome is transported inside the cell through endocytosis.
  • a neutral to anionic liposome is used.
  • an anionic liposome is used.
  • Using a mixture of, for example, neutral lipids such as HSPC and anionic lipids such as PEG-DSPE results in the formation of anionic liposomes which are less likely to non-specifically bind to normal cells.
  • Specific binding to tumor cells can be achieved by using a tumor targeting antibody such as, for example, a folate receptor antibody, including, for example, folate receptor alpha antibody, folate receptor beta antibody and/or folate receptor delta antibody.
  • At least one (or some) of the lipids is/are amphipathic lipids, defined as having a hydrophilic and a hydrophobic portions (typically a hydrophilic head and a hydrophobic tail).
  • the hydrophobic portion typically orients into a hydrophobic phase (e.g., within the bilayer), while the hydrophilic portion typically orients toward the aqueous phase (e.g., outside the bilayer).
  • the hydrophilic portion can comprise polar or charged groups such as carbohydrates, phosphate, carboxylic, sulfato, amino, sulfhydryl, nitro, hydroxy and other like groups.
  • the hydrophobic portion can comprise apolar groups that include without limitation long chain saturated and unsaturated aliphatic hydrocarbon groups and groups substituted by one or more aromatic, cyclo-aliphatic or heterocyclic group(s).
  • amphipathic compounds include, but are not limited to, phospholipids, aminolipids and sphingolipids.
  • the lipids are phospholipids.
  • Phospholipids include without limitation phosphatidylcholine, phosphatidylethanolamine, phosphatidylglycerol, phosphatidylinositol, phosphatidylserine, and the like. It is to be understood that other lipid membrane components, such as cholesterol, sphingomyelin, and cardiolipin, can be used.
  • the lipids comprising the liposomes provided herein can be anionic and neutral (including zwitterionic and polar) lipids including anionic and neutral
  • Neutral lipids exist in an uncharged or neutral zwitterionic form at a selected pH. At physiological pH, such lipids include, for example,
  • DOPG dioleoylphosphatidylglycerol
  • diacylphosphatidylethanolamine diacylphosphatidylethanolamine, ceramide, sphingomyelin, cephalin, cholesterol, cerebrosides and diacylglycerols.
  • zwitterionic lipids include without limitation dioleoylphosphatidylcholine (DOPC), dimyristoylphosphatidylcholine
  • DMPC dioleoylphosphatidylserine
  • DOPS dioleoylphosphatidylserine
  • Anionic lipids are negatively charged at physiological pH. These lipids include without limitation phosphatidylglycerol, cardiolipin, diacylphosphatidylserine, diacylphosphatidic acid, N-dode- canoyl phosphatidylethanolamines, N-succinyl phosphatidylethanolamines, N- glutarylphosphatidylethanolamines, lysylphosphatidylglycerols,
  • POPG palmitoyloleyolphosphatidylglycerol
  • non-cationic lipids Collectively, anionic and neutral lipids are referred to herein as non-cationic lipids. Such lipids may contain phosphorus but they are not so limited. Examples of non- cationic lipids include lecithin, lysolecithin, phosphatidylethanolamine,
  • lysophosphatidylethanolamine dioleoylphosphati- dylethanolamine (DOPE), dipalmitoyl phosphatidyl ethanolamine (DPPE), dimyristoylphosphoethanolamine (DMPE), distearoyl-phosphatidy 1 -ethanolamine (DSPE), palmitoyloleoyl- phosphatidylethanolamine (POPE) palmitoyloleoylphosphatidylcholine (POPC), egg phosphatidylcholine (EPC), distearoylphosphatidylcholine (DSPC),
  • DOPE dioleoylphosphati- dylethanolamine
  • DPPE dipalmitoyl phosphatidyl ethanolamine
  • DMPE dimyristoylphosphoethanolamine
  • DSPE distearoyl-phosphatidy 1 -ethanolamine
  • POPE palmitoyloleoyl- phosphatidylethanolamine
  • POPC palmi
  • dioleoylphosphatidylcholine DOPC
  • dipalmitoylphosphatidylcholine DPPC
  • dioleoylphosphatidylglycerol DOPG
  • dipalmitoylphosphatidylglycerol DPPG
  • palmitoyloleyolphosphatidylglycerol POPG
  • 16-0-monom ethyl PE 16-0- dimethyl PE
  • 18-1 -trans PE palmitoyloleoyl-phosphati dylethanolamine
  • POPE palmitoyloleoyl-phosphati dylethanolamine
  • SOPE l-stearoyl-2- oleoylphosphatidyethanolamine
  • the liposomes may be assembled using any liposomal assembly method using liposomal components (also referred to as liposome components) known in the art.
  • Liposomal components include, for example, lipids such as DSPE, HSPC, cholesterol and derivatives of these components.
  • lipids such as DSPE, HSPC, cholesterol and derivatives of these components.
  • Other suitable lipids are commercially available for example, by Avanti Polar Lipids, Inc. (Alabaster, Alabama, U.S.A.).
  • a partial listing of available negatively or neutrally charged lipids suitable for making anionic liposomes can be, for example, at least one of the following: DLPC, DMPC, DPPC, DSPC, DOPC, DMPE, DPPE, DOPE, DMPA'Na, DPPA'Na, DOPA'Na, DMPGvNa, DPPG'Na, DOPG'Na, DMPS'Na, DPPS'Na, DOPS'Na, DOPE-Glutaryl-(Na)2, Tetramyristoyl Cardiolipin » (Na)2, DSPE-mPEG-200ONa, DSPE-mPEG-500ONa, and DSPE- Maleimide PEG-200ONa.
  • Lipid derivatives can include, for example, at least, the bonding (preferably covalent bonding) of one or more steric stabilizers and/or functional groups to the liposomal component after which the steric stabilizers and/or functional groups should be considered part of the liposomal components.
  • Functional groups comprises groups that can be used to attach a liposomal component to another moiety such as a protein. Such functional groups include, at least, maleimide.
  • steric stabilizers include at least one from the group consisting of polyethylene glycol (PEG); poly-L-lysine (PLL);
  • GM1 monosialoganglioside
  • PVP poly(vinyl pyrrolidone)
  • PAA poly(acrylamide)
  • GM1 monosialoganglioside
  • PVP poly(vinyl pyrrolidone)
  • PAA poly(acrylamide)
  • GM1 monosialoganglioside
  • PVP poly(vinyl pyrrolidone)
  • PAA poly(acrylamide)
  • PAA poly(2-methyl-2-oxazoline
  • phosphatidyl polyglycerol phosphatidyl polyglycerol
  • poly[N-(2-hydroxypropyl) methacrylamide] amphiphilic poly-N-vinylpyrrolidones; L- amino-acid-based polymer; and polyvinyl alcohol.
  • the components of a liposome can include any molecule(s) (i.e., chemical/reagent/protein) that is bound to it
  • the components of the provided liposomes include, at least, a member selected from the group DSPE, DSPE- PEG, DSPE-maleimide, HSPC; HSPC-PEG; HSPC-maleimide; cholesterol; cholesterol- PEG; and cholesterol-maleimide.
  • the components of the provided liposomes include DSPE, DSPE-PEG, DSPE-maleimide, HSPC; HSPC-PEG; HSPC- maleimide; cholesterol; cholesterol-PEG; and cholesterol-maleimide.
  • the liposomal components that make up the liposome comprises DSPE; DSPE-FITC; DSPE-maleimide; cholesterol; and HSPC.
  • At least one component of the liposome lipid bilayer is functionalized (or reactive).
  • a functionalized component is a component that comprises a reactive group that can be used to crosslink reagents and moieties to the lipid. If the lipid is functionalized, any liposome that it forms is also functionalized.
  • the reactive group is one that will react with a crosslinker (or other moiety) to form crosslinks.
  • the reactive group in the liposome lipid bilayer is located anywhere on the lipid that allows it to contact a crosslinker and be crosslinked to another moiety (e.g., a steric stabilizer or targeting moiety).
  • the reactive group is in the head group of the lipid, including for example a phospholipid.
  • the reactive group is a maleimide group.
  • Maleimide groups can be crosslinked to each other in the presence of dithiol crosslinkers including but not limited to dithiolthrietol (DTT).
  • contemplated reactive groups include but are not limited to other thiol reactive groups, amino groups such as primary and secondary amines, carboxyl groups, hydroxyl groups, aldehyde groups, alkyne groups, azide groups, carbonyls, halo acetyl (e.g., iodoacetyl) groups, imidoester groups, N-hydroxysuccinimide esters, sulfhydryl groups, and pyridyl disulfide groups.
  • thiol reactive groups amino groups such as primary and secondary amines, carboxyl groups, hydroxyl groups, aldehyde groups, alkyne groups, azide groups, carbonyls, halo acetyl (e.g., iodoacetyl) groups, imidoester groups, N-hydroxysuccinimide esters, sulfhydryl groups, and pyridyl disulfide groups.
  • the provided liposomes further comprise an immunostimulatory agent, a detectable marker, or both disposed on its exterior.
  • the immunostimulatory agent or detectable marker can be ionically bonded or covalently bonded to an exterior of the liposome, including, for example, optionally to a steric stabilizer component of the liposome.
  • immunostimulatory agents also known as immunostimulants, and immunostimulators, refer to substances that stimulate the immune system by inducing activation or increasing activity of any of its components.
  • immunostimulatory agents can include one or more of a hapten, an adjuvant, a protein immunostimulating agent, a nucleic acid immunostimulating agent, and a chemical immunostimulating agent.
  • Many adjuvants contain a substance designed to stimulate immune responses, such as lipid A, Bortadella pertussis or Mycobacterium tuberculosis derived proteins.
  • adjuvants are commercially available as, for example, Freund's Incomplete Adjuvant and Complete Adjuvant (Difco Laboratories, Detroit, Mich.); Merck Adjuvant 65 (Merck and Company, Inc., Rahway, N.J.); AS-2 (SmithKline Beecham, Philadelphia, Pa.);
  • aluminum salts such as aluminum hydroxide gel (alum) or aluminum phosphate; salts of calcium, iron or zinc; an insoluble suspension of acylated tyrosine; acylated sugars;
  • the immunostimulant can be at least one selected from the group consisting of fluorescein, D P, beta glucan, beta-l,3-glucan, beta-l,6-glucan.
  • a detectable marker may, for example, include, at least, a radioisotope, a fluorescent compound, a bioluminescent compound, chemiluminescent compound, a metal chelator, an enzyme, a dye, an ink, a magnetic compound, a biocatalyst or a pigment that is detectable by any suitable means known in the art, e.g., magnetic resonance imaging (MRI), optical imaging, fluorescent/luminescent imaging, or nuclear imaging techniques.
  • MRI magnetic resonance imaging
  • optical imaging fluorescent/luminescent imaging
  • nuclear imaging techniques e.g., nuclear imaging techniques.
  • the immunostimulatory agent and/or detectable marker is attached to the exterior by co-incubating it with the liposome.
  • the immunostimulatory agent and/or detectable marker may be associated with the liposomal membrane by hydrophobic interactions or by an ionic bond such as an avidin/biotin bond or a metal chelation bond (e.g., Ni-NTA).
  • the immunostimulatory agent or detectable marker may be covalently bonded to the exterior of the liposome such as, for example, by being covalently bonded to a liposomal component or to the steric stabilizer which is the PEG.
  • the provided liposomes enclose an interior space.
  • the interior space comprises, but is not limited to, an aqueous solution.
  • the interior space comprises a comprises an alpha or D-gamma polyglutamated antifolate as provided herein.
  • the interior space further comprises a pharmaceutically acceptable carrier such as trehalose.
  • the trehalose is present at about 5% to 20% weight percent of trehalose or any combination of one or more lyoprotectants or cryoprotectants at a total concentration of 5% to 20%.
  • the interior space comprises buffer.
  • the buffer is HEPES buffer or citrate buffer.
  • the citrate buffer is at a concentration of between 5 to 200 mM.
  • the interior space has a pH of between 2.8 to 6.
  • the interior space of the liposome comprises sodium acetate and/or calcium acetate.
  • the interior space of the liposome comprises a total concentration of sodium acetate and calcium acetate of between 50 mM to 500 mM.
  • the targeted pegylated liposomal polyglutamated (e.g., pentaglutamated or hexaglutamated) antifolate comprises a medium comprising a liposome including an interior space; an aqueous alpha (L-alpha or D-alpha) or D-gamma polyglutamated antifolate disposed within the interior space; and a targeting moiety comprising a protein with specific affinity for at least one folate receptor, and wherein the targeting moiety disposed at the exterior of the liposome.
  • the medium is an aqueous solution.
  • the interior space, the exterior space (e.g., the medium), or both the interior space and the medium contains one or more lyoprotectants or cryoprotectants which are listed above.
  • the cryoprotectant is mannitol, trehalose, sorbitol, or sucrose.
  • the liposomes may comprise a steric stabilizer that can increase their longevity in circulation.
  • the steric stabilizer may be at least one member selected from the group consisting of polyethylene glycol (PEG), poly-L-lysine (PLL), monosialoganglioside (GM1), poly(vinyl pyrrolidone) (PVP), poly(acrylamide) (PAA), poly(2-methyl-2- oxazoline), poly(2-ethyl-2-oxazoline), phosphatidyl polyglycerol, poly[N-(2- hydroxypropyl) methacrylamide], amphiphilic poly-N-vinylpyrrolidones, L-amino-acid- based polymer, and polyvinyl alcohol.
  • the steric stabilizer or the population of steric stabilizer is PEG.
  • the steric stabilizer is a PEG.
  • the PEG has a number average molecular weight (Mn) of 200 to 5000 daltons.
  • Mn number average molecular weight
  • the liposomal alpha (L-alpha or D-alpha) or D-gamma polyglutamated antifolate (LPA or PLPA) is water soluble. That is, the liposomal polyglutamated (e.g., pentaglutamated or hexaglutamated) antifolate is in the form of an aqueous solution.
  • the LPA or PLPA comprises an interior space that contains less than 200,000 molecules of the alpha (L-alpha or D-alpha) or D-gamma polyglutamated antifolate. In some embodiments, the LPA or PLPA contains between 10,000 to 100,000 molecules of the alpha (L-alpha or D-alpha) or D-gamma
  • the LPA or PLPA contains between 10,000 to 100,000 molecules of the alpha (L-alpha or D-alpha) or D-gamma
  • the LPA or PLPA contains between 10,000 to 100,000 molecules of the alpha (L-alpha or D-alpha) or D-gamma
  • the interior space of the LPA or PLPA contains less than 200,000 molecules of an alpha (L-alpha or D-alpha) or D-gamma polyglutamated antifolate selected from the group consisting of: polyglutamated MTX, polyglutamated PMX, polyglutamated LTX, polyglutamated AG2034, polyglutamated RTX,
  • the liposome contains less than 200,000 molecules of alpha (L- alpha or D-alpha) or D-gamma polyglutamated PMX. In some embodiments, the liposome contains less than 200,000 molecules of alpha (L-alpha or D-alpha) or D- gamma polyglutamated MTX. In some embodiments, the liposome contains less than 200,000 molecules of alpha (L-alpha or D-alpha) or D-gamma polyglutamated RTX.
  • the liposome contains less than 200,000 molecules of molecules of alpha (L-alpha or D-alpha) or D-gamma pentaglutamated LTX. In some embodiments, the liposome contains less than 200,000 molecules of molecules of alpha (L-alpha or D- alpha) or D-gamma hexaglutamated LTX.
  • the interior space of the LPA or PLPA contains between 10,000 to 100,000 molecules of an alpha (L-alpha or D-alpha) or D-gamma polyglutamated antifolate selected from the group consisting of: polyglutamated MTX, polyglutamated PMX, polyglutamated LTX, polyglutamated AG2034, polyglutamated RTX, polyglutamated pintrexim, polyglutamated pralatrexate, polyglutamated AG2034, polyglutamated GW1843, polyglutamated aminopterin, and polyglutamated LY309887.
  • an alpha (L-alpha or D-alpha) or D-gamma polyglutamated antifolate selected from the group consisting of: polyglutamated MTX, polyglutamated PMX, polyglutamated LTX, polyglutamated AG2034, polyglutamated RTX, polyglutamated pintrexim, polyglutamated pralatrexate, polyglutamated AG2034, polyglutamated
  • the liposome contains between 10,000 to 100,000 molecules of alpha (L-alpha or D-alpha) or D-gamma polyglutamated PMX. In some embodiments, the liposome contains between 10,000 to 100,000 molecules of alpha (L-alpha or D- alpha) or D-gamma polyglutamated MTX. In some embodiments, the liposome contains between 10,000 to 100,000 molecules of alpha (L-alpha or D-alpha) or D-gamma polyglutamated RTX. In some embodiments, the liposome contains between 10,000 to 100,000 molecules of alpha (L-alpha or D-alpha) or D-gamma pentaglutamated LTX. In some embodiments, the liposome contains between 10,000 to 100,000 molecules of alpha (L-alpha or D-alpha) or D-gamma hexaglutamated LTX.
  • the interior space of the LPA or PLPA contains less than 200,000 molecules of an alpha (L-alpha or D-alpha) or D-gamma pentaglutamated antifolate selected from the group consisting of pentaglutamated MTX, pentaglutamated PMX, pentaglutamated LTX, pentaglutamated AG2034, pentaglutamated RTX, pentaglutamated piritrexim, pentaglutamated pralatrexate, pentaglutamated AG2034, pentaglutamated GW1843, pentaglutamated aminopterin, and pentaglutamated
  • an alpha (L-alpha or D-alpha) or D-gamma pentaglutamated antifolate selected from the group consisting of pentaglutamated MTX, pentaglutamated PMX, pentaglutamated LTX, pentaglutamated AG2034, pentaglutamated RTX, pentaglutamated piritrexim, pentaglutamated pra
  • the liposome contains less than 200,000 molecules of an alpha (L-alpha or D-alpha) or D-gamma pentaglutamated PMX. In some embodiments,
  • the liposome contains less than 200,000 molecules of an alpha (L-alpha or D-alpha) or D-gamma pentaglutamated MTX. In some embodiments, the liposome contains less than 200,000 molecules of an alpha (L-alpha or D-alpha) or D-gamma pentaglutamated RTX. In some embodiments, the liposome contains less than 200,000 molecules of an alpha (L-alpha or D-alpha) or D-gamma pentaglutamated RTX.
  • the interior space of the LPA or PLPA contains less than 200,000 molecules of an alpha (L-alpha or D-alpha) or D-gamma hexaglutamated antifolate selected from the group consisting of hexaglutamated MTX, hexaglutamated PMX, hexaglutamated LTX, hexaglutamated AG2034, hexaglutamated RTX, hexaglutamated piritrexim, hexaglutamated pralatrexate, hexaglutamated AG2034, hexaglutamated GW1843, hexaglutamated aminopterin, and hexaglutamated LY309887.
  • an alpha (L-alpha or D-alpha) or D-gamma hexaglutamated antifolate selected from the group consisting of hexaglutamated MTX, hexaglutamated PMX, hexaglutamated LT
  • the liposome contains less than 200,000 molecules of an alpha (L- alpha or D-alpha) or D-gamma hexaglutamated PMX. In some embodiments, the liposome contains less than 200,000 molecules of an alpha (L-alpha or D-alpha) or D- gamma hexaglutamated MTX. In some embodiments, the liposome contains less than 200,000 molecules of an alpha (L-alpha or D-alpha) or D-gamma hexaglutamated RTX. In some embodiments, the liposome contains less than 200,000 molecules of an alpha (L- alpha or D-alpha) or D-gamma hexaglutamated RTX.
  • the liposomal antifolate is pegylated (i.e., a pegylated liposomal alpha (L-alpha or D-alpha) or D-gamma polyglutamated (e.g., pentaglutamated or hexagluatamated) antifolate (PLPA or PLPA)).
  • the PLPA or PLPA is water soluble. That is, the PLPA or PLPA is in the form an aqueous solution.
  • the PLPA or PLPA comprises an interior space that contains less than 200,000 molecules of alpha (L-alpha or D-alpha) or D-gamma polyglutamated antifolate.
  • the PLPA or PLPA contains between 10,000 to 100,000 molecules of alpha (L-alpha or D-alpha) or D-gamma polyglutamated antifolate. In further embodiments, the PLPA or PLPA contains between 10,000 to 100,000 molecules of alpha (L-alpha or D-alpha) or D-gamma pentaglutamated antifolate. In some embodiments, the PLPA or PLPA contains between 10,000 to 100,000 molecules of alpha (L-alpha or D-alpha) or D-gamma polyglutamated antifolate. In further,
  • the PLPA or PLPA contains between 10,000 to 100,000 molecules of alpha (L-alpha or D-alpha) or D-gamma hexaglutamated antifolate.
  • the interior space of the PLPA or PLPA contains less than 200,000 molecules of alpha (L-alpha or D-alpha) or D-gamma polyglutamated antifolate selected from the group consisting of: polyglutamated MTX, polyglutamated PMX, polyglutamated LTX, polyglutamated AG2034, polyglutamated RTX, polyglutamated pintrexim, polyglutamated pralatrexate, polyglutamated AG2034, polyglutamated GW1843, polyglutamated aminopterin, and polyglutamated LY309887.
  • the liposome contains contains less than 200,000 molecules of alpha or D-gamma polyglutamated PMX.
  • the PLPA or PLPA contains less than 200,000 molecules of alpha or D-gamma polyglutamated MTX. In some embodiments, the PLPA or PLPA contains less than 200,000 molecules of alpha or D-gamma polyglutamated RTX. In some embodiments, the PLPA or PLPA contains less than 200,000 molecules of alpha or D-gamma pentaglutamated LTX. In some embodiments, the PLPA or PLPA contains less than 200,000 molecules of alpha or D- gamma hexaglutamated LTX.
  • the interior space of the PLPA or PLPA contains between 10,000 to 100,000 molecules of alpha (L-alpha or D-alpha) or D-gamma polyglutamated antifolate selected from the group consisting of: polyglutamated MTX, polyglutamated PMX, polyglutamated LTX, polyglutamated AG2034, polyglutamated RTX, polyglutamated pintrexim, polyglutamated pralatrexate, polyglutamated AG2034, polyglutamated GW1843, polyglutamated aminopterin, and polyglutamated LY309887.
  • alpha (L-alpha or D-alpha) or D-gamma polyglutamated antifolate selected from the group consisting of: polyglutamated MTX, polyglutamated PMX, polyglutamated LTX, polyglutamated AG2034, polyglutamated RTX, polyglutamated pintrexim, polyglutamated pralatrexate, polyglutamated AG2034, polyglutamated
  • the liposome contains between 10,000 to 100,000 molecules of alpha (L-alpha or D-alpha) or D-gamma polyglutamated PMX. In some embodiments, the PLPA or PLPA contains between 10,000 to 100,000 molecules of alpha or D-gamma polyglutamated MTX. In some embodiments, the PLPA or PLPA contains between 10,000 to 100,000 molecules of alpha or D-gamma polyglutamated RTX. In some embodiments, the PLPA or PLPA contains between 10,000 to 100,000 molecules of alpha (L-alpha or D-alpha) or D-gamma pentaglutamated LTX. In some embodiments, the PLPA or PLPA contains between 10,000 to 100,000 molecules of alpha (L-alpha or D-alpha) or D-gamma hexaglutamated LTX.
  • the interior space of the PLPA or PLPA contains less than 200,000 molecules of alpha (L-alpha or D-alpha) or D-gamma pentaglutamated antifolate selected from the group consisting of pentaglutamated MTX, pentaglutamated PMX, pentaglutamated LTX, pentaglutamated AG2034, pentaglutamated RTX, pentaglutamated piritrexim, pentaglutamated pralatrexate, pentaglutamated AG2034, pentaglutamated GW1843, pentaglutamated aminopterin, and pentaglutamated LY309887.
  • pentaglutamated MTX pentaglutamated PMX
  • pentaglutamated LTX pentaglutamated AG2034
  • pentaglutamated RTX pentaglutamated piritrexim
  • pentaglutamated pralatrexate pentaglutamated AG2034, pentaglutamated GW1843, pentaglutamated aminopter
  • the PLPA or PLPA contains less than 200,000 molecules of pentaglutamated PMX. In some embodiments, the PLPA or PLPA contains less than 200,000 molecules of alpha (L-alpha or D-alpha) or D-gamma pentaglutamated MTX. In some embodiments, the PLPA or PLPA contains less than 200,000 molecules of alpha (L-alpha or D-alpha) or D-gamma pentaglutamated RTX. In some embodiments, the PLPA or PLPA contains less than 200,000 molecules of alpha (L-alpha or D-alpha) or D-gamma pentaglutamated RTX.
  • the interior space of the PLPA or PLPA contains less than 200,000 molecules of alpha (L-alpha or D-alpha) or D-gamma hexaglutamated antifolate selected from the group consisting of hexaglutamated MTX, hexaglutamated PMX, hexaglutamated LTX, hexaglutamated AG2034, hexaglutamated RTX,
  • the PLPA or PLPA contains less than 200,000 molecules of hexaglutamated PMX. In some embodiments, the PLPA or PLPA contains less than 200,000 molecules of alpha (L-alpha or D-alpha) or D-gamma hexaglutamated MTX.
  • the PLPA or PLPA contains less than 200,000 molecules of alpha (L-alpha or D-alpha) or D-gamma hexaglutamated RTX. In some embodiments, the PLPA or PLPA contains less than 200,000 molecules of alpha (L-alpha or D-alpha) or D- gamma hexaglutamated RTX.
  • the interior space of the PLPA or PLPA contains between 10,000 to 100,000 molecules of alpha (L-alpha or D-alpha) or D-gamma pentaglutamated antifolate selected from the group consisting of pentaglutamated MTX, pentaglutamated PMX, pentaglutamated LTX, pentaglutamated AG2034,
  • the PLPA or PLPA contains between 10,000 to 100,000 molecules of alpha or D-gamma pentaglutamated PMX. In some embodiments, the PLPA or PLPA contains between 10,000 to 100,000 molecules of alpha or D-gamma pentaglutamated MTX. In some embodiments, the PLPA or PLPA contains between 10,000 to 100,000 molecules of pentaglutamated RTX. In some embodiments, the PLPA or PLPA contains between 10,000 to 100,000 molecules of alpha or D-gamma pentaglutamated RTX.
  • the interior space of the PLPA or PLPA contains between 10,000 to 100,000 molecules of alpha (L-alpha or D-alpha) or D-gamma hexaglutamated antifolate selected from the group consisting of hexaglutamated MTX, hexaglutamated PMX, hexaglutamated LTX, hexaglutamated AG2034, hexaglutamated RTX, hexaglutamated piritrexim, hexaglutamated pralatrexate, hexaglutamated AG2034, hexaglutamated GW1843, hexaglutamated aminopterin, and hexaglutamated LY309887.
  • alpha L-alpha or D-alpha
  • D-gamma hexaglutamated antifolate selected from the group consisting of hexaglutamated MTX, hexaglutamated PMX, hexaglutamated LTX,
  • the PLPA or PLPA contains between 10,000 to 100,000 molecules of alpha or D-gamma hexaglutamated PMX. In some embodiments, the PLPA or PLPA contains between 10,000 to 100,000 molecules of alpha or D-gamma hexaglutamated MTX. In some embodiments, the PLPA or PLPA contains between 10,000 to 100,000 molecules of hexaglutamated RTX. In some embodiments, the PLPA or PLPA contains between 10,000 to 100,000 molecules of alpha or D-gamma hexaglutamated RTX.
  • the pH of solutions comprising the liposome composition is from pH 5 to 8 or from pH 2 to 6.
  • the disclosure provides a liposomal polyglutamated antifolate composition wherein the liposome is pegylated and comprises an alpha (L- alpha or D-alpha) or D-gamma polyglutamated antifolate and targeting moiety attached to one or both of a PEG and the exterior of the liposome, and wherein the targeting moiety has a specific affinity for a surface antigen on a target cell of interest.
  • liposomes may generally be referred to herein as "targeted liposomes,” e.g., liposomes including one or more targeting moieties or biodistribution modifiers on the surface of, or otherwise attached to, the liposomes.
  • the targeting moiety of the targeted liposomes can be any moiety or agent that is capable of specifically binding a desired target (e.g., an antigen target expressed on the surface of a target cell of interest).
  • a desired target e.g., an antigen target expressed on the surface of a target cell of interest.
  • the targeted liposome specifically and preferentially binds to a target on the surface of a target cell of interest that internalizes the targeted liposome into which the liposome encapsulated alpha or D-gamma polyglutamated cytotoxic agent (e.g., polyglutamated antifolates, such as pentaglutamated or hexaglutamated PMX, LTX, and MTX) exerts its cytotoxic effect.
  • the target cell is a cancer cell, a tumor cell or a metastatic cell.
  • the targeting liposomes are immunoliposomes.
  • attach or attached refers, for example, to any type of bonding such as covalent bonding, ionic bonding (e.g., avidin-biotin) bonding by hydrophobic
  • a detectable marker, a steric stabilizer, a liposome, a liposomal component, an immunostimulating agent may be attached to each other directly, by a maleimide functional group, or by a PEG-malemide group.
  • the targeting moiety attached to the liposome is a polypeptide.
  • the targeting moiety is an antibody or a fragment of an antibody.
  • the targeting moiety comprises one or more of an antibody, a humanized antibody, an antigen binding fragment of an antibody, a single chain antibody, a single-domain antibody, a bi-specific antibody, a synthetic antibody, a pegylated antibody, and a multimeric antibody.
  • the targeting moiety has the specific affinity for an epitope on a tumor cell surface antigen that is present on a tumor cell but absent or inaccessible on a non-tumor cell.
  • the targeting moiety further comprises one or more of an
  • the targeting moiety of the liposomal alpha (L-alpha or D-alpha) or D-gamma polyglutamated antifolate (LP A) or a pegylated liposomal alpha (L-alpha or D-alpha) or D-gamma polyglutamated antifolate (PLPA) liposome is anionic or neutral.
  • the targeting moiety of the LPA or PLPA liposome is cationic.
  • the targeting moiety LPA or PLPA liposome composition comprises at least 10% liposome entrapped alpha (L-alpha or D-alpha) or D-gamma polyglutamated antifolate.
  • the targeting moiety -LPA or targeting moiety -PLPA liposomes have a diameter in the range of 20 nm to 200 nm. In further embodiments, the liposomes have a diameter in the range of 80 nm to 120 nm.
  • the targeting moiety -LPA or targeting moiety -PLPA comprises a polypeptide targeting moiety such as an antibody or an antibody fragment and the targeting moiety binds a target antigen with an equilibrium dissociation constant (Kd) in a range of 0.5xl0 "10 to lOxlO "6 as determined using BIACORE analysis.
  • the targeting moiety-LPA or targeting moiety-PLPA comprises a polypeptide targeting moiety.
  • the targeting moiety-LPA or targeting moiety-PLPA comprises a polypeptide targeting moiety such as an antibody or an antibody fragment and the targeting moiety has a specific affinity for a target antigen selected from the group consisting of GO MB, CD56, TACSTD2 (TROP2), CEACAM5, Folate receptor- ex, Folate receptor- ⁇ , Folate receptor- ⁇ , Mucin 1, STEAPl, Mesothelin, Nectin 4, ENPP3, Guanylyl cyclase C (GCC), SLC44A4, NaPi2b, CD70 (TNFSF7), CA9 (Carbonic anhydrase), 5T4 (TPBG), SLTRK6, SC-16, Tissue factor, LIV-1 (ZIP6), CGEN-15027, P-Cadherin, Fibronectin Extra-domain B (ED-B), VEGFR2 (CD309), Tenascin, Collagen IV, Periostin, endothelin receptor,
  • a target antigen selected
  • the targeting moiety comprises a polypeptide targeting moiety such as an antibody or an antibody fragment and the targeting moiety has binding specificity for a folate receptor.
  • the targeting moiety binds a a folate receptor with an equilibrium dissociation constant (Kd) in a range of 0.5x10-10 to 10x10 6 as determined using BIACORE analysis.
  • the folate receptor bound by the targeting moiety is one or more folate receptors selected from the group consisting of: folate receptor alpha (FR-a), folate receptor beta (FR- ⁇ ), and folate receptor delta (FR- ⁇ ).
  • the targeting moiety is an antibody or antigen binding portion of an antibody that specifically binds a target of interest expressed on the surface of a targeted cell of interest. In some embodiments, the targeting moiety is a full-length antibody. In some embodiments, the targeting moiety is an antigen binding portion of an antibody. In some embodiments, the targeting moiety comprises one or more
  • CDRs complementarity determining regions
  • suitable proteins that can serve as targeting moieties for the disclosed targeted liposomes include a full-length human antibody, a humanized antibody, a chimeric antibody, an antigen binding fragment of an antibody, a single chain antibody, a single-domain antibody, a bi- specific antibody, a synthetic antibody, a pegylated antibody and a multimeric antibody.
  • the antibody of the provided targeted liposomes can have a combination of the above characteristics.
  • a humanized antibody can be an antigen binding fragment and can be pegylated and multimerized as well.
  • humanized antibody refers to forms of non-human (e.g., murine) antibodies that are specific immunoglobulin chains, chimeric immunoglobulins, or fragments thereof that contain minimal non-human (e.g., murine) sequences.
  • humanized antibodies are human immunoglobulins in which residues from the complementary determining region (CDR) are replaced by residues from the CDR of a non-human species (e.g.
  • the Fv framework region (FR) residues of a human immunoglobulin are replaced with the corresponding residues in an antibody from a non-human species that has the desired specificity, affinity, and capability.
  • the humanized antibody can be further modified by the substitution of additional residues either in the Fv framework region and/or within the replaced non-human residues to refine and optimize antibody specificity, affinity, and/or capability.
  • the humanized antibody will comprise substantially all of at least one, and typically two or three, variable domains containing all or substantially all of the CDR regions that correspond to the non-human
  • the humanized antibody can also comprise at least a portion of an immunoglobulin constant region or domain (Fc), typically that of a human immunoglobulin. Examples of methods used to generate humanized antibodies are described in U.S. Pat. Nos. 5,225,539 and 5,639,641.
  • folate receptors are distinct from reduced folate carriers (RFCs) and exploit different pathways for bringing folates and antifolates into cells.
  • the targeting moiety specifically binds a folate receptor.
  • the targeting moiety specifically binds a folate receptor selected from folate receptor alpha, folate receptor beta and folate receptor delta.
  • Antibodies to folate receptor alpha can routinely be generated using techniques known in the art.
  • sequences of numerous anti-folate receptor antibodies are in the public domain and/or commercially available and are readily obtainable.
  • Murine antibodies against folate receptor are examples of antibodies that can be used as targeting moieties of the disclosed targeted liposome is a murine antibody against folate receptor.
  • the sequence of these antibodies are known and are described, for example, in U.S. Pat. Nos. 5,646,253; 8,388,972; 8,871,206; and 9, 133,275 and in Intl. Appl. Nos. PCT/US2011/056966 and PCT/US2012/046672.
  • the gene for the antibodies can be synthesized and placed into a transient expression vector and the antibody was produced in HEK-293 transient expression system.
  • the antibody can be a complete antibody, a Fab, or any of the various antibody variations discussed herein or otherwise known in the art.
  • the targeted liposomes comprise from 30 to 500 targeting moieties (e.g., 30 to 250 targeting moieties or 30-200 targeting moieties). In some embodiments, the provided targeted liposomes contain less than 220 targeting moieties, less than 200 targeting moieties, or less than targeting 175 moieties. In some embodiments, the targeting moiety is non-covalently bonded to the outside of the liposome (e.g., via ionic interaction or a GPI anchor).
  • the molecules on the outside of the targeted liposome include a lipid, a targeting moiety, a steric stabilizer (e.g., a PEG), a maleimide, and a cholesterol.
  • the targeting moiety is covalently bound via a maleimide functional group.
  • the targeting moiety is covalently bound to a liposomal component or a steric stabilizer such as a PEG molecule.
  • all the targeting moieties are bound to one component of the liposome such as a PEG. In other embodiments, the targeting moieties are bound to different
  • targeting moieties may be bound to the lipid components or cholesterol, some targeting moieties may be bound to the steric stabilizer (e.g., PEG) and still other targeting moieties may be bound to a detectable marker or to another targeting moiety.
  • steric stabilizer e.g., PEG
  • the targeting moiety of the targeted liposome has affinity and specificity (i.e., specifically binds) for an antigen expressed on the surface of a cancer cell.
  • the targeting moiety of the targeted liposome has affinity and specificity for one or more antigens selected from the group consisting of folate receptor alpha, folate receptor beta, and folate receptor delta.
  • the targeting moiety has specific affinity (i.e., specifically binds) an antigen selected from the group consisting of folate receptor alpha, folate receptor beta, and folate receptor delta.
  • the targeting moiety has specific affinity for at least two antigens selected from the group consisting of folate receptor alpha, folate receptor beta, and folate receptor delta. In another embodiment, the targeting moiety has specific affinity for three antigens which are, for example, folate receptor alpha; folate receptor beta; and folate receptor delta.
  • the targeting moiety may have affinity and specificity to an epitope of the antigen because sometimes a targeting moiety does not bind the complete antigen but just an epitope of many epitopes in an antigen.
  • epitopes or "antigenic determinant” are used interchangeably herein and refer to that portion of an antigen capable of being recognized and specifically bound by a particular antibody or binding moiety.
  • the antigen is a polypeptide
  • epitopes can be formed both from contiguous amino acids and noncontiguous amino acids juxtaposed by tertiary folding of a protein. Epitopes formed from contiguous amino acids are typically retained upon protein denaturing, whereas epitopes formed by tertiary folding are typically lost upon protein denaturing.
  • An epitope typically includes at least 3, and more usually, at least 5 or 8-10 amino acids in a unique spatial conformation.
  • the targeting moiety has specific affinity for an epitope on a tumor cell surface antigen that is present on a tumor cell but absent or inaccessible on a non-tumor cell.
  • the tumor antigen is on the surface of both normal cells and malignant cancer cells but the tumor epitope is only exposed in a cancer cell.
  • a tumor antigen may experience a confirmation change in cancer causing cancer cell specific epitopes to be present.
  • a targeting moiety with specific affinity to epitopes described herein are useful and are encompassed by the disclosed compositions and methods.
  • the tumor cell with the cancer cell specific epitope(s) is a cancer cell. Examples of such tumor cell surface antigens include, folate receptor alpha, folate receptor beta and folate receptor delta.
  • the liposome composition is provided as a
  • composition containing the liposome and a carrier, e.g., a
  • a buffer substance is added to maintain an optimal pH for storage stability of the pharmaceutical composition.
  • the pH of the pharmaceutical composition is between 6.0 and 7.5. In some embodiments, the pH is between 6.3 and 7.0. In further embodiments, the pH is 6.5. Ideally the pH of the pharmaceutical composition allows for both stability of liposome membrane lipids and retention of the entrapped entities.
  • Histidine, hydroxyethylpiperazine-ethylsulfonate (HEPES), morpholipoethyl sulfonate (MES), succinate, tartrate, and citrate, typically at 2-20 mM concentration, are exemplary buffer substances.
  • Other suitable carriers include, e.g., water, buffered aqueous solution, 0.4% NaCl, and 0.3% glycine.
  • Protein, carbohydrate, or polymeric stabilizers and tonicity adjusters can be added, e.g., gelatin, albumin, dextran, or polyvinylpyrrolidone.
  • the tonicity of the composition can be adjusted to the physiological level of 0.25-0.35 mol/kg with glucose or a more inert compound such as lactose, sucrose, mannitol, or dextrin.
  • glucose or a more inert compound such as lactose, sucrose, mannitol, or dextrin.
  • These compositions can routinely be sterilized using conventional, sterilization techniques known in the art (e.g., by filtration).
  • the resulting aqueous solutions can be packaged for use or filtered under aseptic conditions and lyophilized, the lyophilized preparation being combined with a sterile aqueous medium prior to administration.
  • the provided pharmaceutical liposome compositions can also contain other pharmaceutically acceptable auxiliary substances as required to approximate
  • the liposome suspension may include lipid-protective agents which protect lipids against free-radical and lipid- peroxidative damages on storage.
  • Lipophilic free-radical quenchers such as alpha- tocopherol and water-soluble iron-specific chelators, such as ferrioxamine, are suitable.
  • the liposome concentration in the provided fluid pharmaceutical formulations can vary widely depending upon need, e.g., from less than about 0.05% usually or at least about 2-10% to as much as 30 to 50% by weight and will be selected primarily by fluid volumes, and viscosities, in accordance with the particular mode of administration selected.
  • the concentration may be increased to lower the fluid load associated with treatment. This may be particularly desirable in patients having atherosclerosis-associated congestive heart failure or severe hypertension.
  • liposome pharmaceutical compositions composed of irritating lipids may be diluted to low concentrations to lessen inflammation at the site of administration.
  • Some embodiments relate to a method of delivering a targeted pegylated liposomal formulation of a alpha (L-alpha or D-alpha) or D-gamma polyglutamated antifolate, to a tumor expressing folate receptor on its surface.
  • An exemplary method comprises the step of administering at least one of any of the compositions comprising a liposome in this disclosure in an amount to deliver a therapeutically effective dose of the targeted pegylated liposomal alpha (L-alpha or D-alpha) or D-gamma polyglutamated antifolate to the tumor.
  • the amount of liposome pharmaceutical composition administered will depend upon the particular polyglutamated antifolate therapeutic entity entrapped inside the liposomes, the disease state being treated, the type of liposomes being used, and the judgment of the clinician. Generally the amount of liposome pharmaceutical composition administered will be sufficient to deliver a therapeutically effective dose of the particular therapeutic entity.
  • the quantity of liposome pharmaceutical composition necessary to deliver a therapeutically effective dose can be determined by routine in vitro and in vivo methods, common in the art of drug testing. See, for example, D. B. Budman, A. H. Calvert, E. K. Rowinsky (editors). Handbook of Anticancer Drug Development, LWW, 2003.
  • a therapeutic entity delivered via the pharmaceutical liposome composition and provides at least the same or higher activity than the activity obtained by administering the same amount of the therapeutic entity in its routine non-liposome formulation.
  • the dosages for the liposome pharmaceutical composition is in a range for example, between about 0.005 and about 500 mg of the therapeutic entity per kilogram of body weight, most often, between about 0.1 and about 100 mg therapeutic entity/kg of body weight.
  • an "effective amount” refers to a dosage of an agent sufficient to provide a medically desirable result.
  • the effective amount will vary with the desired outcome, the particular condition being treated or prevented, the age and physical condition of the subject being treated, the severity of the condition, the duration of the treatment, the nature of the concurrent or combination therapy (if any), the specific route of administration and like factors within the knowledge and expertise of the health practitioner.
  • An “effective amount” can be determined empirically and in a routine manner, in relation to the stated purpose.
  • the term “subject” and “patient” is used interchangeably and has the same meaning. It is preferred generally that a maximum dose be used, that is, the highest safe dose according to sound medical judgment.
  • an effective amount may be that amount of the agent (e.g., alpha (L-alpha or D-alpha) or D-gamma polyglutamated antifolate) that reduces the tumor volume or load (as for example determined by imaging the tumor).
  • Effective amounts can also routinely be assessed by the presence and/or frequency of cancer cells in the blood or other body fluid or tissue (e.g., a biopsy). If the tumor is impacting the normal functioning of a tissue or organ, then the effective amount can routinely be assessed by measuring the normal functioning of the tissue or organ. In some instances the effective amount is the amount required to lessen or eliminate one or more, and preferably all, symptoms.
  • Terms such as “treating,” or “treatment,” or “to treat” refer to both (a) therapeutic measures that cure, slow down, lessen symptoms of, and/or halt progression of a diagnosed pathologic condition or disorder and (b) prophylactic or preventative measures that prevent and/or slow the development of a targeted disease or condition.
  • subjects in need of treatment include those already with the cancer or condition; those at risk of having the cancer or condition; and those in whom the infection or condition is to be prevented.
  • a subject is successfully "treated” according to the methods provided herein if the subject shows, e.g., total, partial, or transient amelioration or elimination of a symptom associated with the disease or condition (e.g., cancer, rheumatoid arthritis).
  • compositions comprising the provided alpha (L-alpha or D- alpha) or D-gamma polyglutamated antifolate compositions (e.g., liposomes containing a pentaglutamated or hexaglutamated antifolate) are also provided.
  • Pharmaceutical compositions are sterile compositions that comprise a sample liposome and preferably antifolate(s), preferably in a pharmaceutically-acceptable carrier.
  • delivery vehicle refers generally to any compositions that acts to assist, promote or facilitate entry of polyglutamated antifolates into a cell, for example, viral sequences, viral material, or lipid or liposome formulations.
  • pharmaceutically-acceptable carrier refers to for example, one or more compatible solid or liquid filler, diluents or encapsulating substances which are suitable for administration to a human or other subject.
  • carrier denotes an organic or inorganic ingredient, natural or synthetic, with which liposome compositions are combined to facilitate administration.
  • the components of the pharmaceutical compositions are comingled in a manner that precludes interaction that would substantially impair their desired pharmaceutical efficiency.
  • Suitable buffering agents include acetic acid and a salt (1-2% W/V); citric acid and a salt (1-3% W/V); boric acid and a salt (0.5-2.5%) W/V); and phosphoric acid and a salt (0.8-2%> W/V).
  • Suitable preservatives include benzalkonium chloride (0.003- 0.03% W/V); chlorobutanol (0.3-0.9% W/V); and parabens (0.01-0.25% W/V).
  • the administration route is an injection.
  • the injection is by a parenteral route elected from an intramuscular, subcutaneous, intravenous, intraarterial, intraperitoneal, intraarticular, intraepidural, intrathecal, intravenous, intramuscular, or intra sternal injection.
  • the administration route is an infusion.
  • the administration route is oral, nasal, mucosal, sublingual, intratracheal, ophthalmic, rectal, vaginal, ocular, topical, transdermal, pulmonary, or inhalation.
  • PLPAs and/or targeted-PLPA is prepared as an infusion composition, an injection composition, a parenteral composition, or a topical
  • the injection includes one or more of:
  • the PLPA and/or targeted- PLPA is a liquid solution or a suspension.
  • solid forms suitable for solution in, or suspension in, liquid vehicles prior to injection are also provided herein.
  • the targeted pegylated liposomal alpha (L-alpha or D-alpha) or D-gamma polyglutamated antifolate is formulated as an enteric-coated tablet or gel capsule according to methods known in the art.
  • the targeted pegylated liposomal alpha (L-alpha or D- alpha) or D-gamma polyglutamated antifolate formulations are administered to a tumor of the central nervous system using a slow, sustained intracranial infusion of the liposomes directly into the tumor (e.g., a convection-enhanced delivery (CED)).
  • CED convection-enhanced delivery
  • the formulations are directly applied to tissue surfaces.
  • compositions are further described herein or otherwise known in the art.
  • compositions can be conveniently delivered in the form of an aerosol spray presentation from pressurized packs or a nebulizer, with the use of a suitable propellant, e.g., dichlorodifluoromethane, trichlorofluoromethane, ichlorotetrafluoroethane, carbon dioxide or other suitable gas.
  • a suitable propellant e.g., dichlorodifluoromethane, trichlorofluoromethane, ichlorotetrafluoroethane, carbon dioxide or other suitable gas.
  • the dosage unit can be determined by providing a valve to deliver a metered amount.
  • they can formulated for parenteral administration by injection, e.g., by bolus injection or continuous infusion.
  • Formulations for injection can be presented in unit dosage form, e.g., in ampoules or in multi-dose containers.
  • Pharmaceutical parenteral formulations include aqueous solutions of the ingredients.
  • Aqueous injection suspensions can contain substances which increase the viscosity of the suspension, such as sodium carboxymethyl cellulose, sorbitol, or dextran.
  • suspensions of liposomes can be prepared as oil-based suspensions.
  • Suitable lipophilic solvents or vehicles include fatty oils such as sesame oil, or synthetic fatty acid esters, such as ethyl oleate or triglycerides.
  • the non-targeted or targeted pegylated liposomal alpha (L-alpha or D-alpha) or D-gamma polyglutamated antifolates can be in powder form or lyophilized form for constitution with a suitable vehicle, e.g., sterile pyrogen-free water, before use.
  • a suitable vehicle e.g., sterile pyrogen-free water
  • compositions e.g., alpha (L-alpha or D-alpha) or D-gamma polyglutamated antifolates and liposomes containing the alpha (L-alpha or D-alpha) or D- gamma polyglutamated antifolates
  • compositions have applications, in vivo, ex vivo and in vitro.
  • the compositions have in vitro applications.
  • In vitro use may include uses such as cell culturing and tissue engineering where selective treatment of a subpopulation of cells is desired.
  • the cells can be treated with a sample composition or sample liposome as discussed to address cancerous subpopulations of cells.
  • the cancerous subpopulation may arise because the donor originally has cancer or because the cells spontaneously transform during in vitro procedures.
  • the liposome compositions are provided in a kit comprising a container with the liposomes, and optionally, a container with the entity (antigen) targeted or preferentially bound by liposomes, and an instruction, e.g., procedures or information related to using the liposome composition in one or more applications.
  • instruction can be provided via any medium, e.g., hard paper copy, electronic medium, or access to a database or website containing the instruction.
  • the disclosure provides a method of killing a hyperproliferative cell that comprises contacting a hyperproliferative cell with a delivery vehicle (e.g., liposome) comprising alpha (L-alpha or D-alpha) or D-gamma
  • a delivery vehicle e.g., liposome
  • alpha L-alpha or D-alpha
  • D-gamma D-gamma
  • polyglutamated e.g., pentaglutamated or hexaglutamated
  • antifolate e.g., pentaglutamated or hexaglutamated
  • the delivery vehicle is a liposome that comprises alpha polyglutamated antifolate. In some embodiments, the delivery vehicle is a liposome that comprises L- alpha polyglutamated antifolate. In some embodiments, the delivery vehicle is a liposome that comprises D-alpha polyglutamated antifolate. In some embodiments, the delivery vehicle is a liposome that comprises D-gamma polyglutamated antifolate.
  • the alpha or D-gamma polyglutamated antifolate is a member selected from the group consisting of: polyglutamated methotrexate (MTX), polyglutamated pemetrexed (PMX), polyglutamated lometrexol (LTX), polyglutamated AG2034, polyglutamated raltitrexed (RTX), polyglutamated piritrexim, polyglutamated
  • MTX polyglutamated methotrexate
  • PMX polyglutamated pemetrexed
  • LTX polyglutamated lometrexol
  • RTX polyglutamated raltitrexed
  • piritrexim polyglutamated piritrexim
  • the alpha or D- gamma polyglutamated antifolate comprises a pentaglutamated antifolate selected from the group consisting of pentaglutamated MTX, pentaglutamated PMX, pentaglutamated LTX, pentaglutamated AG2034, pentaglutamated RTX, pentaglutamated piritrexim, pentaglutamated pralatrexate, pentaglutamated AG2034, pentaglutamated GW1843, pentaglutamated aminopterin, and pentaglutamated LY309887.
  • a pentaglutamated antifolate selected from the group consisting of pentaglutamated MTX, pentaglutamated PMX, pentaglutamated LTX, pentaglutamated AG2034, pentaglutamated RTX, pentaglutamated piritrexim, pentaglutamated pralatrexate, pentaglutamated AG2034, pentaglutamated GW1843, pentaglutamated amin
  • the alpha or D-gamma polyglutamated antifolate comprises pentaglutamated PMX. In some embodiments, the alpha or D-gamma polyglutamated antifolate comprises pentaglutamated MTX. In some embodiments, the alpha or D-gamma polyglutamated antifolate comprises pentaglutamated RTX. In some embodiments, the alpha or D-gamma polyglutamated antifolate comprises pentaglutamated LTX.
  • the alpha or D-gamma polyglutamated antifolate comprises a hexaglutamated antifolate selected from the group consisting of hexaglutamated MTX, hexaglutamated PMX, hexaglutamated LTX, hexaglutamated AG2034, hexaglutamated RTX, hexaglutamated piritrexim, hexaglutamated pralatrexate, hexaglutamated AG2034, hexaglutamated GW1843, hexaglutamated aminopterin, and hexaglutamated LY309887.
  • a hexaglutamated antifolate selected from the group consisting of hexaglutamated MTX, hexaglutamated PMX, hexaglutamated LTX, hexaglutamated AG2034, hexaglutamated RTX, hexaglutamated piritrexim
  • the alpha or D-gamma polyglutamated antifolate comprises hexaglutamated PMX. In some embodiments, the alpha or D-gamma polyglutamated antifolate comprises hexaglutamated MTX. In some embodiments, the alpha or D-gamma polyglutamated antifolate comprises hexaglutamated RTX. In some embodiments, the alpha or D-gamma polyglutamated antifolate comprises hexaglutamated LTX. In some embodiments, the delivery vehicle is a liposome. In further embodiments, the liposome is pegylated.
  • the delivery vehicle comprises a targeting moiety on its surface that specifically binds an antigen on the surface of the hyperproliferative cell. In further embodiments, the delivery vehicle comprises a targeting moiety that specifically binds a cell surface antigen on the surface of the hyperproliferative cell selected from the group consisting of GO MB, CD56, TACSTD2 (TROP2),
  • CEACAM5 Folate receptor-a, Folate receptor- ⁇ , Folate receptor- ⁇ , Mucin 1, STEAP1, Mesothelin, Nectin 4, ENPP3, Guanylyl cyclase C (GCC), SLC44A4, NaPi2b, CD70 (TNFSF7), CA9 (Carbonic anhydrase), 5T4 (TPBG), SLTRK6, SC-16, Tissue factor, LIV-1 (ZIP6), CGEN- 15027, P-Cadherin, Fibronectin Extra-domain B (ED-B),
  • VEGFR2 (CD309), Tenascin, Collagen IV, Periostin, endothelin receptor, HER 2, EGFR, CD30, CD79b, CD 19, CD 138, CD74, CD37, CD 19, CD22, CD33, and CD98.
  • the delivery vehicle is a liposome
  • the liposome comprises a targeting moiety that specifically binds comprises a targeting moiety that specifically binds a cell surface antigen on the surface of the hyperproliferative cell selected from the group consisting of GONMB, CD56, TACSTD2 (TROP2), CEACAM5, Folate receptor-a, Folate receptor- ⁇ , Folate receptor- ⁇ , Mucin 1, STEAPl, Mesothelin, Nectin 4, ENPP3, Guanylyl cyclase C (GCC), SLC44A4, NaPi2b, CD70 (TNFSF7), CA9 (Carbonic anhydrase), 5T4 (TPBG), SLTRK6, SC-16, Tissue factor, LIV-1 (ZIP6), CGEN-15027, P-Cadherin, Fibronectin Extra-domain B (ED-B), VEGFR2 (CD309), Tenascin,
  • the disclosure provides a method of inhibiting the proliferation of a tumor cell that comprises contacting the tumor cell with a delivery vehicle (e.g., liposome) comprising a
  • polyglutamated e.g., pentaglutamated or hexaglutamated
  • antifolate e.g., pentaglutamated or hexaglutamated
  • the alpha (L-alpha or D-alpha) or D-gamma polyglutamated antifolate is a member selected from the group consisting of: polyglutamated methotrexate (MTX), polyglutamated pemetrexed (PMX), polyglutamated lometrexol (LTX), polyglutamated AG2034, polyglutamated raltitrexed (RTX), polyglutamated piritrexim, polyglutamated pralatrexate, polyglutamated AG2034, polyglutamated GW1843, polyglutamated aminopterin, and polyglutamated LY309887.
  • MTX polyglutamated methotrexate
  • PMX polyglutamated pemetrexed
  • LTX polyglutamated lometrexol
  • RTX polyglutamated raltitrexed
  • piritrexim polyglutamated piritrexim
  • polyglutamated pralatrexate polyglutamated AG2034, polyglu
  • the alpha (L-alpha or D-alpha) or D-gamma polyglutamated antifolate comprises a pentaglutamated antifolate selected from the group consisting of pentaglutamated MTX, pentaglutamated PMX, pentaglutamated LTX, pentaglutamated AG2034, pentaglutamated RTX, pentaglutamated piritrexim, pentaglutamated pralatrexate, pentaglutamated AG2034, pentaglutamated GW1843, pentaglutamated aminopterin, and pentaglutamated
  • a pentaglutamated antifolate selected from the group consisting of pentaglutamated MTX, pentaglutamated PMX, pentaglutamated LTX, pentaglutamated AG2034, pentaglutamated RTX, pentaglutamated piritrexim, pentaglutamated pralatrexate, pentaglutamated AG2034, pentaglutamated GW1843, pentagluta
  • the alpha (L-alpha or D-alpha) or D-gamma polyglutamated antifolate comprises pentaglutamated PMX. In some embodiments, the alpha (L-alpha or D-alpha) or D-gamma polyglutamated antifolate comprises
  • the alpha (L-alpha or D-alpha) or D- gamma polyglutamated antifolate comprises pentaglutamated RTX.
  • the alpha (L-alpha or D-alpha) or D-gamma polyglutamated antifolate comprises pentaglutamated LTX.
  • the alpha (L-alpha or D-alpha) or D-gamma polyglutamated antifolate comprises a hexaglutamated antifolate selected from the group consisting of hexaglutamated MTX, hexaglutamated PMX,
  • the alpha (L-alpha or D-alpha) or D-gamma polyglutamated antifolate comprises hexaglutamated PMX.
  • the alpha (L-alpha or D-alpha) or D-gamma polyglutamated antifolate comprises hexaglutamated MTX. In some embodiments, the alpha (L-alpha or D-alpha) or D-gamma polyglutamated antifolate comprises hexaglutamated RTX. In some embodiments, the alpha (L-alpha or D-alpha) or D-gamma polyglutamated antifolate comprises hexaglutamated LTX. In some embodiments, the delivery vehicle is a liposome. In further embodiments, the liposome is pegylated.
  • the delivery vehicle comprises a targeting moiety on its surface that specifically binds an antigen on the surface of the hyperproliferative cell.
  • the delivery vehicle comprises a targeting moiety that specifically binds a cell surface antigen on the surface of the tumor cell selected from the group consisting of GONMB, CD56, TACSTD2 (TROP2), CEACAM5, Folate receptor- ex, Folate receptor- ⁇ , Folate receptor- ⁇ , Mucin 1, STEAPl, Mesothelin, Nectin 4, ENPP3, Guanylyl cyclase C (GCC), SLC44A4, NaPi2b, CD70 (TNFSF7), CA9 (Carbonic anhydrase), 5T4 (TPBG), SLTRK6, SC-16, Tissue factor, LIV-1 (ZIP6), CGEN-15027, P-Cadherin, Fibronectin Extra-domain B (ED-B), VEGFR2 (CD309), Tenascin,
  • the delivery vehicle is a liposome
  • the liposome comprises a targeting moiety that specifically binds comprises a targeting moiety that specifically binds a cell surface antigen on the surface of the tumor cell selected from the group consisting of GONMB, CD56, TACSTD2 (TROP2), CEACAM5, Folate receptor-a, Folate receptor- ⁇ , Folate receptor- ⁇ , Mucin 1, STEAPl, Mesothelin, Nectin 4, ENPP3, Guanylyl cyclase C (GCC), SLC44A4, NaPi2b, CD70 (TNFSF7), CA9 (Carbonic anhydrase), 5T4 (TPBG),
  • the disclosure provides a method for treating a hyperproliferative disease that comprises administering an effective amount of a delivery vehicle (e.g., liposome) comprising alpha (L-alpha or D-alpha) or D-gamma
  • a delivery vehicle e.g., liposome
  • alpha L-alpha or D-alpha
  • D-gamma D-gamma
  • the administered delivery vehicle is a liposome that comprises alpha polyglutamated antifolate.
  • the administered delivery vehicle is a liposome that comprises L-alpha polyglutamated antifolate.
  • the administered delivery vehicle is a liposome that comprises D-alpha polyglutamated antifolate.
  • the administered delivery vehicle is a liposome that comprises D-gamma polyglutamated antifolate.
  • the administered alpha or D-gamma polyglutamated antifolate is a member selected from the group consisting of: polyglutamated
  • the administered alpha or D-gamma polyglutamated antifolate comprises a pentaglutamated antifolate selected from the group consisting of pentaglutamated MTX, pentaglutamated PMX, pentaglutamated LTX, pentaglutamated AG2034,
  • the administered alpha or D-gamma polyglutamated antifolate comprises pentaglutamated PMX.
  • the administered alpha or D-gamma polyglutamated antifolate comprises pentaglutamated MTX.
  • the administered the alpha or D-gamma polyglutamated antifolate comprises pentaglutamated RTX.
  • the administered alpha or D-gamma polyglutamated antifolate comprises pentaglutamated LTX.
  • the administered alpha or D-gamma polyglutamated antifolate comprises a hexaglutamated antifolate selected from the group consisting of hexaglutamated MTX, hexaglutamated PMX, hexaglutamated LTX, hexaglutamated AG2034, hexaglutamated RTX, hexaglutamated piritrexim, hexaglutamated pralatrexate, hexaglutamated AG2034, hexaglutamated GW1843, hexaglutamated aminopterin, and hexaglutamated LY309887.
  • the administered alpha or D-gamma polyglutamated antifolate comprises hexaglutamated PMX. In some embodiments, the administered alpha or D- gamma polyglutamated antifolate comprises hexaglutamated MTX. In some
  • the administered the alpha or D-gamma polyglutamated antifolate comprises hexaglutamated RTX. In some embodiments, the administered alpha or D- gamma polyglutamated antifolate comprises hexaglutamated LTX. In some
  • the administered delivery vehicle is a liposome.
  • the liposome is pegylated.
  • the delivery vehicle comprises a targeting moiety on its surface that specifically binds an antigen on the surface of a target cell of interest.
  • the delivery vehicle comprises a targeting moiety that specifically binds a cell surface antigen selected from the group consisting of GONMB, CD56, TACSTD2 (TROP2), CEACAM5, Folate receptor-a, Folate receptor- ⁇ , Folate receptor- ⁇ , Mucin 1, STEAP1, Mesothelin, Nectin 4, E PP3, Guanylyl cyclase C (GCC), SLC44A4, NaPi2b, CD70 (T FSF7), CA9 (Carbonic anhydrase), 5T4 (TPBG), SLTRK6, SC-16, Tissue factor, LIV-1 (ZIP6), CGEN-15027, P-Cadherin, Fibronectin Extra-domain B (ED-B), VEGFR2 (CD309), Tenascin, Collagen IV, Periostin, endothelin receptor, HER 2, EGFR, CD30, CD79b, CD 19, CD 138, CD74, CD37, CD 19, CD22, CD
  • CEACAM5 Folate receptor-a, Folate receptor- ⁇ , Folate receptor- ⁇ , Mucin 1, STEAP1, Mesothelin, Nectin 4, ENPP3, Guanylyl cyclase C (GCC), SLC44A4, NaPi2b, CD70 (TNFSF7), CA9 (Carbonic anhydrase), 5T4 (TPBG), SLTRK6, SC-16, Tissue factor, LIV-1 (ZIP6), CGEN-15027, P-Cadherin, Fibronectin Extra-domain B (ED-B),
  • VEGFR2 (CD309), Tenascin, Collagen IV, Periostin, endothelin receptor, HER 2, EGFR, CD30, CD79b, CD 19, CD 138, CD74, CD37, CD 19, CD22, CD33, and CD98.
  • the disclosure provides a method for treating a disorder of the immune system (e.g., an autoimmune disease such as rheumatoid arthritis) that comprises administering an effective amount of a delivery vehicle (e.g., liposome) comprising alpha (L-alpha or D-alpha) or D-gamma polyglutamated (e.g.,
  • the administered delivery vehicle is a liposome that comprises alpha polyglutamated antifolate. In some embodiments, the administered delivery vehicle is a liposome that comprises L-alpha polyglutamated antifolate. In some embodiments, the administered delivery vehicle is a liposome that comprises D-alpha polyglutamated antifolate. In some embodiments, the administered delivery vehicle is a liposome that comprises D-gamma polyglutamated antifolate.
  • the administered alpha or D-gamma polyglutamated antifolate is a member selected from the group consisting of: polyglutamated methotrexate (MTX), polyglutamated pemetrexed (PMX), polyglutamated lometrexol (LTX), polyglutamated AG2034, polyglutamated raltitrexed (RTX), polyglutamated piritrexim, polyglutamated pralatrexate, polyglutamated AG2034, polyglutamated GW1843, polyglutamated aminopterin, and polyglutamated LY309887.
  • MTX polyglutamated methotrexate
  • PMX polyglutamated pemetrexed
  • LTX polyglutamated lometrexol
  • RTX polyglutamated raltitrexed
  • piritrexim polyglutamated piritrexim
  • polyglutamated pralatrexate polyglutamated AG2034, polyglutamated GW1843, polyglutamated
  • the administered polyglutamated antifolate comprises an alpha (L-alpha or D-alpha) or D-gamma pentaglutamated antifolate selected from the group consisting of pentaglutamated MTX, pentaglutamated PMX, pentaglutamated LTX, pentaglutamated AG2034,
  • the administered alpha or D-gamma polyglutamated antifolate comprises a hexaglutamated PMX.
  • the administered polyglutamated antifolate comprises an alpha (L-alpha or D-alpha) or D- gamma hexaglutamated antifolate selected from the group consisting of hexaglutamated MTX, hexaglutamated PMX, hexaglutamated LTX, hexaglutamated AG2034, hexaglutamated RTX, hexaglutamated piritrexim, hexaglutamated pralatrexate, hexaglutamated AG2034, hexaglutamated GW1843, hexaglutamated aminopterin, and hexaglutamated LY309887.
  • alpha (L-alpha or D-alpha) or D- gamma hexaglutamated antifolate selected from the group consisting of hexaglutamated MTX, hexaglutamated PMX, hexaglutamated LTX, hexa
  • the administered alpha or D-gamma polyglutamated antifolate comprises a hexaglutamated PMX. In some embodiments, the administered alpha (L-alpha or D-alpha) or D-gamma polyglutamated antifolate comprises alpha or D-gamma pentaglutamated MTX. In some embodiments, the administered alpha (L-alpha or D-alpha) or D-gamma polyglutamated antifolate comprises alpha or D-gamma hexaglutamated MTX. In some embodiments, administered alpha (L-alpha or D-alpha) or D-gamma polyglutamated antifolate comprises a pentaglutamated RTX.
  • administered alpha (L-alpha or D-alpha) or D-gamma polyglutamated antifolate comprises a hexaglutamated RTX.
  • the administered alpha or D-gamma polyglutamated antifolate comprises pentaglutamated pralatrexate (PTX).
  • the administered alpha or D- gamma polyglutamated antifolate comprises hexaglutamated pralatrexate (PTX).
  • the administered alpha or D-gamma polyglutamated antifolate comprises lometrexol (LTX).
  • the administered alpha or D-gamma polyglutamated antifolate comprises lometrexol (LTX). In some embodiments, the administered alpha or D-gamma polyglutamated antifolate comprises pentaglutamated lometrexol (LTX). In some embodiments, the administered alpha or D-gamma polyglutamated antifolate comprises hexaglutamated lometrexol (LTX).
  • the administered delivery vehicle is a liposome.
  • the liposome is pegylated.
  • the delivery vehicle comprises a targeting moiety on its surface that specifically binds an antigen on the surface of a target cell of interest.
  • the delivery vehicle comprises a targeting moiety that specifically binds a cell surface antigen selected from the group consisting of GONMB, CD56, TACSTD2 (TROP2), CEACAM5, Folate receptor-a, Folate receptor- ⁇ , Folate receptor- ⁇ , Mucin 1, STEAPl, Mesothelin, Nectin 4, ENPP3, Guanylyl cyclase C (GCC), SLC44A4, NaPi2b, CD70 (TNFSF7), CA9
  • a targeting moiety that specifically binds a cell surface antigen selected from the group consisting of GONMB, CD56, TACSTD2 (TROP2), CEACAM5, Folate receptor-a, Folate receptor- ⁇ , Folate receptor- ⁇ , Mucin 1, STEAPl, Mesothelin, Nectin 4, ENPP3, Guanylyl cyclase C (GCC), SLC44A4, NaPi2b, CD70 (TNFSF7), CA9
  • the delivery vehicle is a liposome
  • the liposome comprises a targeting moiety that specifically binds a cell surface antigen selected from the group consisting of GONMB, CD56, TACSTD2 (TROP2), CEACAM5, Folate receptor- ⁇ , Folate receptor- ⁇ , Folate receptor- ⁇ , Mucin 1, STEAPl, Mesothelin, Nectin 4, ENPP3, Guanylyl cyclase C (GCC), SLC44A4, NaPi2b, CD70 (TNFSF7), CA9 (Carbonic anhydrase), 5T4 (TPBG),
  • a targeting moiety that specifically binds a cell surface antigen selected from the group consisting of GONMB, CD56, TACSTD2 (TROP2), CEACAM5, Folate receptor- ⁇ , Folate receptor- ⁇ , Folate receptor- ⁇ , Mucin 1, STEAPl, Mesothelin, Nectin 4, ENPP3, Guanylyl cyclase C (GCC), SLC
  • the disclosure provides a method for treating cancer that comprises administering an effective amount of a delivery vehicle (e.g., liposome) comprising alpha (L-alpha or D-alpha) or D-gamma polyglutamated (e.g.,
  • the cancer is a cancer selected from the group consisting of: lung (e.g., non-small lung cancer), pancreatic, breast cancer, ovarian, lung, prostate, head and neck, gastric, gastrointestinal, colon, esophageal, cervical, kidney, biliary duct, gallbladder, and a hematologic malignancy (e.g., a leukemia or lymphoma).
  • the administered delivery vehicle is a liposome that comprises alpha polyglutamated antifolate.
  • the administered delivery vehicle is a liposome that comprises L-alpha polyglutamated antifolate. In some embodiments, the administered delivery vehicle is a liposome that comprises D-alpha polyglutamated antifolate. In some embodiments, the administered delivery vehicle is a liposome that comprises D-gamma polyglutamated antifolate.
  • the administered alpha (L-alpha or D-alpha) or D-gamma polyglutamated antifolate is a member selected from the group consisting of: polyglutamated methotrexate (MTX), polyglutamated pemetrexed (PMX), polyglutamated lometrexol (LTX), polyglutamated AG2034, polyglutamated raltitrexed (RTX), polyglutamated piritrexim, polyglutamated pralatrexate, polyglutamated AG2034, polyglutamated GW1843, polyglutamated aminopterin, and polyglutamated LY309887.
  • MTX polyglutamated methotrexate
  • PMX polyglutamated pemetrexed
  • LTX polyglutamated lometrexol
  • RTX polyglutamated raltitrexed
  • piritrexim polyglutamated piritrexim
  • polyglutamated pralatrexate polyglutamated AG2034, poly
  • the administered alpha (L-alpha or D-alpha) or D-gamma polyglutamated antifolate comprises a pentaglutamated antifolate selected from the group consisting of pentaglutamated MTX, pentaglutamated PMX, pentaglutamated LTX, pentaglutamated AG2034,
  • pentaglutamated RTX pentaglutamated piritrexim
  • pentaglutamated pralatrexate pentaglutamated AG2034, pentaglutamated GW1843, pentaglutamated aminopterin, and pentaglutamated LY309887.
  • the administered alpha (L-alpha or D-alpha) or D-gamma polyglutamated antifolate comprises a hexaglutamated antifolate selected from the group consisting of hexaglutamated MTX, hexaglutamated PMX, hexaglutamated LTX, hexaglutamated AG2034, hexaglutamated RTX, hexaglutamated piritrexim, hexaglutamated pralatrexate, hexaglutamated AG2034, hexaglutamated GW1843, hexaglutamated aminopterin, and hexaglutamated LY309887.
  • a hexaglutamated antifolate selected from the group consisting of hexaglutamated MTX, hexaglutamated PMX, hexaglutamated LTX, hexaglutamated AG2034, hexaglutamated RTX,
  • the administered alpha (L-alpha or D-alpha) or D-gamma polyglutamated antifolate comprises pentaglutamated PMX. In some embodiments, the administered alpha (L-alpha or D-alpha) or D-gamma polyglutamated antifolate comprises hexaglutamated PMX. In some embodiments, the administered alpha (L-alpha or D- alpha) or D-gamma polyglutamated antifolate comprises pentaglutamated MTX. In some embodiments, the administered alpha (L-alpha or D-alpha) or D-gamma polyglutamated antifolate comprises hexaglutamated MTX.
  • the administered alpha (L-alpha or D-alpha) or D-gamma polyglutamated antifolate comprises pentaglutamated RTX. In some embodiments, the administered alpha (L-alpha or D- alpha) or D-gamma polyglutamated antifolate comprises hexaglutamated RTX. In some embodiments, the administered alpha (L-alpha or D-alpha) or D-gamma polyglutamated antifolate comprises pentaglutamated LTX. In some embodiments, the administered alpha (L-alpha or D-alpha) or D-gamma polyglutamated antifolate comprises
  • the administered delivery vehicle is a liposome.
  • the liposome is pegylated.
  • the delivery vehicle comprises a targeting moiety on its surface that specifically binds an antigen on the surface of a target cell of interest.
  • the delivery vehicle comprises a targeting moiety that specifically binds a cell surface antigen selected from the group consisting of GONMB, CD56, TACSTD2 (TROP2), CEACAM5, Folate receptor-a, Folate receptor- ⁇ , Folate receptor- ⁇ , Mucin 1, STEAPl, Mesothelin, Nectin 4, ENPP3, Guanylyl cyclase C (GCC), SLC44A4, NaPi2b, CD70 (TNFSF7), CA9
  • a targeting moiety that specifically binds a cell surface antigen selected from the group consisting of GONMB, CD56, TACSTD2 (TROP2), CEACAM5, Folate receptor-a, Folate receptor- ⁇ , Folate receptor- ⁇ , Mucin 1, STEAPl, Mesothelin, Nectin 4, ENPP3, Guanylyl cyclase C (GCC), SLC44A4, NaPi2b, CD70 (TNFSF7), CA9
  • the delivery vehicle is a liposome
  • the liposome comprises a targeting moiety that specifically binds a cell surface antigen selected from the group consisting of GONMB, CD56, TACSTD2 (TROP2), CEACAM5, Folate receptor- ⁇ , Folate receptor- ⁇ , Folate receptor- ⁇ , Mucin 1, STEAPl, Mesothelin, Nectin 4, ENPP3, Guanylyl cyclase C (GCC), SLC44A4, NaPi2b, CD70 (TNFSF7), CA9 (Carbonic anhydrase), 5T4 (TPBG),
  • a targeting moiety that specifically binds a cell surface antigen selected from the group consisting of GONMB, CD56, TACSTD2 (TROP2), CEACAM5, Folate receptor- ⁇ , Folate receptor- ⁇ , Folate receptor- ⁇ , Mucin 1, STEAPl, Mesothelin, Nectin 4, ENPP3, Guanylyl cyclase C (GCC), SLC
  • the delivery vehicle is a liposome that comprises alpha polyglutamated antifolate.
  • the administered delivery vehicle is a liposome that comprises L-alpha polyglutamated antifolate.
  • the administered delivery vehicle is a liposome that comprises D-alpha polyglutamated antifolate.
  • the administered delivery vehicle is a liposome that comprises D-gamma polyglutamated antifolate.
  • the disclosure provides a method for treating lung cancer (e.g., non-small lung cancer) that comprises administering an effective amount of a delivery vehicle (e.g., liposome) comprising alpha (L-alpha or D-alpha) or D-gamma polyglutamated (e.g., pentaglutamated or hexaglutamated) antifolate to a subject having or at risk of having lung cancer.
  • a delivery vehicle e.g., liposome
  • alpha L-alpha or D-alpha
  • D-gamma polyglutamated e.g., pentaglutamated or hexaglutamated
  • the disclosure provides a method for treating lung cancer (e.g., non-small lung cancer) that comprises administering an effective amount of a delivery vehicle (e.g., liposome) comprising alpha (L-alpha or D-alpha) or D-gamma polyglutamated (e.g., pentaglutamated or hexaglutamated
  • the administered delivery vehicle is a liposome that comprises D-alpha polyglutamated antifolate. In some embodiments, the administered delivery vehicle is a liposome that comprises D-gamma polyglutamated antifolate. In some embodiments, the administered alpha or D-gamma polyglutamated antifolate is a member selected from the group consisting of: polyglutamated methotrexate (MTX), polyglutamated pemetrexed (PMX), polyglutamated lometrexol (LTX), polyglutamated AG2034, polyglutamated raltitrexed (RTX), polyglutamated piritrexim, polyglutamated pralatrexate,
  • MTX polyglutamated methotrexate
  • PMX polyglutamated pemetrexed
  • LTX polyglutamated lometrexol
  • RTX polyglutamated AG2034, polyglutamated raltitrexed
  • piritrexim polyglutamated pralatre
  • the administered alpha or D-gamma polyglutamated antifolate comprises a pentaglutamated antifolate selected from the group consisting of pentaglutamated MTX, pentaglutamated PMX, pentaglutamated LTX, pentaglutamated AG2034, pentaglutamated RTX, pentaglutamated piritrexim, pentaglutamated pralatrexate, pentaglutamated AG2034, pentaglutamated GW1843, pentaglutamated aminopterin, and pentaglutamated LY309887.
  • the administered alpha or D-gamma polyglutamated antifolate comprises a pentaglutamated antifolate selected from the group consisting of pentaglutamated MTX, pentaglutamated PMX, pentaglutamated LTX, pentaglutamated AG2034, pentaglutamated RTX, pentaglutamated piritrexim, pentaglutamated pralatrexate, pentaglutamated
  • hexaglutamated antifolate selected from the group consisting of hexaglutamated MTX, hexaglutamated PMX, hexaglutamated LTX, hexaglutamated AG2034, hexaglutamated RTX, hexaglutamated piritrexim, hexaglutamated pralatrexate, hexaglutamated AG2034, hexaglutamated GW1843, hexaglutamated aminopterin, and hexaglutamated LY309887.
  • the administered alpha or D-gamma polyglutamated antifolate comprises pentaglutamated PMX.
  • the administered alpha or D-gamma polyglutamated antifolate comprises hexaglutamated PMX. In some embodiments, the administered alpha or D-gamma polyglutamated antifolate comprises pentaglutamated MTX. In some embodiments, the administered alpha or D-gamma polyglutamated antifolate comprises hexaglutamated MTX. In some embodiments, the administered alpha or D-gamma polyglutamated antifolate comprises pentaglutamated RTX. In some embodiments, the administered alpha or D-gamma polyglutamated antifolate comprises hexaglutamated RTX.
  • the administered alpha or D-gamma polyglutamated antifolate comprises pentaglutamated LTX. In some embodiments, the administered alpha or D-gamma polyglutamated antifolate comprises hexaglutamated LTX. In some embodiments, the administered delivery vehicle is a liposome. In further embodiments, the liposome is pegylated. In additional
  • the delivery vehicle comprises a targeting moiety on its surface that specifically binds an antigen on the surface of a lung cancer (e.g., non-small cell lung cancer) cell.
  • the delivery vehicle comprises a targeting moiety that specifically binds a cell surface antigen selected from the group consisting of Mucin 1, Nectin 4, NaPi2b, CD56, EGFR, and SC-16.
  • the delivery vehicle is a liposome, and the liposome comprises a targeting moiety that specifically binds a cell surface antigen selected from the group consisting of Mucin 1, Nectin 4, NaPi2b, CD56, EGFR, and SC-16.
  • the disclosure provides a method for treating pancreatic cancer that comprises administering an effective amount of a delivery vehicle (e.g., liposome) comprising alpha or D-gamma polyglutamated (e.g., pentaglutamated or hexaglutamated) antifolate to a subject having or at risk of having pancreatic cancer.
  • a delivery vehicle e.g., liposome
  • alpha or D-gamma polyglutamated antifolate e.g., pentaglutamated or hexaglutamated
  • the administered delivery vehicle is a liposome that comprises alpha polyglutamated antifolate.
  • the administered delivery vehicle is a liposome that comprises L-alpha polyglutamated antifolate.
  • the administered delivery vehicle is a liposome that comprises D-alpha polyglutamated antifolate.
  • the administered delivery vehicle is a liposome that comprises D-gamma polyglutamated antifolate.
  • the administered alpha or D-gamma polyglutamated antifolate is a member selected from the group consisting of: polyglutamated methotrexate (MTX), polyglutamated pemetrexed (PMX), polyglutamated lometrexol (LTX), polyglutamated AG2034, polyglutamated raltitrexed (RTX), polyglutamated piritrexim, polyglutamated pralatrexate, polyglutamated AG2034, polyglutamated GW1843, polyglutamated aminopterin, and polyglutamated LY309887.
  • the administered alpha or D-gamma polyglutamated antifolate comprises a pentaglutamated antifolate selected from the group consisting of
  • pentaglutamated MTX pentaglutamated MTX
  • pentaglutamated PMX pentaglutamated LTX
  • pentaglutamated AG2034 pentaglutamated RTX
  • pentaglutamated piritrexim pentaglutamated
  • the administered alpha or D-gamma polyglutamated antifolate comprises a hexaglutamated antifolate selected from the group consisting of hexaglutamated MTX, hexaglutamated PMX, hexaglutamated LTX, hexaglutamated AG2034, hexaglutamated RTX, hexaglutamated piritrexim, hexaglutamated pralatrexate, hexaglutamated AG2034, hexaglutamated GW1843, hexaglutamated aminopterin, and hexaglutamated LY309887.
  • the administered alpha (L-alpha or D-alpha) or D-gamma polyglutamated antifolate comprises pentaglutamated PMX.
  • the administered alpha (L-alpha or D-alpha) or D-gamma polyglutamated antifolate comprises
  • the administered alpha (L-alpha or D- alpha) or D-gamma polyglutamated antifolate comprises pentaglutamated MTX. In some embodiments, the administered alpha (L-alpha or D-alpha) or D-gamma polyglutamated antifolate comprises hexaglutamated MTX. In some embodiments, the administered alpha (L-alpha or D-alpha) or D-gamma polyglutamated antifolate comprises
  • the administered alpha (L-alpha or D- alpha) or D-gamma polyglutamated antifolate comprises hexaglutamated RTX. In some embodiments, the administered alpha (L-alpha or D-alpha) or D-gamma polyglutamated antifolate comprises pentaglutamated LTX. In some embodiments, the administered alpha (L-alpha or D-alpha) or D-gamma polyglutamated antifolate comprises
  • the administered delivery vehicle is a liposome.
  • the liposome is pegylated.
  • the delivery vehicle comprises a targeting moiety on its surface that specifically binds an antigen on the surface of a pancreatic cancer cell.
  • the delivery vehicle comprises a targeting moiety that specifically binds a cell surface antigen selected from the group consisting of TACSTD2 (TROP2), Mucin 1, Mesothelin, Guanylyl cyclase C (GCC), SLC44A4, and Nectin 4.
  • the delivery vehicle is a liposome
  • the liposome comprises a targeting moiety that specifically binds a cell surface antigen selected from the group consisting of TACSTD2 (TROP2), Mucin 1, Mesothelin, Guanylyl cyclase C (GCC), SLC44A4, and Nectin 4.
  • TROP2 TACSTD2
  • Mucin 1 Mesothelin
  • GCC Guanylyl cyclase C
  • SLC44A4 SLC44A4
  • Nectin 4 a cell surface antigen selected from the group consisting of TACSTD2 (TROP2), Mucin 1, Mesothelin, Guanylyl cyclase C (GCC), SLC44A4, and Nectin 4.
  • the disclosure provides a method for treating breast cancer (e.g., triple negative breast cancer (estrogen receptor " , progesterone receptor " , and HER2) that comprises administering an effective amount of a delivery vehicle (e.g., liposome) comprising alpha (L-alpha or D-alpha) or D-gamma
  • a delivery vehicle e.g., liposome
  • the administered delivery vehicle is a liposome that comprises alpha polyglutamated antifolate.
  • the administered delivery vehicle is a liposome that comprises L-alpha polyglutamated antifolate. In some embodiments, the administered delivery vehicle is a liposome that comprises D-alpha polyglutamated antifolate. In some embodiments, the administered delivery vehicle is a liposome that comprises D-gamma polyglutamated antifolate. In some embodiments, the administered alpha (L-alpha or D-alpha) or D- gamma polyglutamated antifolate is a member selected from the group consisting of: polyglutamated methotrexate (MTX), polyglutamated pemetrexed (PMX),
  • polyglutamated lometrexol LTX
  • polyglutamated AG2034 polyglutamated raltitrexed
  • polyglutamated piritrexim polyglutamated pralatrexate
  • polyglutamated AG2034 polyglutamated GW1843, polyglutamated aminopterin, and polyglutamated LY309887.
  • the administered alpha (L-alpha or D-alpha) or D-gamma polyglutamated antifolate comprises a pentaglutamated antifolate selected from the group consisting of pentaglutamated MTX, pentaglutamated PMX, pentaglutamated LTX, pentaglutamated AG2034, pentaglutamated RTX, pentaglutamated piritrexim, pentaglutamated pralatrexate, pentaglutamated AG2034, pentaglutamated GW1843, pentaglutamated aminopterin, and pentaglutamated LY309887.
  • the administered alpha (L-alpha or D-alpha) or D-gamma polyglutamated antifolate comprises a pentaglutamated antifolate selected from the group consisting of
  • the administered alpha (L-alpha or D-alpha) or D-gamma polyglutamated antifolate comprises pentaglutamated PMX.
  • the administered alpha (L-alpha or D-alpha) or D-gamma polyglutamated antifolate comprises hexaglutamated PMX.
  • the administered alpha (L-alpha or D-alpha) or D-gamma polyglutamated antifolate comprises pentaglutamated MTX.
  • the administered alpha (L-alpha or D-alpha) or D-gamma polyglutamated antifolate comprises hexaglutamated MTX.
  • the administered alpha (L-alpha or D-alpha) or D-gamma polyglutamated antifolate comprises pentaglutamated RTX.
  • the administered alpha (L-alpha or D-alpha) or D-gamma polyglutamated antifolate comprises hexaglutamated RTX. In some embodiments, the administered alpha (L-alpha or D-alpha) or D-gamma polyglutamated antifolate comprises pentaglutamated LTX. In some embodiments, the administered alpha (L-alpha or D-alpha) or D-gamma polyglutamated antifolate comprises hexaglutamated LTX. In some embodiments, the administered delivery vehicle is a liposome. In further embodiments, the liposome is pegylated.
  • the delivery vehicle comprises a targeting moiety on its surface that specifically binds an antigen on the surface of a breast cancer cell.
  • the delivery vehicle comprises a targeting moiety that specifically binds a cell surface antigen selected from the group consisting of LIV-1 (ZIP6), EGFR, HER2, HER3, Mucin 1, GO MB, and Nectin 4.
  • the delivery vehicle is a liposome, and the liposome comprises a targeting moiety that specifically binds a cell surface antigen selected from the group consisting of: LIV-1 (ZIP6), EGFR, HER2, HER3, Mucin 1, GONMB, and Nectin 4.
  • compositions e.g., liposomes containing alpha (L-alpha or D-alpha) or D-gamma polyglutamated antifolates
  • the provided compositions are administered to subjects having or at risk of having a hematological cancer that is distinguishable by the expression of a tumor specific antigen or tumor associated antigen on its cell surface.
  • the disclosure provides a method for treating cancer that comprises administering an effective amount of a delivery vehicle (e.g., liposome) comprising a targeting moiety and an alpha (L-alpha or D-alpha) or D-gamma
  • the administered delivery vehicle is a liposome that comprises alpha polyglutamated antifolate. In some embodiments, the administered delivery vehicle is a liposome that comprises L-alpha polyglutamated antifolate.
  • the administered delivery vehicle is a liposome that comprises D-alpha polyglutamated antifolate. In some embodiments, the administered delivery vehicle is a liposome that comprises D-gamma polyglutamated antifolate. In some embodiments, the administered alpha or D-gamma polyglutamated antifolate is a member selected from the group consisting of: polyglutamated methotrexate (MTX), polyglutamated pemetrexed (PMX), polyglutamated lometrexol (LTX), polyglutamated AG2034, polyglutamated raltitrexed (RTX), polyglutamated piritrexim, polyglutamated pralatrexate, polyglutamated AG2034, polyglutamated GW1843, polyglutamated aminopterin, and polyglutamated LY309887. In some embodiments, the administered alpha or D-gamma polyglutamated antifolate comprises a pentaglutamated antifolate selected from the group consisting
  • pentaglutamated MTX pentaglutamated MTX
  • pentaglutamated PMX pentaglutamated LTX
  • pentaglutamated AG2034 pentaglutamated RTX
  • pentaglutamated piritrexim pentaglutamated
  • the administered alpha or D-gamma polyglutamated antifolate comprises a hexaglutamated antifolate selected from the group consisting of hexaglutamated MTX, hexaglutamated PMX, hexaglutamated LTX, hexaglutamated AG2034, hexaglutamated RTX, hexaglutamated piritrexim, hexaglutamated pralatrexate, hexaglutamated AG2034, hexaglutamated GW1843, hexaglutamated aminopterin, and hexaglutamated LY309887.
  • the administered alpha or D-gamma polyglutamated antifolate comprises pentaglutamated PMX.
  • the administered alpha or D-gamma polyglutamated antifolate comprises hexaglutamated PMX.
  • the administered alpha or D-gamma polyglutamated antifolate comprises pentaglutamated MTX.
  • the administered alpha or D-gamma polyglutamated antifolate comprises hexaglutamated MTX.
  • the administered alpha or D-gamma polyglutamated antifolate comprises pentaglutamated RTX.
  • the administered alpha or D-gamma polyglutamated antifolate comprises hexaglutamated RTX. In some embodiments, the administered alpha or D-gamma polyglutamated antifolate comprises pentaglutamated LTX. In some embodiments, the administered alpha or D-gamma polyglutamated antifolate comprises hexaglutamated LTX. In some embodiments, the administered delivery vehicle is a liposome. In further embodiments, the liposome is pegylated. In additional embodiments, the delivery vehicle comprises a targeting moiety that specifically binds a cell surface antigen expressed on the surface of a hematological cancer cell.
  • the targeting moiety specifically binds a cell surface antigen selected from the group consisting of CD30, CD79b, CD 19, CD 138, CD74, CD37, CD 19, CD22, CD33, and CD98.
  • the delivery vehicle is a liposome, and the liposome comprises a targeting moiety that specifically binds a cell surface antigen selected from the group consisting of CD30, CD79b, CD 19, CD 138, CD74, CD37, CD 19, CD22, CD33, and CD98.
  • compositions e.g., liposomes containing alpha (L-alpha or D-alpha) or D-gamma polyglutamated antifolates
  • a cancer e.g., a solid tumor, and/or a metastasis that is distinguishable by the expression of a tumor specific antigen or tumor associated antigen on its cell surface.
  • the disclosure provides a method for treating cancer that comprises administering an effective amount of a delivery vehicle (e.g., liposome) comprising a targeting moiety and alpha (L-alpha or D-alpha) or D- gamma polyglutamated (e.g., pentaglutamated or hexaglutamated) antifolate to a subject having or at risk of having a cancer, solid tumor, and/or metastasis that is distinguishable by the expression of a tumor specific antigen or tumor associated antigen on its cell surface cancer, and wherein the targeting moiety is expressed on the surface of the delivery vehicle and specifically binds the tumor specific antigen or tumor associated antigen.
  • a delivery vehicle e.g., liposome
  • alpha L-alpha or D-alpha
  • the administered delivery vehicle is a liposome that comprises alpha polyglutamated antifolate. In some embodiments, the administered delivery vehicle is a liposome that comprises L-alpha polyglutamated antifolate. In some embodiments, the administered delivery vehicle is a liposome that comprises D-alpha polyglutamated antifolate. In some embodiments, the administered delivery vehicle is a liposome that comprises D-gamma polyglutamated antifolate.
  • the administered alpha or D-gamma polyglutamated antifolate is a member selected from the group consisting of: polyglutamated methotrexate (MTX), polyglutamated pemetrexed (PMX), polyglutamated lometrexol (LTX), polyglutamated AG2034, polyglutamated raltitrexed (RTX), polyglutamated piritrexim, polyglutamated pralatrexate,
  • the administered alpha or D-gamma polyglutamated antifolate comprises a pentaglutamated antifolate selected from the group consisting of pentaglutamated MTX, pentaglutamated PMX, pentaglutamated LTX, pentaglutamated AG2034, pentaglutamated RTX, pentaglutamated piritrexim, pentaglutamated pralatrexate, pentaglutamated AG2034, pentaglutamated GW1843, pentaglutamated aminopterin, and pentaglutamated LY309887.
  • the administered alpha or D-gamma polyglutamated antifolate comprises a pentaglutamated antifolate selected from the group consisting of pentaglutamated MTX, pentaglutamated PMX, pentaglutamated LTX, pentaglutamated AG2034, pentaglutamated RTX, pentaglutamated piritrexim, pentaglutamated pralatrexate, pentaglutamated
  • hexaglutamated antifolate selected from the group consisting of hexaglutamated MTX, hexaglutamated PMX, hexaglutamated LTX, hexaglutamated AG2034, hexaglutamated RTX, hexaglutamated piritrexim, hexaglutamated pralatrexate, hexaglutamated AG2034, hexaglutamated GW1843, hexaglutamated aminopterin, and hexaglutamated LY309887.
  • the administered alpha or D-gamma polyglutamated antifolate comprises pentaglutamated PMX.
  • the administered alpha or D-gamma polyglutamated antifolate comprises hexaglutamated PMX. In some embodiments, the administered alpha or D-gamma polyglutamated antifolate comprises pentaglutamated MTX. In some embodiments, the administered alpha or D-gamma polyglutamated antifolate comprises hexaglutamated MTX. In some embodiments, the administered alpha or D-gamma polyglutamated antifolate comprises pentaglutamated RTX. In some embodiments, the administered alpha or D-gamma polyglutamated antifolate comprises hexaglutamated RTX.
  • the administered alpha or D-gamma polyglutamated antifolate comprises pentaglutamated LTX. In some embodiments, the administered alpha or D-gamma polyglutamated antifolate comprises hexaglutamated LTX In some embodiments, the administered delivery vehicle is a liposome. In further embodiments, the liposome is pegylated. In additional
  • the delivery vehicle comprises a targeting moiety that specifically binds a cell surface antigen expressed on the surface of a cancer, a solid tumor, and/or a metastatic cell.
  • targeting moiety specifically binds a cell surface antigen selected from the group consisting of GONMB, CD56, TACSTD2 (TROP2), CEACAM5, Folate receptor-a, Folate receptor- ⁇ , Folate receptor- ⁇ , Mucin 1, STEAP1, Mesothelin, Nectin 4, ENPP3, Guanylyl cyclase C (GCC), SLC44A4, NaPi2b, CD70 (TNFSF7), CA9 (Carbonic anhydrase), 5T4 (TPBG), SLTRK6, SC-16, Tissue factor, LIV-1 (ZIP6), CGEN-15027, P-Cadherin, Fibronectin Extra-domain B (ED-B), VEGFR2 (CD309), Tenascin, Collagen IV, Penostin, endo
  • the delivery vehicle is a liposome
  • the liposome comprises a targeting moiety that specifically binds a cell surface antigen selected from the group consisting of GONMB, CD56, TACSTD2 (TROP2), CEACAM5, Folate receptor-a, Folate receptor- ⁇ , Folate receptor- ⁇ , Mucin 1, STEAPl, Mesothelin, Nectin 4, ENPP3, Guanylyl cyclase C (GCC), SLC44A4, NaPi2b, CD70 (TNFSF7), CA9 (Carbonic anhydrase), 5T4 (TPBG), SLTRK6, SC-16, Tissue factor, LIV-1 (ZIP6), CGEN-15027, P-Cadherin, Fibronectin Extra-domain B (ED-B), VEGFR2 (CD309), Tenascin, Collagen IV, Periostin, endothelin receptor, HER 2, EGFR, CD30, CD79b, CD 19, CD 138,
  • the disclosure provides a method for treating cancer that comprises administering an effective amount of a delivery vehicle (e.g., liposome) comprising a targeting moiety on its surface the specifically binds a folate receptor, and an alpha (L-alpha or D-alpha) or D-gamma polyglutamated (e.g., pentaglutamated or hexaglutamated) antifolate to a subject having or at risk of having a cancer that contains cells expressing the folate receptor on their cell surface.
  • a delivery vehicle e.g., liposome
  • a targeting moiety on its surface the specifically binds a folate receptor
  • an alpha (L-alpha or D-alpha) or D-gamma polyglutamated (e.g., pentaglutamated or hexaglutamated) antifolate e.g., pentaglutamated or hexaglutamated
  • the administered delivery vehicle is a liposome that comprises alpha polyglutamated antif
  • the administered delivery vehicle is a liposome that comprises L-alpha polyglutamated antifolate. In some embodiments, the administered delivery vehicle is a liposome that comprises D-alpha polyglutamated antifolate. In some embodiments, the administered delivery vehicle is a liposome that comprises D-gamma polyglutamated antifolate.
  • the folate receptor is folate receptor alpha, folate receptor beta or folate receptor delta. In some embodiments, the
  • MTX polyglutamated methotrexate
  • PMX polyglutamated pemetrexed
  • LTX polyglutamated lometrexol
  • RTX polyglutamated raltitrexed
  • polyglutamated piritrexim polyglutamated pralatrexate
  • the administered alpha or D-gamma polyglutamated antifolate comprises a pentaglutamated antifolate selected from the group consisting of pentaglutamated MTX, pentaglutamated PMX, pentaglutamated LTX, pentaglutamated AG2034, pentaglutamated RTX, pentaglutamated piritrexim, pentaglutamated pralatrexate, pentaglutamated AG2034, pentaglutamated GW1843, pentaglutamated aminopterin, and pentaglutamated LY309887.
  • the administered alpha or D-gamma polyglutamated antifolate comprises a pentaglutamated antifolate selected from the group consisting of pentaglutamated MTX, pentaglutamated PMX, pentaglutamated LTX, pentaglutamated AG2034, pentaglutamated RTX, pentaglutamated piritrexim, pentaglutamated pralatrexate, pentaglutamated
  • hexaglutamated antifolate selected from the group consisting of hexaglutamated MTX, hexaglutamated PMX, hexaglutamated LTX, hexaglutamated AG2034, hexaglutamated RTX, hexaglutamated piritrexim, hexaglutamated pralatrexate, hexaglutamated AG2034, hexaglutamated GW1843, hexaglutamated aminopterin, and hexaglutamated LY309887.
  • the administered alpha or D-gamma polyglutamated antifolate comprises pentaglutamated PMX.
  • the administered alpha or D-gamma polyglutamated antifolate comprises hexaglutamated PMX.
  • the administered alpha or D-gamma polyglutamated antifolate comprises pentaglutamated MTX.
  • the administered alpha or D-gamma polyglutamated antifolate comprises hexaglutamated MTX.
  • the administered alpha or D-gamma polyglutamated antifolate comprises pentaglutamated RTX.
  • the administered alpha or D-gamma polyglutamated antifolate comprises hexaglutamated RTX.
  • the administered alpha or D-gamma polyglutamated antifolate comprises pentaglutamated LTX. In some embodiments, the administered alpha or D-gamma polyglutamated antifolate comprises hrexaglutamated LTX In some embodiments, the administered delivery vehicle is a liposome. In further embodiments, the liposome is pegylated. As disclosed herein, the folate receptor targeted pegylated liposomes containing alpha or D-gamma
  • polyglutamated antifolates are able to deliver high quantities of alpha or D-gamma polyglutamated antifolates to cancer cells and particularly cancer cells that express folate receptors, compared to normal cells (i.e., cells that unlike cancer cells do not actively take up liposomes, and/or do not express folate receptors). Any cancers that express folate receptors may be treated according to the disclosed methods. It should be noted that some cancers may express folate receptors in an early stage while the majority of cancers may express folate receptors at late stages.
  • Cancer that may be treated by the methods of the invention include carcinomas, sarcomas and melanomas.
  • Carcinomas include without limitation to basal cell carcinoma, biliary tract cancer, bladder cancer, breast cancer, cervical cancer, choriocarcinoma, CNS cancer, colon and rectum cancer, kidney or renal cell cancer, larynx cancer, liver cancer, small cell lung cancer, non-small cell lung cancer (NSCLC, including adenocarcinoma, giant (or oat) cell carcinoma, and squamous cell carcinoma), oral cavity cancer, ovarian cancer, pancreatic cancer, prostate cancer, skin cancer (including basal cell cancer and squamous cell cancer), stomach cancer, testicular cancer, thyroid cancer, uterine cancer, rectal cancer, cancer of the respiratory system, and cancer of the urinary system.
  • NSCLC non-small cell lung cancer
  • Sarcomas are mesenchymal neoplasms that arise in bone (osteosarcomas) and soft tissues (fibrosarcomas).
  • Sarcomas include without limitation liposarcomas (including myxoid liposarcomas and pleiomorphic liposarcomas), leiomyosarcomas,
  • rhabdomyosarcomas malignant peripheral nerve sheath tumors (also called malignant schwannomas, neurofibrosarcomas, or neurogenic sarcomas), Ewing's tumors (including Ewing's sarcoma of bone, extraskeletal (i.e., not bone) Ewing's sarcoma, and primitive neuroectodermal tumor), synovial sarcoma, angiosarcomas, hemangiosarcomas, lymphangiosarcomas, Kaposi's sarcoma, hemangioendothelioma, desmoid tumor (also called aggressive fibromatosis ), dermatofibrosarcoma protuberans (DFSP), malignant fibrous histiocytoma (MFH), hemangiopericytoma, malignant mesenchymoma, alveolar soft-part sarcoma, epithelioid sarcoma, clear cell sarcoma,
  • Melanomas are tumors arising from the melanocytic system of the skin and other organs.
  • Examples of melanoma include without limitation lentigomaligna melanoma, superficial spreading melanoma, nodular melanoma, and acral lentiginous melanoma.
  • the cancer treated by one or more of the methods disclosed herein is a solid tumor lymphoma.
  • solid tumor lymphoma include Hodgkin's lymphoma, Non-Hodgkin's lymphoma, and B cell lymphoma.
  • the cancer treated by one or more of the methods disclosed herein is bone cancer, brain cancer, breast cancer, colorectal cancer, connective tissue cancer, cancer of the digestive system, endometrial cancer, esophageal cancer, eye cancer, cancer of the head and neck, gastric cancer, intra-epithelial neoplasm, melanoma neuroblastoma, Non-Hodgkin's lymphoma, non-small cell lung cancer, prostate cancer, retinoblastoma, or rhabdomyosarcoma.
  • the disclosure provides for the use of a composition comprising an alpha (L-alpha or D-alpha) or D-gamma polyglutamated antifolate polyglutamated antifolate for manufacture of a medicament for treatament of a hyperproliferative disease.
  • the polyglutamated antifolate comprise 5 or more glutamyl groups.
  • the pentaglutamated antifolate pentaglutamated or hexaglutamated.
  • the polyglutamated antifolate is a member selected from the group consisting of: polyglutamated methotrexate (MTX), polyglutamated pemetrexed (PMX), polyglutamated lometrexol (LTX), polyglutamated AG2034, polyglutamated raltitrexed (RTX), polyglutamated piritrexim, polyglutamated pralatrexate, polyglutamated AG2034, polyglutamated GW1843, polyglutamated aminopterin, and polyglutamated LY309887.
  • the polyglutamated antifolate is methotrexate (MTX).
  • the polyglutamated antifolate is polyglutamated pemetrexed (PMX).
  • the polyglutamated antifolate is polyglutamated lometrexol (LTX).
  • the polyglutamated methotrexate MTX
  • PMX polyglutamated pemetrexed
  • LTX polyglutamated lometrexol
  • polyglutamated antifolate is polyglutamated AG2034.
  • the polyglutamated antifolate is polyglutamated raltitrexed (RTX).
  • the polyglutamated antifolate is polyglutamated pralatrexate.
  • the polyglutamated antifolate is polyglutamated AG2034.
  • the polyglutamated antifolate is polyglutamated GW1843
  • the polyglutamated antifolate is polyglutamated aminopterin.
  • the polyglutamated antifolate is polyglutamated LY309887.
  • the poplyglutamated antifolate is in a liposome.
  • the hyperproliferative disease is cancer.
  • the cancer is selected from the group consisting of: lung (e.g., non-small lung cancer), pancreatic, breast cancer, ovarian, lung, prostate, head and neck, gastric, gastrointestinal, colon, esophageal, cervical, kidney, biliary duct, gallbladder, and a hematologic malignancy.
  • lung e.g., non-small lung cancer
  • pancreatic breast cancer
  • ovarian ovarian
  • lung prostate
  • head and neck gastric, gastrointestinal, colon, esophageal, cervical, kidney, biliary duct, gallbladder, and a hematologic malignancy.
  • the cancer is pancreatic cancer.
  • the cancer is breast cancer.
  • the cancer is pancreatic cancer. In some embodiments the cancer is triple negative breast cancer. In some embodiments the cancer is lung cancer. In some embodiments the cancer is non-small cell lung cancer. In some embodiments the cancer is leukemia or lymphoma. In some embodiments the hyperproliferative disease is an autoimmune disease. In some embodiments, the hyperproliferative disease is rheumatoid arthritis.
  • compositions contemplated herein e.g., polyglutamated antifolate compositions such as liposome containing a pentaglutamated or hexaglutamated antifolate.
  • Mammalian subjects and in particular, human subjects are preferred.
  • the subjects also include animals such as household pets (e.g., dogs, cats, rabbits, and ferrets), livestock or farm animals (e.g., cows, pigs, sheep, chickens and other poultry), horses such as thoroughbred horses, laboratory animals (e.g., mice, rats, and rabbits), and other mammals.
  • the subjects include fish and other aquatic species.
  • the subjects to whom the agents are delivered may be normal subjects.
  • the subject may have or be at risk of developing a condition that can be diagnosed or that can benefit from delivery of one or more of the provided compositions.
  • such conditions include cancer (e.g., solid tumor cancers or non- solid cancer such as leukemias).
  • these conditions e.g., cancers
  • these antigens specifically bind and internalize the targeted pegylated liposomal alpha (L-alpha or D-alpha) or D-gamma polyglutamated antifolate into the cell.
  • the targeted pegylated liposomal alpha (L- alpha or D-alpha) or D-gamma polyglutamated antifolate specifically binds a folate receptor (e.g., folate receptor alpha (FR-a), folate receptor beta (FR- ⁇ ) and folate receptor delta (FR- ⁇ )) expressed on the surface of the cancer cell.
  • a folate receptor e.g., folate receptor alpha (FR-a), folate receptor beta (FR- ⁇ ) and folate receptor delta (FR- ⁇ )
  • Tests for diagnosing the conditions that can be treated with the provided compositions are known in the art and will be familiar to the medical practitioner.
  • the determination of whether a cell type expresses folate receptors can be made using commercially available antibodies.
  • laboratory tests include without limitation microscopic analyses, cultivation dependent tests (such as cultures), and nucleic acid detection tests. These include wet mounts, stain-enhanced microscopy, immune microscopy (e.g., FISH), hybridization microscopy, particle agglutination, enzyme-linked immunosorbent assays, urine screening tests, DNA probe hybridization, and serologic tests.
  • the medical practitioner will generally also take a full history and conduct a complete physical examination in addition to running the laboratory tests listed above.
  • a subject having a cancer can, for example, be a subject that has detectable cancer cells.
  • a subject at risk of developing a cancer can, for example, be a subject that has a higher than normal probability of developing cancer.
  • These subjects include, for instance, subjects having a genetic abnormality that has been demonstrated to be associated with a higher likelihood of developing a cancer, subjects having a familial disposition to cancer, subjects exposed to cancer causing agents (i.e., carcinogens) such as tobacco, asbestos, or other chemical toxins, and subjects previously treated for cancer and in apparent remission.
  • the disclosure provides methods for selectively deliver a folate receptor targeted pegylated liposomal alpha (L-alpha or D-alpha) or D-gamma polyglutamated antifolate to a tumor cell expressing a folate receptor on its surface at a rate that is higher (e.g. at least two-fold greater, at least three-fold greater, at least fourfold greater, or at least five-fold greater, than a cell not expressing folate receptor on its cell surface).
  • the delivered pegylated liposome comprises alpha polyglutamated antifolate.
  • the delivered pegylated liposome comprises L-alpha polyglutamated antifolate.
  • the delivered pegylated liposome comprises D-alpha polyglutamated antifolate.
  • the delivered pegylated liposome comprises D-gamma polyglutamated antifolate.
  • the disclosure provides a method of making a liposomal composition disclosed herein.
  • the method includes forming a mixture comprising: (1) a liposomal component; and (2) a alpha (L-alpha or D- alpha) or D-gamma polyglutamated (e.g., pentaglutamated or hexaglutamated) antifolate in aqueous solution.
  • the mixture comprises a pegylated liposomal component. The mixture is then homogenized to form liposomes in the aqueous solution.
  • the mixture can be extruded through a membrane to form liposomes enclosing the alpha (L-alpha or D-alpha) or D-gamma polyglutamated antifolate in an aqueous solution.
  • liposomal components of this disclosure can comprise any lipid (including cholesterol) including functionalized lipids and lipids attached to targeting moieties, detectable labels, and steric stabilizers, or any subset of all of these.
  • bioactive alpha (L-alpha or D-alpha) or D-gamma polyglutamated antifolate in aqueous solution can comprise any reagents and chemicals discussed herein or otherwise known in the art for the interior or exterior of the liposome including, for example, buffers, salts, and cryoprotectants.
  • the disclosure provides a method of making a targeted pegylated liposomal alpha (L-alpha or D-alpha) or D-gamma polyglutamated antifolate (targeted-PLPA) or non-targetd PLPA disclosed herein.
  • the method includes forming a mixture comprising: (1) a liposomal component; (2) a alpha (L-alpha or D-alpha) or D-gamma polyglutamated (e.g., pentaglutamated or hexaglutamated) antifolate in aqueous solution; and (3) the targeting moiety.
  • the mixture is then homogenized to form liposomes in the aqueous solution.
  • the mixture may be extruded through a membrane to form liposomes enclosing the targeted alpha (L-alpha or D-alpha) or D-gamma polyglutamated antifolate in an aqueous solution.
  • the targeted pegylated liposomal components can comprise any lipid (including cholesterol) including functionalized lipids and lipids attached to targeting moieties, detectable labels, and steric stabilizers, or any subset of all of these.
  • the targeted pegylated liposome can comprise any reagents and chemicals discussed herein or otherwise known in the art for the interior or exterior of the liposome including, for example, buffers, salts, and cryoprotectants.
  • the above methods optionally further comprise the step of lyophilizing the composition after the removing step to form a lyophilized composition.
  • targeted- PTPLA or non-targeted-PTPLA in aqueous solution may comprise a cryoprotectant described herein or otherwise known in the art. If the composition is to be lyophilized, a cryoprotectant may be preferred.
  • the method optionally further comprises the step of reconstituting the lyophilized composition by dissolving the composition in a solvent after the lyophilizing step.
  • a solvent after the lyophilizing step, the method optionally further comprises the step of reconstituting the lyophilized composition by dissolving the composition in a solvent after the lyophilizing step.
  • Methods of reconstitution are known in the art.
  • One preferred solvent is water.
  • Other preferred solvents include saline solutions and buffered solutions.
  • liposomes can be made by any method that is known in the art. See, for example, G. Gregoriadis (editor), Liposome Technology, vol. 1-3, 1st edition, 1983; 2nd edition, 1993, CRC Press, 45 Boca Raton, Fla. Examples of methods suitable for making liposome compositions include extrusion, reverse phase evaporation, sonication, solvent ⁇ e.g., ethanol) injection, microfluidization, detergent dialysis, ether injection, and dehydration/rehydration. The size of liposomes can routinely be controlled by controlling the pore size of membranes used for low pressure extrusions or the pressure and number of passes utilized in microfluidization or any other suitable methods known in the art.
  • the alpha (L-alpha or D-alpha) or D-gamma polyglutamated antifolate is contained inside, that is, in the inner (interior) space of the liposomes.
  • substituted ammonium is partially or substantially completely removed from the outer medium surrounding the liposomes.
  • Such removal can be accomplished by any suitable means known in the art ⁇ e.g., dilution, ion exchange chromatography, size exclusion chromatography, dialysis, ultrafiltration, and precipitation).
  • the methods of making liposomal compositions set forth above or otherwise known in the art can optionally further comprise the step of removing polyglutamated antifolate in aqueous solution outside of the liposomes after the extruding step.
  • the disclosure provides a targeted pegylated liposomal alpha (L-alpha or D-alpha) or D-gamma polyglutamated antifolate (PLPA) that selectively targets folate receptors comprising: a liposome including an interior space, a alpha (L-alpha or D-alpha) or D-gamma polyglutamated antifolate disposed within the interior space, a steric stabilizer molecule attached to an exterior of the liposome, and a targeting moiety comprising a protein with specific affinity for at least one folate receptor, said targeting moiety attached to at least one of the steric stabilizer and the exterior of the liposome.
  • a targeted pegylated liposomal alpha (L-alpha or D-alpha) or D-gamma polyglutamated antifolate (PLPA) that selectively targets folate receptors comprising: a liposome including an interior space, a alpha (L-alpha or D-alpha) or D-gam
  • the components of this embodiment may be the same as described for other embodiments, of this disclosure.
  • the targeted pegylated liposomal alpha (L-alpha or D-alpha) or D-gamma polyglutamated antifolate and the steric stabilizer which may be PEG are as described in other parts of this disclosure.
  • the disclosure provides a method of preparing a targeted composition
  • a pegylated liposome including an entrapped and/or encapsulated alpha (L-alpha or D-alpha) or D-gamma polyglutamated antifolate; a targeting moiety an amino acid chain, the amino acid chain comprising a plurality of amino acids, the targeting moiety having a specific affinity for at least one type of folate receptor, the specific affinity being defined to include an equilibrium dissociation constant (Kd) in a range of 0.5xl0 "10 to lOxlO "6 moles [0.05 nanoMole to 10 ⁇ ] for at least one type folate receptor, 47 the targeting moiety attached to one or both of a PEG and an exterior of the liposome, the method comprising: forming a mixture comprising: liposomal components; alpha (L-alpha or D-alpha) or D-gamma polyglutamated antifolate in solution; homogenizing the mixture
  • the processing includes one or more of: thin film hydration, extrusion, in-line mixing, and stirring, and once the particles have been formed, the particles can have their sizes further modified by one or more of extrusion and sonication.
  • the targeted composition comprises at least 10% liposome entrapped polyglutamated antifolate.
  • the liposomes are anionic or neutral.
  • the targeting moiety has the specific affinity for one or more of: folate receptor alpha (FR-a), folate receptor beta (FR- ⁇ ) and folate receptor delta (FR- ⁇ ).
  • the targeting moiety has the specific affinity for folate receptor alpha (FR-a) and folate receptor beta (FR- ⁇ ).
  • the targeting moiety has the specific affinity for an epitope on a tumor cell surface antigen that is present on a tumor cell but absent or inaccessible on a non-tumor cell.
  • the following examples are intended to illustrate but not to limit the disclosure in any manner, shape, or form, either explicitly or implicitly. While they are typical of those that might be used, other procedures, methodologies, or techniques known to those skilled in the art may alternatively be used.
  • the example compositions comprise example liposomes. Both example composition and example liposome are used in the experiments described in the examples section and throughout this disclosure are specific embodiments, of the disclosure and are not meant to define the full scope of the disclosure.
  • FIG. 5 shows chemical formula of alpha pentaglutamate and hexaglutamate pemetrexed.
  • FIG. 6 shows chemical formulae of exemplary L-gamma pentaglutamated and hexaglutamate antifolate compositions encompassed by the disclosure.
  • Gamma HGP was encapsulated in liposomes by the following procedure.
  • the lipid components of the liposome membrane were weighed out and combined as a concentrated solution in ethanol at a temperature of around 65°C.
  • the lipids used were hydrogenated soy phosphatidylcholine, cholesterol, and DSPE-PEG-2000 (l,2-distearoyl-sn-glycero-3-phosphoethanolamine-N- [methoxy(polyethylene glycol)-2000]).
  • the molar ratio of HSPC: Cholesterol: PEG- DSPE was approximately 3 :2:0.15.
  • gG6 was dissolved in an aqueous buffer at a concentration of 20 mg/ml with a pH of 6.5-6.9.
  • the drug solution was heated up to 65°C.
  • the ethanolic lipid solution was injected into the gG6 solution using a small bore needle.
  • the drug solution was well stirred using a magnetic stirrer.
  • the MLVs were fragmented into unilamellar (single bilayer) vesicles of the desired size by high-pressure extrusion using two passes through stacked (track-etched polycarbonate) membranes.
  • the stacked membranes had two layers with a pore size of 200nm and six layers with a pore size of lOOnm.
  • the temperature was maintained above the Tm to ensure plasticity of the lipid membranes.
  • large and heterogeneous in size and lamellarity MLVs turned into small, homogenous (100-120 nm) unilamellar vesicles (ULV) that sequestered the drug in their interior.
  • UUV unilamellar vesicles
  • a Malvern Zetasizer Nano ZS instrument (Southborough, MA) with back scattering detector (90°) was used for measuring the hydrodynamic size (diameter) at 25°C in a quartz micro cuvette.
  • the samples were diluted 50-fold in formulation matrix before analysis.
  • the extra-liposomal gG6 was removed using columns for small volume or tangential flow diafiltration against a suitable buffer for large volume.
  • a suitable buffer for large volume for any buffer solution can be used, in this example the buffer used was 5 mM HEPES, 145 mM Sodium Chloride, pH 6.7.
  • filter sterilization was performed using a 0.22 micron filter.
  • Activated liposomes were prepared by adding DSPE-PEG-maleimide to the lipid composition.
  • the liposomes contained four different lipids: hydrogenated soy phosphatidylcholine (HSPC), cholesterol, l,2-distearoyl-sn-glycero-3- phosphoethanolamine-N-[methoxy(poly ethylene glycol)-2000] (DSPE-PEG-2000), and l,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-[maleimide (polyethylene glycol)- 2000] (DSPE-PEG-maleimide), in ratios of 3 :2:0.1125:0.0375.
  • HSPC hydrogenated soy phosphatidylcholine
  • cholesterol cholesterol
  • DSPE-PEG-maleimide
  • Antibody thiolation was accomplished through use of Traut' s reagent (2- iminothiolane) to attach a sulfhydryl group onto primary amines.
  • Antibodies were suspended in PBS at a concentration of 0.9-1.6 mg/ml.
  • Traut's reagent 14 mM was added to antibody solution at a final concentration of 1-5 mM and then removed through dialysis after one-hour incubation at room temperature.
  • Thiolated antibody was added to activated liposome at a ratio of 60 g/mol phosphate lipids, and the reaction mixture was incubated for one hour at room temperature and over-night at 4uL-cysteine was used to terminate the reaction and unconjugated antibodies were removed through dialysis.
  • Cell viability was determined by CellTiter-Glo®(CTG) luminescent cell viability assay on Day 3 (48 hour) and Day 4 (72 hour). This assay determines the number of viable cells in culture based on quantifying ATP that is present within, which in turn signals the presence of metabolically active cells.
  • the CTG assay uses luciferase as a readout.
  • To assess cell viability Dose response inhibition of pemetrexed, HGP and liposomes on different cancer cell growth were investigated using CellTiter-Glo® luminescent cell viability assay. Human cancer cells were harvested, counted and plated at a same cell density on Day 0. A series of 8 dilutions of each test article were added to the cells on Day 1. Dose response curve were generated and fit using GraphPad Prism and IC50 of each test article were calculated. A lower the IC50 is, the more potent the test article is in term of cancer cell growth inhibition.
  • CCD841 non-cancerous colon epithelial cells
  • cancer cells are similar to the methods used for cancer cells.
  • FIG. 5 shows chemical formula of alpha pentaglutamate and hexaglutamate pemetrexed.
  • FIG. 6 shows chemical formulae of exemplary L-gamma pentaglutamate and hexaglutamate antifolate compositions encompassed by the disclosure.
  • liposomal gG6 liposomal pemetrexed hexaglutamate
  • liposomal gG6 liposomal gamma hexaglutamate
  • liposomal gDG6 its mirror image liposomal gamma-D hexaglutamate
  • liposomal alpha hexaglutamate liposomal alpha hexaglutamate
  • liposomal aG6 liposomal alpha-D hexaglutamate
  • liposomal aDG6 liposomal alpha-D hexaglutamate
  • pemetrexed at the dose of 128 nM appears to be equally effective as liposomal pemetrexed hexaglutamate, whereas the liposomal pemetrexed hexaglutamate at the dose of 32 nM and 64 nM has a better treatment effect than pemetrexed; at 16 nM the treatment effect is lower and similar in magnitude for liposomal pemetrexed hexaglutamate and pemetrexed.
  • liposomal pemetrexed hexaglutamate is significantly less toxic to differentiating human neutrophils in contrast to pemetrexed. This is also supported by neutrophil counts that are better preserved following treatment with the derivatives compared to pemetrexed, at dose ranges from 16 nM to 128 nM (FIG. 15). Strikingly, there does not appear to be any toxicity to the liver cells following treatment with liposomal pemetrexed hexaglutamate at the dose levels studied (FIG. 16). In contrast, pemetrexed at all doses studied is leading to a reduction in the liver cell counts of approximately 40%. And finally, the same trend is seen following treatment of epithelial colon cells (FIG. 17). As shown in this figure, pemetrexed at all doses studied is leading to approximately a >50% decrease in the number of cells compared to approximately a 20% or less decrease after treatment with liposomal pemetrexed hexaglutamate.
  • composition comprising alpha (L-alpha or D-alpha) or D-gamma polyglutamated antifolate.
  • composition may comprise pentaglutamated or hexaglutamated antifolate.
  • the alpha (L-alpha or D-alpha) or D-gamma polyglutamated antifolate may be one or more members selected from the group consisting of: polyglutamated methotrexate (MTX),
  • polyglutamated pemetrexed (PMX), polyglutamated lometrexol (LTX), polyglutamated AG2034, polyglutamated raltitrexed (RTX), polyglutamated pintrexim, polyglutamated pralatrexate, polyglutamated AG2034, polyglutamated GW1843, polyglutamated aminopterin, and polyglutamated LY309887.
  • the composition may comprise alpha (L-alpha or D-alpha) or D-gamma polyglutamated antifolate which may be polyglutamated PMX, MTX, RTX, or LTX.
  • the composition may comprise alpha (L-alpha or D-alpha) or D-gamma polyglutamated antifolate which may include pentaglutamated or hexaglutamated antifolate.
  • the composition may comprise alpha (L-alpha or D-alpha) or D-gamma polyglutamated antifolate which may include pentaglutamated or hexaglutamated PMX, MTX, RTX, and/or LTX.
  • a non-limiting example liposomal alpha (L-alpha or D-alpha) or D-gamma polyglutamated antifolate (LP A) composition may comprise a composition of any of the preceding six paragraphs and the liposome may be optionally pegylated (PLPA).
  • PLPA pegylated
  • the alpha (L-alpha or D-alpha) or D-gamma polyglutamated antifolate may include pentaglutamated or hexaglutamated antifolate.
  • the alpha (L-alpha or D-alpha) or D-gamma polyglutamated antifolate may be one or more members selected from the group consisting of: alpha (L-alpha or D-alpha) or D-gamma polyglutamated methotrexate (MTX), polyglutamated pemetrexed (PMX),
  • polyglutamated lometrexol LTX
  • polyglutamated AG2034 polyglutamated raltitrexed
  • polyglutamated piritrexim polyglutamated pralatrexate
  • polyglutamated AG2034 polyglutamated GW1843, polyglutamated aminopterin, and polyglutamated LY309887.
  • the alpha (L-alpha or D-alpha) or D-gamma polyglutamated antifolate is polyglutamated PMX, MTX, RTX, and/or LTX.
  • the alpha (L-alpha or D-alpha) or D-gamma polyglutamated antifolate may include a pentaglutamated or hexaglutamated antifolate.
  • the alpha (L-alpha or D-alpha) or D-gamma polyglutamated antifolate may include pentaglutamated or hexaglutamated PMX, MTX, RTX, and/or LTX.
  • the liposome may be anionic or neutral.
  • a targeting moiety may be attached to one or both of a PEG and the exterior of the liposome, and the targeting moiety may have a specific affinity for a surface antigen on a target cell of interest.
  • a targeting moiety may be attached to one or both of a PEG and the exterior of the liposome and may be a polypeptide.
  • a targeting moiety may be attached to one or both a PEG and the exterior of the liposome and may be an antibody or a fragment of an antibody.
  • one or more of an immunostimulatory agent, a detectable marker and a maleimide may be disposed on at least one of a PEG and the exterior of the liposome.
  • a polypeptide may bind an antigen with an equilibrium dissociation constant (Kd) in a range of 0.5xl0 "10 to lOxlO "6 as determined using BIACORE analysis.
  • a polypeptide may specifically bind one or more folate receptors selected from the group consisting of: folate receptor alpha (FR-a), folate receptor beta (FR- ⁇ ), and folate receptor delta (FR- ⁇ ).
  • a non-limiting example method of killing a hyperproliferative cell may include contacting a hyperproliferative cell with a liposomal alpha (L-alpha or D-alpha) or D-gamma polyglutamated antifolate composition of any of the preceding thirteen paragraphs.
  • the hyperproliferative cell may be a cancer cell.
  • a non-limiting example method for treating cancer may comprise
  • the cancer may be one or more selected from the group consisting of: lung cancer, pancreatic, breast cancer, ovarian cancer, lung cancer, prostate cancer, head and neck cancer, gastric cancer, gastrointestinal cancer, colon cancer, esophageal cancer, cervical cancer, kidney cancer, biliary duct cancer, gallbladder cancer, and a hematologic malignancy.
  • a non-limiting example maintenance therapy for subjects that are undergoing or have undergone cancer therapy may include administering an effective amount of the alpha (L-alpha or D-alpha) or D-gamma polyglutamated antifolate composition of any of paragraphs [0321]-[0339] to a subject that is undergoing or has undergone cancer therapy.
  • a non-limiting example pharmaceutical composition may include the alpha (L-alpha or D-alpha) or D-gamma polyglutamated antifolate composition of any of paragraphs [0321]-[0339].
  • a non-limiting example method for treating a disorder of the immune system may include administering an effective amount of the alpha (L-alpha or D-alpha) or D- gamma polyglutamated antifolate composition of any of paragraphs [0321]-[0339] to a subject having or at risk of having a disorder of the immune system.
  • a non-limiting example method for treating an infectious may include comprises administering an effective amount of the alpha (L-alpha or D-alpha) or D- gamma polyglutamated antifolate composition of any of paragraphs [0321]-[0339] to a subject having or at risk of having an infectious disease.
  • a non-limiting example method of delivering alpha (L-alpha or D-alpha) or D-gamma polyglutamated antifolate to a tumor expressing a folate receptor on its surface may include administering a polyglutamated antifolate composition of any of paragraphs [0321]-[0339] to a subject having the tumor in an amount to deliver a therapeutically effective dose of the alpha (L-alpha or D-alpha) or D-gamma polyglutamated antifolate to the tumor.
  • a non-limiting example method of preparing a liposomal alpha (L-alpha or D- alpha) or D-gamma polyglutamated antifolate composition which may include alpha (L- alpha or D-alpha) or D-gamma polyglutamated antifolate composition of any of paragraphs [0321]-[0339] includes forming a mixture comprising: liposomal components; alpha (L-alpha or D-alpha) or D-gamma polyglutamated antifolate in solution;
  • a non-limiting example pharmaceutical composition may include an alpha (L- alpha or D-alpha) or D-gamma polyglutamated antifolate composition of any of paragraphs [0321]-[0339].

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Dispersion Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

L'invention concerne, de manière générale, des antifolates polyglutamates, des formulations contenant des liposomes remplis d'antifolates alpha ou D-gamma polyglutamates, des procédés de fabrication des antifolates de polyglutamates, des formulations contenant des liposomes, des procédés d'utilisation d'antifolates de polyglutamates et des formulations contenant des liposomes pour le traitement de maladies hyperprolifératives ( par exemple , le cancer) et des maladies du système immunitaire ( par exemple , une maladie auto-immune telle que la polyarthrite rhumatoïde).
PCT/US2017/046666 2016-08-12 2017-08-12 Antifolates alpha et gamma-d de polyglutamates et leurs utilisations. WO2018031979A1 (fr)

Priority Applications (19)

Application Number Priority Date Filing Date Title
KR1020197005253A KR102584446B1 (ko) 2016-08-12 2017-08-12 알파 및 감마-d 폴리글루타메이트화 항엽산 및 이의 용도
EP22167260.3A EP4052729A1 (fr) 2016-08-12 2017-08-12 Antifolates alpha et gamma-d de polyglutamates et leurs utilisations
CA3033077A CA3033077C (fr) 2016-08-12 2017-08-12 Antifolates alpha et gamma-d de polyglutamates et leurs utilisations
AU2017308158A AU2017308158B2 (en) 2016-08-12 2017-08-12 Alpha and gamma-D polyglutamated antifolates and uses thereof
US16/324,823 US11344628B2 (en) 2016-08-12 2017-08-12 Alpha polyglutamated antifolates and uses thereof
CN201780052159.XA CN109689104A (zh) 2016-08-12 2017-08-12 α和γ-D聚谷氨酸化抗叶酸剂及其用途
JP2019507107A JP7227123B2 (ja) 2016-08-12 2017-08-12 αおよびγ－Ｄポリグルタミン酸化抗葉酸剤およびその使用
EA201990324A EA201990324A1 (ru) 2016-08-12 2017-08-12 Альфа- и гамма-d-полиглутамированные антифолаты и их применение
KR1020247030844A KR20240141854A (ko) 2016-08-12 2017-08-12 알파 및 감마-d 폴리글루타메이트화 항엽산 및 이의 용도
EP17840396.0A EP3496756A4 (fr) 2016-08-12 2017-08-12 Antifolates alpha et gamma-d de polyglutamates et leurs utilisations.
MX2019001756A MX2019001756A (es) 2016-08-12 2017-08-12 Antifolatos poliglutamados alfa y gamma-d y sus usos.
BR112019002497-2A BR112019002497A2 (pt) 2016-08-12 2017-08-12 antifolatos poliglutamatados alfa e gama-d e seus usos
KR1020237032981A KR102708209B1 (ko) 2016-08-12 2017-08-12 알파 및 감마-d 폴리글루타메이트화 항엽산 및 이의 용도
US17/544,191 US20220088219A1 (en) 2016-08-12 2021-12-07 Alpha polyglutamated pemetrexed and uses thereof
US17/544,196 US20220088220A1 (en) 2016-08-12 2021-12-07 Gamma-d polyglutamated pemetrexed and uses thereof
US17/544,182 US20220088218A1 (en) 2016-08-12 2021-12-07 Gamma-d polyglutamated pemetrexed and uses thereof
US17/745,138 US20230115624A1 (en) 2016-08-12 2022-05-16 D glutamate polyglutamated antifolates and uses thereof
JP2023018363A JP7538268B2 (ja) 2016-08-12 2023-02-09 αおよびγ－Ｄポリグルタミン酸化抗葉酸剤およびその使用
AU2023263441A AU2023263441A1 (en) 2016-08-12 2023-11-07 Alpha And Gamma-D Polyglutamated Antifolates And Uses Thereof

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US201662374458P 2016-08-12 2016-08-12
US62/374,458 2016-08-12
US201715675695A 2017-08-11 2017-08-11
US15/675,695 2017-08-11
US15/675,701 2017-08-11
US15/675,701 US20180236098A1 (en) 2016-08-12 2017-08-11 Alpha and gamma-d polyglutamated antifolates and uses thereof

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
US15/675,701 Continuation US20180236098A1 (en) 2016-08-12 2017-08-11 Alpha and gamma-d polyglutamated antifolates and uses thereof

Related Child Applications (5)

Application Number Title Priority Date Filing Date
US16/324,823 A-371-Of-International US11344628B2 (en) 2016-08-12 2017-08-12 Alpha polyglutamated antifolates and uses thereof
US17/544,191 Continuation US20220088219A1 (en) 2016-08-12 2021-12-07 Alpha polyglutamated pemetrexed and uses thereof
US17/544,182 Division US20220088218A1 (en) 2016-08-12 2021-12-07 Gamma-d polyglutamated pemetrexed and uses thereof
US17/544,196 Division US20220088220A1 (en) 2016-08-12 2021-12-07 Gamma-d polyglutamated pemetrexed and uses thereof
US17/745,138 Division US20230115624A1 (en) 2016-08-12 2022-05-16 D glutamate polyglutamated antifolates and uses thereof

Publications (1)

Publication Number Publication Date
WO2018031979A1 true WO2018031979A1 (fr) 2018-02-15

Family

ID=61163263

Family Applications (2)

Application Number Title Priority Date Filing Date
PCT/US2017/046666 WO2018031979A1 (fr) 2016-08-12 2017-08-12 Antifolates alpha et gamma-d de polyglutamates et leurs utilisations.
PCT/US2017/046667 WO2018031980A1 (fr) 2016-08-12 2017-08-12 Antifolates de polyglutamates et leurs utilisations.

Family Applications After (1)

Application Number Title Priority Date Filing Date
PCT/US2017/046667 WO2018031980A1 (fr) 2016-08-12 2017-08-12 Antifolates de polyglutamates et leurs utilisations.

Country Status (1)

Country Link
WO (2) WO2018031979A1 (fr)

Cited By (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021026310A1 (fr) 2019-08-06 2021-02-11 L.E.A.F. Holdings Group Llc Procédés de préparation d'antifolates polyglutamiques et leurs utilisations
EP3752156A4 (fr) * 2018-02-14 2021-10-27 L.E.A.F Holdings Group LLC Pralatrexate gamma-polyglutamaté et utilisations associées
EP3749316A4 (fr) * 2018-02-07 2021-10-27 L.E.A.F Holdings Group LLC Pralatrexate alpha-polyglutamaté et utilisations associées
EP3749314A4 (fr) * 2018-02-07 2022-02-23 L.E.A.F Holdings Group LLC Méthotrexate alpha-polyglutamaté et utilisations associées
EP3749312A4 (fr) * 2018-02-07 2022-02-23 L.E.A.F Holdings Group LLC Lométrexol alpha-polyglutamaté et utilisations associées
EP3749320A4 (fr) * 2018-02-07 2022-03-09 L.E.A.F Holdings Group LLC Aminoptérine alpha-polyglutamatée et utilisations associées
EP3749321A4 (fr) * 2018-02-07 2022-03-09 L.E.A.F Holdings Group LLC Antifolates gamma-polyglutamatés et utilisations associées
EP3752158A4 (fr) * 2018-02-14 2022-03-09 L.E.A.F Holdings Group LLC Aminoptérine gamma polyglutamique et ses utilisations
EP3749313A4 (fr) * 2018-02-07 2022-03-16 L.E.A.F Holdings Group LLC Antifolates alpha-polyglutamatés et utilisations associées
EP3752155A4 (fr) * 2018-02-14 2022-03-16 L.E.A.F Holdings Group LLC Méthotrexate gamma polyglutamique et ses utilisations
US11344628B2 (en) 2016-08-12 2022-05-31 L.E.A.F. Holdings Group Llc Alpha polyglutamated antifolates and uses thereof
EP3749317A4 (fr) * 2018-02-07 2022-06-22 L.E.A.F Holdings Group LLC Pémétrexed alpha-polyglutamaté et utilisations associées
EP3749315A4 (fr) * 2018-02-07 2022-06-22 L.E.A.F Holdings Group LLC Raltitrexed alpha-polyglutamaté et utilisations associées
EP3752157A4 (fr) * 2018-02-14 2022-07-06 L.E.A.F Holdings Group LLC Lométrexol gamma polyglutamique et ses utilisations
EP3749318A4 (fr) * 2018-02-07 2022-07-06 L.E.A.F Holdings Group LLC Raltitrexed gamma-polyglutamaté et utilisations associées
EP3749311A4 (fr) * 2018-02-07 2022-07-06 L.E.A.F Holdings Group LLC Compositions de pémétrexed polyglutamaté gamma et leurs utilisations
US11534498B2 (en) 2016-08-12 2022-12-27 L.E.A.F. Holdings Group Llc Polyglutamated antifolates and uses thereof
US12048766B2 (en) 2018-02-14 2024-07-30 L.E.A.F. Holdings Group Llc Gamma polyglutamated tetrahydrofolates and uses thereof

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114539353B (zh) * 2020-11-26 2024-08-30 南京碳硅人工智能生物医药技术研究院有限公司 培美曲塞多谷氨酸化代谢物及其制备方法

Citations (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4584375A (en) * 1984-08-21 1986-04-22 Rensselaer Polytechnic Institute Fluorine-containing antifolates incapable of polyglutamate formation
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US5639641A (en) 1992-09-09 1997-06-17 Immunogen Inc. Resurfacing of rodent antibodies
US5646253A (en) 1994-03-08 1997-07-08 Memorial Sloan-Kettering Cancer Center Recombinant human anti-LK26 antibodies
US6569432B1 (en) 1995-02-24 2003-05-27 Sloan-Kettering Institute For Cancer Research Prostate-specific membrane antigen and uses thereof
US20050031679A1 (en) * 1998-03-27 2005-02-10 Clemens Unger Method for producing liposomal formulations of active ingredients
US20070270431A1 (en) * 2004-09-29 2007-11-22 Kowa Co., Ltd. Preventive and/or Therapeutic Medicine for Rheumatoid Arthritis
US20080214585A1 (en) * 2007-01-19 2008-09-04 Chelsea Therapeutics, Inc. New classical antifolates
US20090155345A1 (en) * 2005-12-08 2009-06-18 Ben Gurion University Of The Negev Research And Development Authority Methods for affecting liposome composition ultrasound irradiation
US20110280932A1 (en) 2010-05-13 2011-11-17 Pacira Pharmaceuticals, Inc. Sustained release formulation of methotrexate as a disease-modifying antirheumatic drug (dmard) and an anti-cancer agent
US8388972B2 (en) 2006-09-15 2013-03-05 Advanced Accelerator Applications S.A. Human anti-folate receptor alpha antibodies and antibody fragments for the radioimmunotherapy of ovarian carcinoma
US20130259922A1 (en) * 2010-05-21 2013-10-03 Medigene Ag Liposomal formulations of lipophilic compounds
US20130324727A1 (en) * 2011-03-10 2013-12-05 National Science and Techology Development Agency Anti-folate antimalarials with dual-binding modes and their preparation
US20140086939A1 (en) * 2011-02-28 2014-03-27 Michael Karin Compositions and methods for detecting and treating cancer
WO2014046630A1 (fr) * 2012-09-19 2014-03-27 Keskin, Dilek Système d'administration de médicament liposomal ciblé contre la tumeur
US8871206B2 (en) 2010-09-09 2014-10-28 Purdue Research Foundation Anti-human folate receptor beta antibodies and methods of use
US20150239956A1 (en) * 2012-06-27 2015-08-27 Asahi Kasei Medical Co., Ltd. High-affinity antibody and method for manufacturing the same
US9133275B2 (en) 2010-02-24 2015-09-15 Immunogen, Inc. Folate receptor 1 antibodies and immunoconjugates and uses thereof
WO2016025882A2 (fr) 2014-08-14 2016-02-18 L.E.A.F Holdings Group Llc. Médicament à affinité encapsulé dans un liposome

Patent Citations (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4584375A (en) * 1984-08-21 1986-04-22 Rensselaer Polytechnic Institute Fluorine-containing antifolates incapable of polyglutamate formation
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US5639641A (en) 1992-09-09 1997-06-17 Immunogen Inc. Resurfacing of rodent antibodies
US5646253A (en) 1994-03-08 1997-07-08 Memorial Sloan-Kettering Cancer Center Recombinant human anti-LK26 antibodies
US6569432B1 (en) 1995-02-24 2003-05-27 Sloan-Kettering Institute For Cancer Research Prostate-specific membrane antigen and uses thereof
US20050031679A1 (en) * 1998-03-27 2005-02-10 Clemens Unger Method for producing liposomal formulations of active ingredients
US20070270431A1 (en) * 2004-09-29 2007-11-22 Kowa Co., Ltd. Preventive and/or Therapeutic Medicine for Rheumatoid Arthritis
US20090155345A1 (en) * 2005-12-08 2009-06-18 Ben Gurion University Of The Negev Research And Development Authority Methods for affecting liposome composition ultrasound irradiation
US8388972B2 (en) 2006-09-15 2013-03-05 Advanced Accelerator Applications S.A. Human anti-folate receptor alpha antibodies and antibody fragments for the radioimmunotherapy of ovarian carcinoma
US20080214585A1 (en) * 2007-01-19 2008-09-04 Chelsea Therapeutics, Inc. New classical antifolates
US9133275B2 (en) 2010-02-24 2015-09-15 Immunogen, Inc. Folate receptor 1 antibodies and immunoconjugates and uses thereof
US20110280932A1 (en) 2010-05-13 2011-11-17 Pacira Pharmaceuticals, Inc. Sustained release formulation of methotrexate as a disease-modifying antirheumatic drug (dmard) and an anti-cancer agent
US20130259922A1 (en) * 2010-05-21 2013-10-03 Medigene Ag Liposomal formulations of lipophilic compounds
US8871206B2 (en) 2010-09-09 2014-10-28 Purdue Research Foundation Anti-human folate receptor beta antibodies and methods of use
US20140086939A1 (en) * 2011-02-28 2014-03-27 Michael Karin Compositions and methods for detecting and treating cancer
US20130324727A1 (en) * 2011-03-10 2013-12-05 National Science and Techology Development Agency Anti-folate antimalarials with dual-binding modes and their preparation
US20150239956A1 (en) * 2012-06-27 2015-08-27 Asahi Kasei Medical Co., Ltd. High-affinity antibody and method for manufacturing the same
WO2014046630A1 (fr) * 2012-09-19 2014-03-27 Keskin, Dilek Système d'administration de médicament liposomal ciblé contre la tumeur
WO2016025882A2 (fr) 2014-08-14 2016-02-18 L.E.A.F Holdings Group Llc. Médicament à affinité encapsulé dans un liposome

Non-Patent Citations (9)

* Cited by examiner, † Cited by third party
Title
ABRAHAM ET AL.: "Folate analogues. 33. Synthesis of folate and antifolate poly-gamma- glutamates by [(9-fluorenylmethoxy)oxy]carbonyl chemistry and biological evaluation of certain methotrexate polyglutamate polylysine conjugates as inhibitors of the growth of H35 hepatoma", J MED CHEM., vol. 33, no. 2, 1990, pages 711 - 717, XP002418703 *
GONEN ET AL., DRUG RESISTANCE UPDATES, vol. 15, 2012, pages 183 - 210
JONES ET AL., NATURE, vol. 321, 1986, pages 522 - 525
MAMOT ET AL., J. NEURO-ONCOLOGY, vol. 68, 2004, pages 1 - 9
RIECHMANN ET AL., NATURE, vol. 332, 1988, pages 323 - 327
SAITO ET AL., CANCER RESEARCH, vol. 64, 2004, pages 2572 - 2579
See also references of EP3496756A4 *
VERHOEYEN ET AL., SCIENCE, vol. 239, 1988, pages 1534 - 1536
ZWICKE ET AL.: "Utilizing the folate receptor for active targeting of cancer nanotherapeutics", NANO REV ., vol. 3, 2012, pages 18496, XP055347671 *

Cited By (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11344628B2 (en) 2016-08-12 2022-05-31 L.E.A.F. Holdings Group Llc Alpha polyglutamated antifolates and uses thereof
US11701432B2 (en) 2016-08-12 2023-07-18 Le.A.F. Holdings Group Llc Polyglutamated antifolates and uses thereof
US11534498B2 (en) 2016-08-12 2022-12-27 L.E.A.F. Holdings Group Llc Polyglutamated antifolates and uses thereof
EP3749315A4 (fr) * 2018-02-07 2022-06-22 L.E.A.F Holdings Group LLC Raltitrexed alpha-polyglutamaté et utilisations associées
EP3749316A4 (fr) * 2018-02-07 2021-10-27 L.E.A.F Holdings Group LLC Pralatrexate alpha-polyglutamaté et utilisations associées
EP3749320A4 (fr) * 2018-02-07 2022-03-09 L.E.A.F Holdings Group LLC Aminoptérine alpha-polyglutamatée et utilisations associées
EP3749321A4 (fr) * 2018-02-07 2022-03-09 L.E.A.F Holdings Group LLC Antifolates gamma-polyglutamatés et utilisations associées
US12076402B2 (en) 2018-02-07 2024-09-03 L.E.A.F. Holdings Group Llc Alpha polyglutamated antifolates and uses thereof
EP3749313A4 (fr) * 2018-02-07 2022-03-16 L.E.A.F Holdings Group LLC Antifolates alpha-polyglutamatés et utilisations associées
EP3749312A4 (fr) * 2018-02-07 2022-02-23 L.E.A.F Holdings Group LLC Lométrexol alpha-polyglutamaté et utilisations associées
EP3749314A4 (fr) * 2018-02-07 2022-02-23 L.E.A.F Holdings Group LLC Méthotrexate alpha-polyglutamaté et utilisations associées
EP3749317A4 (fr) * 2018-02-07 2022-06-22 L.E.A.F Holdings Group LLC Pémétrexed alpha-polyglutamaté et utilisations associées
US11779584B2 (en) 2018-02-07 2023-10-10 L.E.A.F. Holdings Group Llc Alpha polyglutamated pemetrexed and uses thereof
US11730738B2 (en) 2018-02-07 2023-08-22 L.E.A.F. Holdings Group Llc Alpha polyglutamated pralatrexate and uses thereof
EP3749318A4 (fr) * 2018-02-07 2022-07-06 L.E.A.F Holdings Group LLC Raltitrexed gamma-polyglutamaté et utilisations associées
EP3749311A4 (fr) * 2018-02-07 2022-07-06 L.E.A.F Holdings Group LLC Compositions de pémétrexed polyglutamaté gamma et leurs utilisations
EP3752155A4 (fr) * 2018-02-14 2022-03-16 L.E.A.F Holdings Group LLC Méthotrexate gamma polyglutamique et ses utilisations
EP3752156A4 (fr) * 2018-02-14 2021-10-27 L.E.A.F Holdings Group LLC Pralatrexate gamma-polyglutamaté et utilisations associées
EP3752157A4 (fr) * 2018-02-14 2022-07-06 L.E.A.F Holdings Group LLC Lométrexol gamma polyglutamique et ses utilisations
US11771700B2 (en) 2018-02-14 2023-10-03 L.E.A.F. Holdings Group Llc Gamma polyglutamated lometrexol and uses thereof
US12048766B2 (en) 2018-02-14 2024-07-30 L.E.A.F. Holdings Group Llc Gamma polyglutamated tetrahydrofolates and uses thereof
US12048767B2 (en) 2018-02-14 2024-07-30 L.E.A.F. Holdings Group Llc Gamma polyglutamated pralatrexate and uses thereof
EP3752158A4 (fr) * 2018-02-14 2022-03-09 L.E.A.F Holdings Group LLC Aminoptérine gamma polyglutamique et ses utilisations
WO2021026310A1 (fr) 2019-08-06 2021-02-11 L.E.A.F. Holdings Group Llc Procédés de préparation d'antifolates polyglutamiques et leurs utilisations

Also Published As

Publication number Publication date
WO2018031980A1 (fr) 2018-02-15

Similar Documents

Publication Publication Date Title
US11701432B2 (en) Polyglutamated antifolates and uses thereof
US20230115624A1 (en) D glutamate polyglutamated antifolates and uses thereof
WO2018031979A1 (fr) Antifolates alpha et gamma-d de polyglutamates et leurs utilisations.
CA2957775C (fr) Medicament a affinite encapsule dans un liposome
OA19187A (en) Polyglutamated antifolates and uses thereof.
OA19185A (en) Alpha and Gamma-D polyglutamated antifolates and uses thereof.

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 17840396

Country of ref document: EP

Kind code of ref document: A1

ENP Entry into the national phase

Ref document number: 3033077

Country of ref document: CA

ENP Entry into the national phase

Ref document number: 2017308158

Country of ref document: AU

Date of ref document: 20170812

Kind code of ref document: A

Ref document number: 2019507107

Country of ref document: JP

Kind code of ref document: A

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 20197005253

Country of ref document: KR

Kind code of ref document: A

ENP Entry into the national phase

Ref document number: 2017840396

Country of ref document: EP

Effective date: 20190312

REG Reference to national code

Ref country code: BR

Ref legal event code: B01A

Ref document number: 112019002497

Country of ref document: BR

ENP Entry into the national phase

Ref document number: 112019002497

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20190207